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   The	  first	  chapter	  of	  this	  thesis	  deals	  with	  automating	  data	  gathering	  for	  single	  cell	  microfluidic	  
tests.	  The	  programs	  developed	  saved	  significant	  amounts	  of	  time	  with	  no	  loss	  in	  accuracy.	  The	  
technology	  from	  this	  chapter	  was	  applied	  to	  experiments	  in	  both	  Chapters	  4	  and	  5.	  	  
The	  second	  chapter	  describes	  the	  use	  of	  statistical	  learning	  to	  prognose	  if	  an	  anti-­‐angiogenic	  
drug	  (Bevacizumab)	  would	  successfully	  treat	  a	  glioblastoma	  multiforme	  tumor.	  This	  was	  conducted	  by	  
first	  measuring	  protein	  levels	  from	  92	  blood	  samples	  using	  the	  DNA-­‐encoded	  antibody	  library	  platform.	  
This	  allowed	  the	  measure	  of	  35	  different	  proteins	  per	  sample,	  with	  comparable	  sensitivity	  to	  ELISA.	  Two	  
statistical	  learning	  models	  were	  developed	  in	  order	  to	  predict	  whether	  the	  treatment	  would	  succeed.	  
The	  first,	  logistic	  regression,	  predicted	  with	  85%	  accuracy	  and	  an	  AUC	  of	  0.901	  using	  a	  five	  protein	  panel.	  
These	  five	  proteins	  were	  statistically	  significant	  predictors	  and	  gave	  insight	  into	  the	  mechanism	  behind	  
anti-­‐angiogenic	  success/failure.	  The	  second	  model,	  an	  ensemble	  model	  of	  logistic	  regression,	  kNN,	  and	  
random	  forest,	  predicted	  with	  a	  slightly	  higher	  accuracy	  of	  87%.	  	  
The	  third	  chapter	  details	  the	  development	  of	  a	  photocleavable	  conjugate	  that	  multiplexed	  cell	  
surface	  detection	  in	  microfluidic	  devices.	  The	  method	  successfully	  detected	  streptavidin	  on	  coated	  
beads	  with	  92%	  positive	  predictive	  rate.	  Furthermore,	  chambers	  with	  0,	  1,	  2,	  and	  3+	  beads	  were	  
statistically	  distinguishable.	  The	  method	  was	  then	  used	  to	  detect	  CD3	  on	  Jurkat	  T	  cells,	  yielding	  a	  
positive	  predictive	  rate	  of	  49%	  and	  false	  positive	  rate	  of	  0%.	  	  
The	  fourth	  chapter	  talks	  about	  the	  use	  of	  measuring	  T	  cell	  polyfunctionality	  in	  order	  to	  predict	  
whether	  a	  patient	  will	  succeed	  an	  adoptive	  T	  cells	  transfer	  therapy.	  In	  15	  patients,	  we	  measured	  10	  
proteins	  from	  individual	  T	  cells	  (~300	  cells	  per	  patient).	  The	  polyfunctional	  strength	  index	  was	  
calculated,	  which	  was	  then	  correlated	  with	  the	  patient’s	  progress	  free	  survival	  (PFS)	  time.	  52	  other	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parameters	  measured	  in	  the	  single	  cell	  test	  were	  correlated	  with	  the	  PFS.	  No	  statistical	  correlator	  has	  
been	  determined,	  however,	  and	  more	  data	  is	  necessary	  to	  reach	  a	  conclusion.	  	  
Finally,	  the	  fifth	  chapter	  talks	  about	  the	  interactions	  between	  T	  cells	  and	  how	  that	  affects	  their	  
protein	  secretion.	  It	  was	  observed	  that	  T	  cells	  in	  direct	  contact	  selectively	  enhance	  their	  protein	  
secretion,	  in	  some	  cases	  by	  over	  5	  fold.	  This	  occurred	  for	  Granzyme	  B,	  Perforin,	  CCL4,	  TNFa,	  and	  IFNg.	  IL-­‐
10	  was	  shown	  to	  decrease	  slightly	  upon	  contact.	  This	  phenomenon	  held	  true	  for	  T	  cells	  from	  all	  patients	  
tested	  (n=8).	  Using	  single	  cell	  data,	  the	  theoretical	  protein	  secretion	  frequency	  was	  calculated	  for	  two	  
cells	  and	  then	  compared	  to	  the	  observed	  rate	  of	  secretion	  for	  both	  two	  cells	  not	  in	  contact,	  and	  two	  
cells	  in	  contact.	  In	  over	  90%	  of	  cases,	  the	  theoretical	  protein	  secretion	  rate	  matched	  that	  of	  two	  cells	  not	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Chapter  1:  Automated  Data  Gathering  in  Single  Cell  Microfluidic  Protein  
Assays  
1.1  -­‐  Introduction  
Microfluidic	  devices	  show	  great	  promise	  in	  advancing	  the	  proteomics	  field	  [1,	  2,	  3].	  The	  
miniaturization	  of	  proteomeic	  tests	  allows	  for	  the	  generation	  of	  large	  number	  of	  statistics.	  One	  caveat	  of	  
increasing	  the	  number	  of	  statistics	  is	  the	  increased	  amount	  of	  man-­‐hours	  necessary	  to	  gather	  and	  
analyze	  the	  data.	  For	  example,	  analyzing	  four	  of	  the	  Heath	  Lab’s	  single	  cell	  (SC)	  microfluidic	  proteomic	  
tests	  per	  week	  requires	  approximately	  14.5	  hours.	  Furthermore,	  as	  the	  number	  of	  microfluidic	  chambers	  
increases,	  the	  probability	  of	  human	  error	  increases	  as	  well.	  	  These	  random	  errors	  are	  difficult	  to	  detect	  
in	  downstream	  analysis.	  Therefore,	  a	  method	  to	  automate	  SC	  data	  gathering	  and	  analysis	  would	  both	  
save	  time	  and	  reduce	  random	  errors.	  	  	  
	   Computer	  vision	  has	  opened	  the	  doors	  to	  new	  technologies,	  with	  a	  diverse	  set	  of	  applications,	  
from	  self-­‐driving	  cars	  to	  cancer	  diagnostics	  [4].	  Huang	  et	  al.	  used	  computer	  vision	  to	  image	  cells	  and	  
related	  the	  cell	  morphology	  to	  the	  patient’s	  survival	  time	  [5].	  Other	  groups	  have	  utilized	  computer	  vision	  
for	  more	  simple	  purposes;	  for	  instance,	  Loukas	  et	  al.	  have	  generated	  algorithms	  to	  determine	  with	  high	  
accuracy	  if	  an	  element	  in	  a	  microscope	  image	  is	  a	  cell	  or	  not	  [6]	  This	  technology	  is	  desirable	  in	  
microfluidics,	  as	  it	  would	  allow	  for	  the	  automation	  of	  cell	  counting.	  	  
	   Using	  computer	  vision	  to	  automate	  the	  microfluidic	  devices	  is	  the	  subject	  of	  this	  chapter.	  There	  
are	  two	  tasks	  to	  automating	  the	  data	  gathering	  and	  analysis	  of	  single	  cell	  microfluidic	  tests:	  (1)	  
automating	  fluorescence	  signal	  gathering	  from	  the	  ELISA-­‐like	  test	  and	  (2)	  automating	  cell	  counting.	  	  
The	  protein	  fluorescence	  signal	  from	  the	  Heath	  Lab’s	  SC	  tests	  can	  easily	  be	  applied	  to	  computer	  
vision	  algorithms	  because	  the	  devices	  are	  organized	  in	  a	  regularly	  spaced	  matrix	  with	  multiple	  reference	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markers.	  In	  contrast,	  automating	  our	  cell	  counting	  is	  more	  difficult	  because	  video	  files	  are	  used	  [7].	  
Analyzing	  cells	  from	  video	  files	  requires	  specialized	  software,	  since	  features	  must	  be	  tracked	  between	  
frames	  [8].	  Since	  this	  method	  of	  cell	  counting	  with	  video	  files	  was	  not	  readily	  adapted	  towards	  
automation,	  a	  method	  was	  developed	  in-­‐house	  to	  create	  a	  full-­‐view	  image	  of	  the	  single	  cell	  microfluidic	  
device,	  using	  image-­‐stitching.	  	  These	  files	  were	  the	  equivalent	  of	  500	  microscope	  images	  stitched	  
together	  to	  give	  a	  full-­‐view	  of	  the	  microfluidic	  device’s	  chambers.	  This	  image	  can	  then	  be	  used	  in	  an	  
automated	  cell	  counting	  program.	  	  
With	  a	  full-­‐view	  of	  the	  cells	  and	  fluorescence	  signal	  in	  the	  microfluidic	  device,	  the	  two	  
automating	  tasks	  share	  a	  common	  goal:	  find	  and	  index	  each	  single	  cell	  chamber.	  From	  there,	  the	  
automated	  cell	  counting	  algorithm	  must	  use	  computer	  vision	  to	  identify	  cells	  to	  obtain	  a	  cell	  count	  in	  
the	  chamber,	  which	  has	  been	  demonstrated	  previously	  [9,	  10].	  Whereas	  the	  automated	  fluorescence	  
signal	  analysis	  algorithm	  must	  locate	  the	  different	  fluorescent	  protein	  signals	  and	  quantify	  them.	  After	  
these	  specific	  tasks,	  each	  program	  must	  then	  organize	  the	  gathered	  data	  into	  a	  readable	  format,	  
suitable	  for	  downstream	  statistical	  analysis.	  	  
	   These	  two	  algorithms	  have	  not	  only	  saved	  time	  but	  also	  allowed	  us	  to	  perform	  tests	  that	  would	  
previously	  be	  considered	  too	  cumbersome	  to	  perform	  and	  analyze.	  The	  complex	  experiment	  performed	  
in	  Chapter	  5.2.6	  (T	  cell	  communication	  project)	  was	  made	  possible	  using	  this	  technology.	  	  
1.2  –  Materials  and  Methods  
1.2.1  –  Automated  Cell  Counter  
1.2.1.1  –  Microfluidic  Device  
The	  polydimethylsiloxane	  (PDMS)	  microfluidic	  device	  was	  created	  using	  a	  special	  aluminum	  
casing,	  in	  order	  to	  make	  the	  PDMS’	  top	  surface	  flat.	  The	  schematic	  for	  the	  device	  is	  shown	  in	  Figure	  1.	  
The	  wafer	  (colored	  blue)	  with	  the	  microfluidic	  pattern	  is	  sandwiched	  between	  two	  aluminum	  blocks.	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These	  blocks	  are	  fastened	  together	  with	  screws.	  A	  10:1	  ratio	  of	  A:B	  Sylgard	  184	  PDMS	  (Dow	  Corning)	  is	  
mixed	  and	  poured	  into	  the	  top	  aluminum	  block’s	  window.	  The	  aluminum	  block	  casing	  is	  then	  placed	  in	  a	  
vacuum	  chamber	  for	  1	  hour	  to	  remove	  bubbles	  from	  the	  PDMS.	  Next,	  flat	  plastic	  pieces	  are	  placed	  
overtop	  the	  window	  of	  the	  top	  aluminum	  block,	  and	  the	  entire	  casing	  is	  placed	  in	  an	  80	  °C	  oven	  for	  20-­‐
25	  minutes.	  A	  second,	  thin	  layer	  of	  PDMS	  is	  made	  concurrently,	  as	  described	  in	  Chapter	  4.2.1.	  	  The	  
PDMS	  is	  removed	  from	  the	  oven	  and	  allowed	  to	  cool	  for	  15	  minutes.	  The	  cured	  PDMS	  is	  then	  removed	  
from	  the	  aluminum	  casing,	  its	  control-­‐valve	  holes	  are	  punched,	  and	  then	  it	  is	  adhered	  to	  the	  second,	  
thin	  layer	  of	  PDMS.	  This	  is	  baked	  for	  1.5	  hours	  at	  80	  °C.	  Holes	  are	  then	  punched	  for	  flow-­‐channels.	  The	  
device	  is	  then	  adhered	  to	  a	  DEAL	  barcode	  substrate	  and	  baked	  for	  2	  hours	  at	  80	  °C.	  The	  device	  is	  then	  
stored	  in	  a	  dessicator	  (<	  20%	  humidity)	  for	  a	  maximum	  of	  one	  week.	  	  
	  
Figure	  1:	  3D	  model	  of	  aluminum	  casing	  to	  make	  flat-­‐top	  PDMS.	  The	  wafer	  is	  colored	  blue	  and	  is	  placed	  in	  between	  the	  two	  




1.2.1.2  –  Stitched  Image  Acquisition  
To	  perform	  automated	  computer	  vision	  cell	  counting,	  a	  full-­‐view	  image	  of	  the	  microfluidic	  
device	  must	  be	  generated.	  This	  was	  accomplished	  by	  using	  the	  “Stage	  Overview”	  function	  of	  the	  
Olympus	  IX81	  CellSens	  software.	  	  
	   The	  microfluidic	  device	  was	  secured	  on	  the	  stage	  of	  the	  Olympus	  IX81	  and	  multiple	  tasks	  were	  
performed	  to	  ensure	  the	  image	  quality	  would	  be	  sufficient	  for	  subsequent	  computer	  vision	  algorithms:	  
First,	  if	  the	  device	  chambers’	  were	  not	  run	  parallel	  with	  the	  stage’s	  X-­‐axis,	  the	  device	  was	  rotated	  to	  
make	  them	  parallel.	  Second,	  the	  device	  was	  made	  completely	  flat	  on	  the	  stage,	  which	  was	  checked	  by	  
focusing	  on	  the	  cells	  on	  one	  side	  of	  the	  device	  and	  then	  making	  sure	  the	  cells	  were	  still	  in	  focus	  on	  the	  
other	  side.	  The	  stage	  was	  adjusted	  to	  ensure	  the	  device	  was	  completely	  flat.	  Finally,	  the	  lighting	  
(brightness/contrast)	  from	  one	  side	  the	  device	  to	  the	  other	  was	  checked	  for	  any	  drastic	  differences.	  	  
The	  “Stage	  Overview”	  function	  was	  then	  selected,	  and	  bounds	  were	  set	  as	  the	  top-­‐left	  and	  
bottom-­‐right	  of	  the	  microfluidic	  chambers.	  A	  stitched	  image	  was	  then	  acquired	  at	  10x	  magnification	  and	  
saved	  as	  a	  .jpeg	  file.	  The	  files	  acquired	  were	  ~500	  images	  stitched	  together	  to	  generate	  an	  image	  with	  a	  
pixel	  resolution	  of	  35k	  by	  15k.	  
1.2.1.3  –  Computer  Vision  to  Isolate  Microfluidic  Chambers  
	   Once	  the	  full-­‐view	  image	  of	  the	  microfluidic	  device	  was	  acquired,	  the	  image	  was	  loaded	  into	  a	  
custom	  written	  Matlab	  program	  (see	  Appendix	  A	  for	  full	  code).	  The	  program	  receives	  user	  input	  for	  the	  
following:	  x	  and	  y	  bounds	  of	  the	  microfluidic	  chambers,	  rotation	  of	  the	  slide,	  start	  of	  the	  first	  single	  cell	  
chamber,	  and	  the	  optimum	  binary	  threshold	  to	  visualize	  the	  cells.	  This	  binary	  threshold	  allows	  the	  
program	  to	  convert	  a	  grayscale	  image	  into	  a	  binary	  image.	  This	  binary	  image	  is	  used	  to	  help	  the	  program	  
identify	  both	  the	  chambers,	  as	  well	  as	  the	  cells	  within	  those	  chambers.	  Figure	  2	  shows	  the	  general	  flow	  
of	  the	  program:	  stitched	  images	  of	  microfluidic	  devices	  were	  acquired	  as	  shown	  in	  Figure	  2a	  (zoomed	  in	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Figure	  2:	  Automated	  Single	  Cell	  Detection	  flow	  of	  chamber	  cropping.	  a)	  The	  stitched	  full-­‐view	  image	  of	  five	  chambers.	  b)	  Binary	  imaged	  of	  the	  same	  chambers,	  
with	  plots	  of	  average	  intensity	  along	  both	  axes.	  c)	  Cropped	  out	  chamber	  with	  cell	  boxed	  in	  green.	  
for	  clarity).	  This	  is	  converted	  to	  binary	  using	  a	  user-­‐defined	  threshold	  (Figures	  2b).	  The	  computer	  plots	  
the	  average	  intensity	  of	  the	  binary	  image	  by	  row	  and	  by	  column	  (Figure	  2b),	  and	  uses	  this	  information	  to	  
crop	  out	  a	  chamber	  (Figure	  2c).	  	  
	  
	  
1.2.1.4  –  Detection  of  Cells  in  Single  Cell  Chambers  
	   Once	  a	  single	  cell	  chambers	  is	  located	  by	  the	  program,	  the	  number	  of	  cells	  is	  determined	  using	  
two	  cell-­‐identification	  methods.	  First,	  a	  feature	  finding	  method	  identifies	  circular	  regions-­‐of-­‐interest	  
(ROIs)	  using	  the	  binary	  image	  of	  the	  single	  cell	  chamber.	  If	  the	  cells	  size	  is	  known,	  one	  can	  gate	  these	  
ROIs	  by	  the	  cell	  size.	  The	  ROIs	  found	  using	  this	  method	  are	  put	  into	  a	  list	  of	  “possible	  cells.”	  Next,	  the	  
program	  crops	  out	  these	  “possible	  cells”	  regions	  from	  the	  original	  grayscale	  image.	  One	  characteristic	  
feature	  of	  T	  cells	  imaged	  on	  light	  microscopes	  is	  a	  distinct	  white	  nucleus/cytoplasm,	  with	  a	  dark	  
membrane	  (Figure	  3).	  The	  program	  takes	  advantage	  of	  these	  characteristic	  by	  taking	  a	  cross-­‐section	  of	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  Figure	  4:	  Flow	  of	  Automated	  Genepix	  program	  flow.	  a)	  The	  full	  single	  cell	  device	  is	  cropped	  into	  blocks.	  b)	  A	  single	  block	  with	  16	  features	  is	  then	  further	  chopped	  up	  
into	  chambers.	  c)	  A	  single	  chamber	  is	  analyzed	  by	  locating	  the	  reference	  and	  then	  all	  proteins	  relative	  to	  that	  reference.	  The	  protein	  levels	  are	  quantified	  and	  stored	  
in	  a	  dataset.	  
intensity	  from	  the	  cell	  (Figure	  3a).	  This	  intensity	  graph	  will	  show	  one	  large	  peak,	  bounded	  by	  two	  minor	  
troughs	  (Figure	  3b).	  	  
	  
Figure	  3:	  Cell	  detection	  method.	  a)	  Grayscale	  image	  of	  cropped	  single	  cell.	  Green	  line	  shows	  where	  the	  cross-­‐section	  trace	  was	  
taken.	  b)	  Cross-­‐section	  trace	  of	  the	  cell	  in	  part	  a.	  The	  trace	  shows	  the	  characteristic	  peak	  in	  the	  cell’s	  center,	  bordered	  by	  two	  
troughs.	  	  
1.2.2  –  Automated  Genepix  Analysis  
1.2.2.1  –  Protein  Signal  Gathering  
The	  fluorescent	  protein	  signal	  from	  the	  single	  cell	  tests	  produce	  a	  multilayered	  .tif	  file.	  This	  .tif	  
file	  is	  fed	  into	  a	  custom	  written	  Matlab	  program	  (full	  code	  in	  Appendix	  B).	  	  
	   The	  goal	  of	  this	  Matlab	  program	  is	  to	  isolate	  each	  single	  cell	  chamber,	  extract	  the	  protein	  signal	  
data	  from	  that	  chamber,	  and	  organize	  the	  data	  for	  output.	  The	  general	  flow	  of	  gathering	  the	  protein	  
signal	  from	  these	  images	  is	  shown	  in	  Figure	  4.	  First,	  the	  user	  identifies	  the	  four	  corners	  of	  the	  device	  by	  
clicking	  on	  the	  reference	  signals.	  The	  program	  uses	  this	  information	  to	  cut	  up	  the	  “blocks”	  of	  the	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chamber	  (Figure	  4b).	  These	  blocks	  each	  contain	  16	  single	  cell	  chambers,	  each	  with	  a	  reference	  signal.	  
The	  program	  locates	  these	  reference	  signals	  using	  a	  rectangular	  feature	  finding	  method	  [regionprops(‘	  
BoundingBox’)],	  and	  ensures	  16	  of	  these	  features	  exist.	  If	  16	  were	  not	  found,	  the	  program	  shifts	  the	  
block’s	  frame	  from	  side-­‐to-­‐side	  in	  order	  to	  find	  any	  feature	  that	  may	  have	  been	  cut	  off.	  If	  this	  fails,	  the	  
program	  ignores	  the	  current	  block.	  	  
	   When	  16	  reference	  features	  are	  successfully	  found,	  their	  locations	  are	  used	  to	  isolate	  each	  
single	  cell	  chamber	  (Figure	  4c).	  These	  chambers	  are	  cropped	  out	  and	  stored	  as	  individual	  chambers	  
objects.	  The	  user	  inputs	  an	  excel	  file	  with	  the	  order	  of	  proteins,	  as	  well	  as	  the	  location	  of	  the	  reference	  
signal.	  This	  allows	  that	  program	  to	  identify	  the	  protein	  locations	  and	  identities	  in	  the	  chambers.	  Because	  
the	  protein	  signals	  are	  uniformly	  patterned	  using	  barcodes,	  offset	  distances	  from	  the	  reference	  signal	  
can	  be	  used	  to	  identify	  each	  protein.	  The	  protein	  signals	  are	  cropped	  out,	  averaged,	  and	  saved	  for	  each	  
chamber.	  The	  program	  performs	  an	  outlier	  detection	  by	  removing	  any	  outlier	  pixel	  values	  using	  the	  
“removeoutliers”	  function	  [11].	  
	   The	  automated	  program’s	  output	  was	  compared	  to	  a	  reference	  dataset.	  This	  reference	  dataset	  
was	  analyzed	  using	  the	  Genepix	  Pro	  “Block”	  arrays,	  using	  three	  circular	  features	  per	  barcode	  feature.	  
This	  method	  is	  called	  the	  “reference”	  because	  it	  is	  the	  standard	  for	  data	  analysis	  in	  the	  Heath	  Lab.	  Using	  
the	  program’s	  output,	  as	  well	  as	  the	  reference,	  multiple	  quality	  metrics	  were	  calculated:	  
1) Average  Error = |x!!"#$%&#'( −!!!! x!!"#"$"%&"|	  





2) Percent	  of	  automated	  signals	  within	  range	  of	  reference	  (example:	  percent	  of	  cells	  within	  
20%	  of	  the	  reference	  signal)	  =	  	  
1  𝑖𝑓   |x!!"#$%&#'( − x!!"#"$"%&"|x!!"#"$"%&" < 0.20  𝑖𝑓   |x!!"#$%&#'( − x!!"#"$"%&"|x!!"#"$"%&" > 0.2
!!!!
𝑛 	  
	   After	  comparing	  the	  hand-­‐analyzed	  data	  to	  the	  automated	  program’s	  data,	  the	  data	  that	  did	  not	  
match	  between	  the	  two	  were	  investigated	  further.	  This	  involved	  using	  the	  genepix	  program	  to	  get	  the	  
most	  accurate	  value	  possible	  by	  using	  the	  rectangle	  tool	  for	  each	  feature	  (Accurate	  Value).	  This	  is	  
considered	  more	  accurate	  than	  the	  reference	  method	  because	  the	  accurate	  method	  uses	  45%	  more	  
data.	  Using	  this	  “accurate	  value”	  for	  each	  point,	  we	  were	  able	  to	  determine	  if	  the	  hand-­‐analysis	  or	  
automated	  program	  was	  closer	  to	  the	  true	  value.	  	  
1.2.2.2  –  Local  Background  Subtraction  
	   Because	  the	  devices	  had	  non-­‐uniform	  background	  signals,	  a	  local	  background	  subtraction	  
method	  was	  created	  to	  generate	  background	  values	  for	  each	  block	  down	  the	  slide.	  This	  was	  done	  by	  
averaging	  the	  signal	  for	  proteins	  from	  zero	  cell	  chambers	  in	  its	  row,	  as	  well	  as	  the	  two	  neighboring	  rows.	  
This	  was	  performed	  for	  all	  rows	  of	  the	  device,	  generating	  background	  levels	  for	  every	  protein	  per	  row.	  	  
1.3  –  Results  
1.3.1  -­‐  Automated  Cell  Counter  
	   Using	  this	  program,	  the	  accuracy	  of	  cell	  detection	  was	  99.7%	  for	  over	  3900	  data	  points	  when	  
user	  input	  was	  performed	  in	  the	  case	  of	  questionable	  cells.	  The	  cells	  that	  were	  missed	  were	  obscured	  by	  
foreign	  debris	  or	  were	  unnaturally	  stretched	  out,	  which	  negated	  the	  program’s	  ability	  to	  measure	  a	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clean	  trace	  of	  the	  cell’s	  cross	  section.	  The	  average	  time	  required	  was	  7±4	  minutes	  without	  user	  input	  
and	  14±10	  minutes	  with	  user	  input.	  	  
1.3.2  -­‐  Automated  Genepix  Analysis  
	   The	  automated	  genepix	  program	  was	  used	  to	  analyze	  a	  total	  of	  11	  single	  cell	  device	  (~100,000	  
protein	  signal	  data	  points)	  and	  the	  average	  percent	  error	  was	  calculated	  at	  5.8%.	  These	  errors	  were	  
broken	  down	  into	  the	  magnitude	  of	  the	  signal	  for	  which	  the	  error	  occurred	  on:	  90%	  of	  the	  errors	  
occurred	  for	  signals	  less	  than	  400	  fluorescence	  intensity	  units,	  9%	  occurred	  between	  400	  and	  2000,	  and	  
1%	  were	  from	  signals	  greater	  than	  20,000	  fluorescence	  intensity	  units.	  	  
	   Furthermore,	  a	  subset	  of	  these	  errors	  were	  scrutinized	  in	  depth	  by	  comparing	  the	  automated	  
and	  reference	  values	  to	  the	  accurate	  value.	  Of	  the	  subset	  of	  errors	  that	  were	  scrutinized,	  the	  automated	  
program	  was	  closer	  to	  the	  accurate	  value	  64%	  of	  the	  time.	  Therefore,	  it	  was	  concluded	  that	  these	  errors	  
were	  not	  problematic,	  as	  the	  automated	  program	  was	  closer	  to	  the	  actual	  value	  more	  often	  than	  the	  
reference.	  	  
	   A	  second	  method	  of	  accuracy	  was	  used,	  where	  the	  percent	  of	  signals	  within	  a	  certain	  
percentage	  range	  of	  the	  reference	  was	  calculated.	  99.94%	  of	  protein	  signals	  has	  a	  percent	  difference	  of	  




Figure	  5:	  Graph	  showing	  the	  fraction	  of	  features	  that	  matched	  within	  a	  certain	  percent	  similarity	  between	  the	  Automated	  and	  
Reference	  datasets.	  For	  instance,	  a	  fraction	  of	  0.9	  feature	  values	  matched	  within	  a	  10%	  similar.	  	  
	   A	  representative	  graph	  of	  background	  level	  vs.	  row	  using	  the	  standard	  method	  and	  local	  
background	  subtraction	  is	  shown	  in	  Figure	  6.	  Implementation	  of	  local	  background	  subtraction	  improved	  
the	  number	  of	  detected	  proteins	  detected	  as	  significant	  by	  an	  average	  of	  29%	  in	  a	  full	  single	  cell	  test.	  In	  
a	  photocleavable	  experiment	  to	  identify	  Jurkat	  cells	  (Chapter	  3),	  using	  local	  background	  subtraction	  
improved	  the	  fraction	  of	  cells	  found	  by	  61%.	  	  
	  
Figure	  6:	  Background	  subtraction	  methods	  compared.	  Averaging	  the	  background	  for	  the	  entire	  device	  yields	  the	  red	  line,	  which	  
stays	  constant	  for	  every	  block	  repeat.	  The	  blue	  line	  shows	  the	  local	  background	  value,	  which	  monotonically	  changes	  from	  one	  
side	  of	  the	  device	  to	  the	  other.	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1.4  –  Discussion  
	   The	  advantage	  of	  these	  programs	  is	  not	  only	  that	  time	  is	  saved	  but	  also	  that	  errors	  become	  
systematic	  and	  it	  allows	  us	  to	  perform	  experiments	  that	  were	  previously	  cumbersome	  to	  analyze.	  For	  
instance,	  performing	  the	  experiments	  in	  Chapter	  5.2.6	  without	  automated	  would	  have	  required	  
approximately	  4.8	  hours	  extra	  processing	  time	  per	  device.	  See	  Table	  1	  for	  timing	  differences.	  
Additionally,	  because	  a	  stitched	  image	  is	  taken	  instead	  of	  videos,	  the	  labor	  required	  to	  run	  the	  
experiment	  is	  reduced,	  allowing	  the	  experimentalist	  to	  run	  multiple	  devices	  to	  increase	  statistics.	  Both	  
programs	  have	  another	  advantage	  in	  that,	  in	  the	  case	  of	  the	  program’s	  failure,	  the	  user	  can	  simply	  
analyze	  the	  data	  by	  hand.	  
Table	  1:	  Timing	  differences	  between	  reference	  analysis	  method	  and	  automated	  analysis.	  






Time	  Saved	  with	  
Automated	  Analysis	  (hrs)	  
Making	  PDMS	   1.25	   1.375	   -­‐0.175	  
Capturing	  Video/Image	   0.25	   0.167	   0.0833	  
Analyzing	  Cell	  Counts	   2.5	   0.1	   2.4	  
Analyzing	  Fluor	  Counts	   2.5	   0.1	   2.4	  
TOTAL	   6.5	   1.74	   4.8	  
	  
	   Furthermore,	  the	  automated	  cell	  counting	  program	  has	  been	  extended	  to	  analyzing	  
fluorescence	  intensity	  in	  addition	  to	  counting	  cells	  (Chapter	  5.2.6).	  This	  has	  allowed	  us	  to	  phenotype	  our	  
cells	  on	  chip,	  which	  increases	  the	  information	  gained	  from	  each	  cell	  in	  a	  single	  cell	  experiment.	  	  
	   The	  cell	  counting	  program	  performed	  extremely	  well	  with	  healthy	  cells;	  however,	  the	  program	  
does	  not	  account	  for	  dead	  cells.	  This	  could	  become	  an	  issue	  when	  cell	  viability	  is	  low	  and	  the	  user	  wants	  
to	  account	  for	  chambers	  with	  dead	  or	  apoptotic	  T	  cells.	  Because	  dead/apoptotic	  T	  cells	  have	  lower	  
contrast	  than	  healthy	  T	  cells	  on	  light	  microscopes,	  it	  is	  difficult	  to	  identify	  them	  in	  a	  sensitive	  manner.	  
This	  is	  because	  their	  detection	  will	  require	  the	  program	  to	  accept	  lower	  contrast	  features	  as	  potential	  
dead	  cells,	  which	  would	  consequently	  increase	  the	  amount	  of	  noise	  accepted.	  One	  option	  for	  detecting	  
12	  
	  
dead/apoptotic	  cells	  would	  be	  to	  perform	  a	  fluorescent	  stain	  before	  the	  experiment,	  and	  then	  using	  the	  
fluorescent	  cell	  detection	  method	  developed	  for	  Chapter	  5.2.6.	  Live/dead	  stains	  could	  be	  used	  for	  dead	  
cells	  and	  Annexin	  V	  for	  apoptotic	  cells.	  	  
1.5  –  Conclusions  
	   Two	  automated	  programs	  have	  been	  developed	  that	  automated	  cell	  counting	  and	  fluorescence	  
signal	  gathering	  in	  single	  cell	  microfluidics	  tests.	  The	  cell	  counting	  algorithm	  reduced	  the	  time	  required	  
to	  analyze	  a	  single	  device	  from	  2.5	  to	  0.1	  hours,	  without	  any	  appreciable	  loss	  in	  accuracy.	  The	  
automated	  fluorescence	  signal	  gathering	  program	  was	  comparable	  in	  accuracy	  to	  manual	  analysis,	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Chapter  2:  Predicting  Glioblastoma  Patient  Response  to  Anti-­‐Angiogenic  
Therapy  using  Statistical  Leaning  Methods  
Abbreviations  
LR:	  	   Logistic	  Regression	  
GBM:	  	   Glioblastoma	  Multiforme	  
kNN:	  	   k-­‐Nearest	  Neighbors	  
RF:	  	   Random	  Forests	  
DEAL:	  	   DNA-­‐Encoded	  antibody	  libraries	  
CV:	  	   Coefficient	  of	  Variation	  
AUC:	  	   Area	  under	  the	  Curve	  
	  
2.1  -­‐  Introduction  
Using	  biomarkers	  to	  diagnose	  before	  bulk	  symptoms	  arise	  has	  received	  extensive	  attention	  in	  
the	  medical	  community	  [1,	  2,	  3,	  4].	  For	  example,	  in	  pregnancy	  tests,	  human	  chorionic	  gonadotropin	  
(hCG)	  can	  be	  detected	  in	  the	  user’s	  urine	  after	  its	  levels	  double	  in	  blood/urine	  every	  ~72	  hours	  after	  
conception	  [5].	  This	  application	  shows	  the	  impactful	  promise	  in	  diagnosing	  conditions	  in	  the	  body	  before	  
bulk	  symptoms	  are	  displayed.	  	  
In	  cancer	  diagnostics	  and	  prognostics,	  multiple	  biomarkers	  are	  typically	  necessary	  due	  to	  the	  
subtlety	  of	  the	  disease	  [6].	  This	  is	  because	  the	  state	  of	  cancer	  is	  not	  as	  drastically	  transformative	  to	  the	  
body	  as	  something	  like	  pregnancy.	  Cancer	  is	  constantly	  kept	  in	  check	  by	  nutrient	  limitations	  via	  blood	  
vessels,	  DNA	  repair	  mechanisms,	  basement	  membrane	  sequestration,	  and	  the	  immune	  system	  [7].	  
Therefore,	  in	  order	  to	  diagnose	  a	  cancer	  before	  it	  becomes	  metastatic	  and/or	  displays	  symptoms,	  one	  
must	  look	  for	  subtle	  alterations	  in	  general	  cell	  functioning.	  	  
Cancer	  diagnostics	  using	  biomarkers	  began	  with	  the	  discovery	  that	  free	  DNA	  was	  present	  in	  the	  
bloodstream	  of	  cancer	  patients,	  which	  included	  mutated	  gene	  products	  from	  the	  tumor	  [8].	  However,	  
the	  presence	  of	  mutated	  genomic	  material	  does	  not	  necessarily	  imply	  functional	  changes	  in	  the	  gene’s	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product:	  protein	  levels	  [1].	  Genes	  must	  be	  translated	  and	  transcribed	  into	  proteins	  in	  order	  to	  exact	  a	  
function	  on	  the	  body	  [9].	  Therefore,	  in	  order	  to	  determine	  if	  functional	  changes	  are	  present	  in	  the	  body,	  
one	  must	  detect	  proteins	  as	  a	  biomarker.	  	  
Proteins	  have	  been	  used	  as	  biomarkers	  for	  a	  wide	  array	  of	  applications,	  including	  diagnostic	  for	  
Alzheimer’s	  disease,	  rheumatoid	  arthritis,	  and	  different	  forms	  of	  cancer	  [10,	  11].	  Many	  methods	  exist	  
for	  protein	  detection,	  including	  2-­‐D	  PAGE,	  mass	  spectrometry,	  surface-­‐enhanced	  laser	  
desorption/ionization,	  and	  enzyme	  linked	  immunosorbant	  assays	  (ELISAs)	  [12,	  13,	  14,	  15].	  Each	  method	  
has	  its	  own	  advantage,	  with	  ELISAs	  being	  very	  accurate	  and	  selective	  for	  a	  small	  number	  of	  protein	  
targets	  [14].	  A	  multiplexed	  ELISA-­‐platform	  was	  previously	  developed	  in	  the	  Heath	  lab,	  and	  showed	  high	  
accuracy	  in	  detecting	  blood	  proteins	  [13].	  A	  multiplexed	  and	  accurate	  detection	  system	  is	  advantageous	  
in	  cancer	  diagnostics	  where	  malignant	  transformations	  are	  preceded	  by	  subtle	  changes	  in	  specific	  
proteins	  [16,	  6],	  especially	  if	  the	  tumor	  is	  difficult	  to	  assess,	  such	  as	  in	  the	  case	  of	  Glioblastoma	  
Multiforme	  (GBM)	  [17].	  
GBM	  is	  one	  of	  the	  most	  deadly	  forms	  of	  cancer,	  with	  a	  post-­‐diagnosis	  median	  survival	  time	  of	  
12-­‐18	  months	  with	  standard	  care	  [18,	  19].	  Surgical	  resection,	  radiation,	  and	  temozolomide	  have	  
improved	  survival;	  however,	  reoccurrence	  is	  common	  [20].	  	  Bevacizumab,	  a	  VEGF	  blocking	  antibody,	  has	  
shown	  promise	  in	  treating	  these	  cases	  by	  altering	  tumor	  vasculature	  [21].	  	  
Over	  a	  century	  ago,	  it	  was	  observed	  that	  tumors	  promote	  blood	  vessel	  growth,	  but	  only	  in	  1971	  
did	  anti-­‐angiogenic	  drugs	  become	  a	  topic	  in	  the	  research	  community	  [22,	  23].	  For	  three	  decades,	  
antiangiogenic	  drugs,	  like	  Bevacizumab,	  have	  shown	  promise	  as	  anti-­‐tumor	  drugs	  in	  both	  preclinical	  and	  
clinical	  trials	  [24].	  Though	  the	  exact	  mechanism	  is	  not	  fully	  established,	  Bevacizumab	  can	  reduce	  tumor	  
bulk.	  This	  can	  inhibit	  tumor	  vasculature	  growth,	  and	  in	  certain	  cases,	  normalize	  the	  vasculature’s	  
structure	  [25,	  26].	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Using	  Bevacizumab	  to	  treat	  GBM	  requires	  time	  to	  determine	  whether	  the	  drug	  is	  working,	  
typically	  on	  the	  order	  of	  months	  to	  see	  if	  it	  is	  effective	  [27].	  Furthermore,	  GBM	  is	  a	  difficult	  tumor	  to	  
assess:	  two	  reasons	  for	  this	  are	  false-­‐positive	  assessments	  and	  differences	  in	  scan	  interpretation	  
between	  doctors	  [21].	  Therefore,	  it	  is	  difficult	  for	  doctors	  to	  determine	  if	  Bevacizumab	  is	  working.	  
During	  this	  time,	  the	  drug	  may	  have	  no	  effect,	  costing	  money	  to	  the	  patient	  for	  an	  ineffective	  drug	  
(Bevacizumab	  is	  ~$100,000	  per	  year),	  and	  wasting	  time	  that	  could	  be	  spent	  trying	  other	  drugs	  [28].	  
Furthermore,	  anti-­‐angiogeneic	  drugs	  come	  with	  side	  effects,	  including	  thromboembolism,	  
gastrointestinal	  perforation,	  and	  hypertension	  [29,	  30].	  Therefore,	  creating	  a	  prognostic	  method	  to	  
determine	  if	  the	  drug	  is	  working	  at	  an	  early	  stage	  is	  desirable.	  	  
In	  this	  project,	  a	  multiplexed	  ELISA	  diagnostic	  platform	  is	  applied	  to	  prognose	  if	  GBM	  patients	  
responding	  to	  a	  Bevacizumab	  treatment.	  Two	  mathematical	  models	  were	  developed	  which	  were	  used	  to	  
predict	  whether	  a	  patient	  had	  a	  growing	  tumor	  at	  that	  time	  point.	  	  
2.2  –  Materials  and  Methods  
2.2.1  -­‐  DNA-­‐Encoded  Antibody  Libraries  
DNA-­‐Encoded	  antibody	  libraries	  (DEAL)	  were	  used	  as	  a	  capture	  antibody	  for	  the	  ELISA	  [31].	  
These	  conjugates	  are	  monoclonal	  antibodies	  linked	  to	  a	  single	  stranded	  DNA	  (ssDNA).	  The	  ssDNA	  is	  
unique	  for	  each	  antibody,	  which	  will	  hybridize	  to	  its	  unique	  complement	  ssDNA.	  The	  complementary	  
strands,	  which	  will	  be	  discussed	  in	  more	  detail	  in	  Chapter	  2.2.2,	  were	  immobilized	  to	  a	  surface.	  DEAL	  
antibody	  conjugates	  are	  then	  immobilized	  to	  this	  surface	  by	  hybridization,	  much	  like	  in	  a	  standard	  96	  
well-­‐plate	  ELISA	  (See	  Appendix	  A,	  Figure	  1).	  	  
	   The	  synthesis	  of	  a	  DEAL	  antibody	  conjugate	  has	  been	  described	  in	  detail	  elsewhere	  [31].	  Briefly,	  
100	  µL	  of	  antibody	  at	  0.5-­‐1	  mg/mL	  and	  50	  µL	  of	  33mer	  ssDNA	  (IDT	  DNA,	  see	  appendix	  X	  for	  ssDNA	  
sequences	  used)	  at	  200	  µM	  were	  desalting	  using	  a	  0.5mL	  Zeba	  column	  (Life	  Technologies).	  Next,	  1uL	  of	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200mM	  succinimidyl	  4-­‐formylbenzoate	  (S-­‐4FB,	  Solulink)	  in	  N,N-­‐dimethylformamide	  (DMF)	  was	  mixed	  
with	  the	  DNA,	  and	  2.2	  µL	  of	  40mM	  succinimidyl	  4-­‐hydrazinonicotinate	  acetone	  hydrazone	  (SANH,	  
Solulink)	  in	  DMF	  with	  the	  antibody.	  Furthermore,	  10	  µL	  of	  DMF	  was	  added	  to	  the	  DNA	  solution	  to	  
increase	  S-­‐4FB	  solubility.	  The	  solutions	  were	  incubated	  at	  room	  temperature	  for	  2	  hrs.	  	  
	   After	  the	  incubation,	  both	  antibody	  and	  DNA	  solutions	  were	  desalted	  again	  with	  a	  Zeba	  column	  
and	  buffer	  exchanged	  into	  pH	  =	  6.0	  citrate	  buffer.	  The	  solutions	  were	  then	  mixed	  and	  allowed	  to	  
incubate	  at	  room	  temperature	  for	  16-­‐18	  hours.	  The	  mixture	  was	  then	  purified	  in	  a	  fast	  protein	  liquid	  
chromatography	  (ÄKTAFPLC,	  GE	  Healthcare).	  	  
2.2.2  -­‐  Spotted  DNA  Microarrays  
	   Patterning	  ssDNA	  for	  the	  DEAL	  antibody	  conjugate	  to	  bind	  to	  was	  accomplished	  using	  a	  non-­‐
contact	  microarray	  printer	  (Sprint	  Inkjet	  Microarrayer,	  Arrayjet).	  ssDNA	  was	  mixed	  in	  either	  ArrayJet	  
Nucleic	  Acid	  Printing	  Buffer	  or	  50%	  Dimethylsulfoxide	  (DMSO)	  in	  water.	  	  
For	  the	  ArrayJet	  Nucleic	  Acid	  Printing	  Buffer,	  10	  µL	  of	  400	  uM	  DNA	  in	  water	  was	  mixed	  15	  µL	  of	  
deionized	  water	  and	  25	  mL	  of	  2x	  Arrayjet	  Nucleic	  Acid	  Printing	  Buffer.	  The	  solution	  was	  mixed	  
thoroughly	  and	  loaded	  into	  the	  ArrayJet	  Microarray	  printer.	  The	  ssDNA	  was	  printed	  on	  poly-­‐L-­‐Lysine	  
slides	  (Thermo	  Scientific)	  and	  allowed	  to	  sit	  overnight	  to	  incubate.	  Next,	  the	  slides	  were	  exposed	  to	  60	  
mJ/cm2	  using	  a	  VWR	  UV-­‐Crosslinker	  [32].	  The	  slides	  were	  then	  stored	  in	  a	  dessicator.	  	  
Slides	  patterned	  with	  50%	  DMSO	  in	  water	  were	  patterned	  in	  a	  similar	  fashion	  to	  the	  ArrayJet	  
nucleic	  acid	  printing	  buffer;	  however,	  ssDNA	  was	  printed	  on	  GAPS	  II	  slides	  (Corning)	  and	  were	  then	  
baked	  for	  2	  hrs	  at	  70	  °C	  after	  overnight	  incubation,	  rather	  than	  exposing	  to	  UV.	  They	  were	  also	  stored	  in	  
a	  dessicator	  until	  use.	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Prior	  to	  their	  use	  in	  an	  ELISA,	  the	  slides	  were	  washed	  with	  either	  PBS	  buffer	  or	  0.02%	  sodium	  
dodecyl	  sulfate	  (SDS)	  in	  water.	  Slides	  were	  dunked	  5x	  in	  the	  PBS	  or	  SDS	  solution	  and	  then	  three	  times	  in	  
deionized	  water.	  
2.2.3  -­‐  PDMS  microwells  
	   	  Polydimethylsiloxane	  (PDMS)	  was	  used	  to	  create	  microwells	  for	  the	  ELISAs.	  PDMS	  was	  made	  
using	  Sylgard	  184	  (Dow	  Corning)	  at	  a	  ratio	  of	  1	  (Part	  B)	  to	  10	  (Part	  A).	  The	  PDMS	  was	  mixed	  thoroughly	  
and	  poured	  onto	  a	  chlorotrimethylsilane	  treated	  silicon	  wafer	  placed	  in	  a	  petri	  dish.	  The	  PDMS	  was	  then	  
cured	  for	  2	  hrs	  at	  80	  °C	  and	  cut	  out	  with	  a	  scalpel.	  Microwells	  were	  created	  using	  a	  3mm	  biopsy	  punch	  
or	  cut	  out	  with	  a	  scalpel.	  	  
	   Prior	  to	  testing,	  the	  PDMS	  was	  washed	  with	  70%	  ethanol	  in	  water	  and	  dried.	  The	  bottom	  surface	  
was	  cleaned	  with	  scotch	  tape	  before	  adhering	  to	  the	  spotted	  DNA	  microarray	  slide.	  	  
2.2.4  -­‐  Running  an  ELISA  test  
	   A	  blocking	  solution	  was	  made	  by	  mixing	  ~450	  mg	  of	  Bovine	  Serum	  Albumin	  (Sigma)	  in	  15	  mL	  of	  
PBS	  (Irvine	  Scientific).	  30-­‐40	  µL	  of	  this	  3%	  BSA	  solution	  was	  added	  to	  each	  microwell	  and	  allowed	  to	  
incubate	  for	  1	  hr	  at	  37	  °C.	  The	  BSA	  was	  removed	  by	  pipetting	  and	  30	  µL	  of	  the	  DEAL	  antibody	  conjugates	  
was	  added	  after	  diluting	  DEAL	  conjugates	  1:50	  in	  3%	  BSA	  (final	  concentration	  of	  100	  ug/mL).	  This	  was	  
incubated	  for	  1.5	  hours	  at	  37	  °C.	  The	  wells	  were	  then	  washed	  three	  times	  with	  BSA,	  and	  30uL	  of	  the	  
protein	  solution	  or	  patient	  serum	  was	  added	  to	  the	  well.	  This	  was	  incubated	  for	  1	  hr.	  The	  wells	  were	  
then	  washed	  three	  times	  with	  BSA	  and	  incubated	  with	  BSA	  for	  15	  min.	  Biotinylated	  secondary	  
antibodies	  were	  diluted	  1:150	  and	  added	  to	  the	  wells	  after	  washing.	  This	  was	  then	  incubated	  for	  1	  hr	  on	  
an	  orbital	  shaker	  at	  37	  °C.	  The	  wells	  were	  washed	  again	  with	  BSA	  three	  times.	  A	  0.5	  mg/mL	  solution	  of	  
Streptavidin-­‐Cy5	  (eBioscience)	  and	  10	  µM	  solution	  of	  Cy3	  conjugated	  ssDNA	  was	  added	  at	  a	  1:100	  
dilution.	  The	  ssDNA	  was	  complementary	  to	  a	  specific	  ssDNA	  barcode,	  which	  would	  then	  become	  the	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reference	  feature.	  Finally,	  the	  wells	  were	  washed	  three	  times	  with	  BSA	  and	  the	  PDMS	  was	  removed	  
from	  the	  slide.	  The	  slides	  were	  then	  dunked	  in	  PBS/0.05%	  Tween-­‐20	  three	  times	  and	  deionized	  water	  
once.	  Slides	  were	  then	  dried	  on	  a	  slide	  spinner	  and	  scanned	  on	  a	  Genepix	  4400A	  scanner.	  	  
	   Data	  was	  gathered	  using	  the	  Genepix	  Pro	  7	  program	  using	  the	  block	  finding	  method.	  The	  blocks	  
consisted	  of	  circle	  regions	  of	  interest	  (ROI)	  that	  were	  aligned	  with	  the	  spotted	  DNA	  features.	  The	  
average	  of	  these	  blocks	  was	  calculated	  automatically	  and	  exported	  to	  an	  excel	  file	  for	  data	  analysis.	  	  
2.2.5  -­‐  Optimizing  Blood  Protein  Measurements  
	   The	  selectivity	  of	  the	  ELISAs	  was	  optimized	  by	  performing	  cross-­‐talk	  checks	  for	  all	  DEAL	  antibody	  
conjugates.	  This	  was	  accomplished	  by	  running	  an	  ELISA	  test,	  as	  described	  in	  Chapter	  2.2.4,	  using	  a	  
mixture	  of	  recombinant	  proteins.	  The	  recombinant	  proteins	  tested	  were	  MIF,	  VEGFR2,	  HGF,	  mouse	  IL-­‐2	  
(mIL-­‐2),	  IL-­‐2,	  IL-­‐13,	  VEGF,	  IL-­‐6,	  mIL-­‐3,	  CXCL13,	  and	  TGFa.	  The	  protein	  concentrations	  were	  all	  10	  ng/mL,	  
except	  HGF,	  which	  was	  at	  50	  ng/mL.	  This	  ELISA	  test	  determined	  cross-­‐reactivity	  of	  the	  secondary	  
detection	  antibodies,	  which	  are	  polyclonal	  and	  tend	  to	  be	  promiscuous.	  In	  the	  test,	  DEAL	  antibody	  
conjugates	  for	  all	  proteins	  were	  added	  to	  11	  different	  wells	  (one	  per	  protein),	  along	  with	  the	  mixture	  of	  
all	  recombinant	  proteins.	  During	  the	  secondary	  antibody	  step,	  only	  one	  secondary	  antibody	  was	  added	  
per	  well.	  The	  slides	  were	  scanned	  and	  the	  signal	  of	  each	  protein	  was	  measured	  in	  each	  well.	  Any	  signal	  
found	  from	  a	  protein	  that	  exceeded	  an	  acceptable	  background	  level	  (determined	  from	  the	  average	  of	  
non-­‐contaminated	  spots	  plus	  two	  standard	  deviations)	  was	  deemed	  “cross-­‐talk.”	  	  
	   	  The	  reproducibility	  of	  the	  ELISAs	  was	  tested	  by	  running	  tests	  with	  the	  same	  sample	  under	  
different	  conditions.	  These	  different	  conditions	  included:	  different	  microwells	  in	  the	  PDMS,	  different	  
DNA	  microarray	  slides	  on	  the	  same	  day,	  different	  slides	  on	  different	  days,	  and	  different	  test	  operators.	  
The	  standard	  recombinant	  sample	  with	  the	  11	  proteins	  from	  Chapter	  2.2.5	  was	  used	  for	  the	  tests.	  The	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protein	  intensities	  were	  measured	  under	  each	  of	  these	  conditions	  and	  the	  coefficient	  of	  variation	  (CV%)	  
was	  calculated	  to	  determine	  how	  much	  variation	  each	  condition	  incurred.	  	  
2.2.6  -­‐  Running  GBM  patient  samples  
Blood	  samples	  were	  collected	  at	  UCLA	  using	  standard	  phlebotomy	  techniques.	  10mL	  collection	  
tubes	  coated	  with	  ACD-­‐A	  anticoagulant	  were	  used	  (BD	  Vacutainer).	  The	  tubes	  were	  centrifuged	  for	  15	  
minutes	  at	  1500	  xg	  and	  plasma	  was	  collected	  and	  aliquot	  at	  200	  µL	  into	  cryovials.	  The	  cryovials	  were	  
frozen	  at	  -­‐80	  °C	  until	  the	  day	  of	  testing.	  	  
The	  ELISAs	  were	  performed	  as	  described	  in	  Chapter	  2.2.4,	  with	  the	  proteins	  listed	  in	  Appendix	  B,	  
Table	  1.	  Patient	  tumors	  were	  classified	  by	  Dr.	  Tim	  Cloughesy	  as	  “Growth”	  and	  “No	  Growth”	  using	  brain	  
scans.	  	  
2.2.7  -­‐  Statistical  Learning  
	   The	  data	  consisted	  of	  n=92	  samples	  from	  20	  different	  patients	  and	  p=35	  proteins	  (see	  full	  list	  of	  
proteins	  in	  Appendix	  X).	  There	  were	  two	  different	  types	  of	  data;	  “Raw”	  and	  “Background	  Subtracted.”	  If	  
not	  specified	  explicitly,	  the	  “Background	  Subtracted”	  dataset	  was	  used	  for	  analysis.	  	  
2.2.7.1  -­‐  Distribution  comparisons    
	   To	  determine	  if	  a	  protein	  was	  expressed	  at	  significantly	  different	  levels	  between	  patients	  who	  
were	  responding	  to	  the	  drug	  (No	  Growth)	  versus	  patients	  not	  responding	  (Growth),	  a	  non-­‐paired	  Mann-­‐
Whitney	  U-­‐Test	  was	  performed	  using	  the	  ranksum()	  function	  in	  Matlab.	  The	  p-­‐values	  were	  calculated	  
and	  scaled	  using	  the	  Bonferroni	  correction	  [33].	  	  
2.2.7.2  -­‐  Logistic  Regression  
	   To	  generate	  a	  statistical	  learning	  model,	  logistic	  regression	  was	  used	  in	  R	  (R	  Project	  for	  Statistical	  
Computing).	  Logistic	  regression	  fits	  binary	  data	  to	  a	  logit	  curve.	  It	  is	  an	  extension	  of	  ordinary	  linear	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regression,	  with	  the	  addition	  of	  a	  link	  function	  and	  no	  necessity	  for	  normally	  distributed	  data	  [34].	  The	  
logistic	  curve	  was	  fit	  to	  the	  patient’s	  response	  to	  the	  drug,	  where	  “Growth”	  =	  1	  and	  “No	  Growth”	  =	  0.	  An	  
algorithm	  was	  developed	  around	  the	  logistic	  curve	  fitting	  as	  shown	  schematically	  in	  Figure	  1.	  After	  
measuring	  the	  protein	  levels	  for	  all	  patients,	  the	  data	  was	  pre-­‐processed.	  This	  included	  background	  
subtraction,	  checking	  for	  missing	  data,	  and	  removing	  patients	  that	  lacked	  drug-­‐response	  data.	  At	  this	  
point,	  the	  algorithm	  randomly	  picks	  a	  subset	  with	  30%	  of	  the	  total	  protein	  predictors.	  The	  patients	  were	  
then	  split	  into	  two	  different	  sets	  (without	  replacement):	  the	  training	  and	  test	  set.	  The	  training	  set	  was	  
80%	  of	  the	  samples	  and	  the	  test	  was	  the	  remaining	  20%.	  The	  training	  set	  was	  plugged	  into	  the	  glm()	  
function	  in	  R.	  Predictions	  for	  the	  test	  set	  were	  then	  calculated	  using	  the	  predict()	  function,	  which	  were	  
then	  compared	  to	  their	  actual	  values	  to	  obtain	  prediction	  quality	  values	  (e.g.,	  accuracy,	  sensitivity,	  
specificity,	  positive	  predictive	  value,	  area	  under	  the	  curve,	  etc.).	  	  
	  
Figure	  1:	  Flow	  chart	  of	  Logistic	  regression	  program.	  This	  method	  was	  used	  to	  find	  the	  optimum	  panel	  of	  proteins	  to	  predict	  
whether	  patients	  had	  growing	  or	  shrinking	  tumors	  in	  response	  to	  Bevacizumab.	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   The	  program	  then	  stores	  information	  about	  these	  quality	  parameters	  about	  the	  current	  model,	  
including	  accuracy,	  sensitivity,	  specificity,	  positive	  and	  negative	  predictive	  value,	  and	  AUC	  was	  calculated	  
by	  integrating	  underneath	  a	  Receiver	  Operating	  Characteristic	  (ROC)	  curve,	  which	  is	  a	  plot	  of	  1-­‐	  
specificity	  vs.	  sensitivity.	  This	  accuracy	  was	  then	  stored	  in	  a	  dataset	  along	  with	  which	  proteins	  were	  used	  
in	  that	  LR	  model.	  The	  algorithm	  then	  creates	  a	  new	  randomized	  set	  of	  training	  and	  test	  samples,	  as	  well	  
as	  a	  new	  random	  subset	  of	  predictors.	  This	  process	  was	  then	  repeated	  10,000	  times	  to	  build	  a	  large	  
dataset.	  	  
	   These	  results	  were	  then	  analyzed	  to	  determine	  which	  proteins	  were	  present	  in	  protein	  panels	  
that	  predicted	  with	  an	  accuracy	  higher	  than	  that	  of	  the	  average	  accuracy	  of	  protein	  panels.	  This	  led	  to	  a	  
subset	  panel	  of	  the	  best	  predicting	  3-­‐5	  proteins,	  which	  were	  then	  tested	  using	  the	  logistic	  regression	  
model	  on	  a	  test	  set	  using	  a	  bagging	  method	  to	  obtain	  a	  final	  prediction	  for	  each	  patient	  [34].	  
	   Throughout	  this	  algorithm,	  the	  studentized	  residual	  (rstudent)	  of	  each	  patient	  was	  logged	  and	  
patients	  with	  rstudent	  values	  larger	  than	  2.5-­‐3	  in	  more	  than	  50%	  of	  models	  were	  removed	  as	  outliers	  
[34].	  	   	  	  
2.2.7.3  -­‐  Ensemble  method  
	   An	  ensemble	  model	  was	  created	  to	  improve	  the	  accuracy	  of	  prediction	  with	  the	  cost	  of	  
interpretability	  [35].	  The	  ensemble	  model	  used	  three	  different	  statistical	  learning	  methods	  to	  predict	  
whether	  a	  patient	  would	  respond	  to	  the	  drug:	  k-­‐Nearest	  Neighbors	  (kNN),	  Logistic	  Regression	  (LR),	  and	  
Random	  Forrest	  (RF).	  The	  models	  were	  trained	  in	  a	  similar	  fashion	  to	  the	  LR	  model	  in	  Chapter	  2.2.6.2;	  
however,	  the	  experimental	  flow	  was	  slightly	  different	  (Figure	  2).	  After	  obtaining	  predictions	  from	  each	  
model,	  they	  were	  correlated	  to	  determine	  how	  similar	  the	  model	  predictions	  were.	  If	  correlations	  
exceed	  0.7-­‐0.8	  for	  the	  models,	  then	  their	  average,	  or	  ensemble	  prediction,	  has	  little	  difference	  from	  the	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individual	  predictions.	  The	  predictions	  were	  then	  averaged	  and	  weighted	  to	  obtain	  a	  final	  prediction.	  
This	  was	  used	  to	  calculate	  quality	  of	  prediction	  values.	  	  
	  
Figure	  2:	  Flow	  chart	  for	  ensemble	  learning	  method.	  This	  method	  was	  used	  to	  determine	  how	  to	  predict	  whether	  a	  patient	  had	  a	  
growing/	  non-­‐growing	  tumor	  in	  response	  to	  Bevacizumab	  treatment.	  	  
2.3  –  Results  
2.3.1  -­‐  Spotted  DNA  Microarrays  
Using	  the	  ArrayJet	  Nucleic	  Acid	  printing	  buffer	  showed	  good	  DNA	  print	  quality.	  The	  average	  
signal	  levels	  ranged	  from	  20,000	  –	  45,000	  fluorescence	  units	  (scanned	  at	  450	  gain	  and	  15%	  power),	  with	  
CV%	  across	  the	  slide	  ranging	  from	  10-­‐25%.	  However,	  the	  signal	  changed	  (or	  “aged”)	  significantly	  over	  
the	  course	  of	  one	  month,	  changing	  by	  ~32%	  per	  week	  on	  average.	  Therefore,	  emphasis	  was	  placed	  on	  
using	  50%	  DMSO	  as	  a	  printing	  buffer.	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   The	  slide	  “aging”	  issue	  with	  50%	  DMSO	  was	  much	  lower	  than	  with	  ArrayJet.	  Over	  the	  course	  of	  
one	  week,	  the	  signal	  of	  50%	  DMSO	  changed	  by	  only	  2.7%.	  Furthermore,	  the	  average	  signal	  ranged	  from	  
30,000	  –	  40,0000	  fluorescence	  units,	  which	  was	  sufficient	  for	  the	  blood	  tests.	  The	  CV%	  of	  DMSO	  was	  low	  
as	  well,	  ranging	  from	  3-­‐5%.	  
	  
Figure	  3:	  Images	  of	  printed	  DNA	  microarrays	  under	  different	  washing	  conditions.	  a)	  Washed	  with	  0.02%	  SDS.	  b)	  Washed	  once	  
with	  PBS.	  
	  	  
With	  the	  50%	  DMSO	  printed	  DNA,	  washing	  with	  0.02%	  SDS	  reduced	  streaking	  of	  the	  DNA	  
compared	  to	  PBS	  (Figure	  3).	  Therefore,	  0.02%	  SDS	  was	  used	  as	  the	  primary	  wash	  solution.	  
2.3.2  -­‐  Optimizing  Blood  Protein  Measurements  
The	  selectivity	  of	  the	  tests	  was	  optimized	  by	  running	  a	  cross-­‐talk	  check	  with	  all	  proteins.	  Figure	  4	  
shows	  a	  truncated	  list	  of	  proteins	  from	  the	  cross-­‐talk	  check.	  VEGF	  and	  VEGFR2	  have	  nonspecific	  
background,	  which	  can	  be	  subtracted	  out	  before	  data	  analysis.	  Otherwise,	  it	  can	  be	  visually	  observed	  
that	  only	  mIL-­‐2	  and	  IL-­‐2	  crosstalk.	  The	  crosstalk	  of	  IL-­‐2	  and	  mIL-­‐2	  was	  then	  tested	  under	  different	  
temperature	  conditions	  (Figure	  5).	  It	  was	  observed	  that	  at	  room	  temperature,	  the	  cross-­‐talk	  was	  7.8%,	  




Figure	  4:	  Truncated	  panel	  of	  protein	  crosstalk.	  The	  diagonal	  shows	  the	  signal	  of	  each	  protein	  measured	  at	  10	  µg/mL	  (or	  50	  
µg.mL	  for	  HGF).	  The	  off	  diagonal	  component	  show	  the	  protein	  cross-­‐talk.	  The	  recombinant	  protein	  that	  was	  introduced	  in	  each	  
well	  is	  shown	  in	  the	  rows.	  The	  protein	  that	  was	  measured	  for	  is	  shown	  in	  the	  columns.	  Ex:	  When	  VEGF	  was	  introduced,	  all	  
proteins	  shown	  slight	  signal	  when	  measured.	  	  
	  




The	  reproducibility	  of	  the	  test	  was	  measured	  for	  multiple	  conditions,	  which	  are	  summarized	  in	  
Table	  1.	  The	  CV%	  between	  different	  users	  was	  the	  most	  variable	  at	  22%.	  This	  was	  well	  within	  the	  range	  
to	  yield	  accurate	  protein	  measurements	  [36].	  The	  device	  reproducibility	  was	  good,	  with	  CV%	  for	  
proteins	  being	  less	  than	  10%.	  CV%	  from	  different	  repeats	  most	  likely	  came	  from	  the	  slight	  difference	  in	  
DNA	  spot	  leading.	  These	  variations	  were	  reduced	  when	  signal	  was	  averaged	  in	  a	  well,	  since	  the	  well-­‐to-­‐
well	  variation	  was	  lower.	  	  
Table	  1:	  Variations	  in	  protein	  measurements	  under	  different	  conditions.	  
	   Average	  %	  CV	  
of	  Cy3	  Signal	  
Average	  %	  CV	  of	  Protein	  
Signal	  (p=4	  proteins)	  
Different	  Repeats	   12.28	   17.7	  
Different	  Wells	   6.32	   12.9	  
Different	  Devices	  (Different	  
Days,	  Same	  User)	  
3.5	   6.7	  
Different	  Users	  (Same	  Day)	   	   22	  
	  
2.3.3  -­‐  Measuring  patient  samples  
Patient	  information	  is	  listed	  in	  Appendix	  A	  Table	  1.	  The	  protein	  measurement	  dataset	  contained	  
n=92	  patient	  samples	  from	  20	  unique	  patients	  at	  different	  time	  points,	  and	  p	  =	  35	  proteins.	  On	  average,	  
the	  patient	  blood	  samples	  were	  collected	  24	  days	  after	  the	  start	  of	  the	  drug	  treatment.	  	  
2.3.4  -­‐  Statistical  Learning  
2.3.4.1  -­‐  Statistically  significant  proteins  
Box	  plots	  of	  select	  protein	  levels	  –	  gated	  on	  tumor	  Growth	  vs.	  No	  Growth	  –	  are	  shown	  in	  Figure	  6.	  A	  full	  
list	  of	  protein	  significance	  values	  are	  shown	  in	  Appendix	  A	  Table	  2.	  Because	  35	  proteins	  were	  tested	  for	  
significance	  at	  one	  time,	  the	  Bonferroni	  Correction	  was	  applied	  and	  the	  true	  significance	  was	  set	  at	  p	  =	  
0.0014	  [33].	  Using	  this	  correction,	  the	  only	  proteins	  that	  showed	  significantly	  different	  levels	  between	  




Figure	  6:	  Box	  plots	  of	  select	  proteins,	  gated	  on	  Growth	  (1)	  or	  No	  Growth	  (0).	  Data	  is	  from	  the	  background	  subtracted	  dataset.	  
Significance	  indicators	  are	  shown	  above	  the	  box	  plots.	  Significance	  thresholds	  are	  lower	  than	  normal	  due	  to	  the	  Bonferroni	  
correction.	  Significance	  markers:	  *	  =	  p	  <	  0.001,	  **	  =	  p	  <	  0.0001.	  
2.3.4.2  -­‐  Logistic  Regression  
	   Before	  fitting	  to	  a	  logistic	  regression	  curve,	  the	  correlation	  matrix	  was	  investigated	  for	  signs	  of	  
collinearity.	  The	  heatmap	  of	  the	  correlation	  matrix	  is	  shown	  in	  Appendix	  A,	  Figure	  2.	  There	  were	  three	  
instances	  of	  collinearity	  in	  the	  data:	  C3	  and	  EGF,	  VEGF	  and	  IL.12,	  and	  MMP2	  and	  IL.1b.	  In	  each	  of	  these	  
cases,	  one	  protein	  was	  removed	  in	  order	  to	  reduce	  the	  chance	  of	  collinearity	  affecting	  standard	  error	  
measurements.	  	  	  
From	  developing	  the	  logistic	  regression	  model,	  it	  was	  found	  that	  the	  bootstrap	  accuracy	  of	  
prediction	  using	  all	  35	  proteins	  was	  73.9%.	  The	  AUC	  was	  0.721,	  which	  is	  generally	  considered	  a	  “C	  
grade”	  in	  a	  standard	  school	  grading	  scale	  [37,	  38].	  The	  full	  list	  of	  prediction	  quality	  values	  for	  the	  
complete	  panel	  of	  proteins	  is	  listed	  in	  Table	  2,	  labeled	  “LR	  Model	  (35	  Proteins).”	  Furthermore,	  a	  subset	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of	  the	  patients	  were	  removed	  as	  outliers	  because	  they	  were	  above	  the	  r-­‐student	  outlier	  threshold	  [34].	  
Three	  of	  92	  patients	  were	  removed,	  resulting	  in	  a	  loss	  of	  ~3%	  of	  the	  total	  patient	  data.	  This	  samples	  
were	  left	  out	  of	  subsequent	  analyses.	  	  
Table	  2:	  Statistical	  learning	  model	  results	  for	  background	  subtracted	  dataset.	  
Model	  Name	  
(Background	  Subtracted)	  
Bagging	  Accuracy	  (%)	   Sensitivity	  (%)	   Specificity	  (%)	   PPV	  (%)	   NPV	  (%)	   AUC	  
LR	  Model	  
(35	  Proteins)	  
73.9	   58.4	   72.7	   59.1	   72.1	   0.751	  
LR	  Model	  
(5	  Proteins)	  
85.2	   75.0	   91.9	   85.8	   84.9	   0.901	  
kNN	   72.3	   50.0	   87.5	   72.2	   72.8	   	  
Random	  Forrest	   75.3	   65.0	   81.9	   70.2	   78.1	   	  
Ensemble	  Model	  	   86.5	   84.8	   87.5	   80	   90.7	   	  
	  
After	  optimization,	  five	  proteins	  were	  found	  to	  be	  significant	  predictors	  in	  the	  fit.	  These	  proteins	  
are	  listed	  in	  Table	  3,	  along	  with	  their	  significance	  values	  and	  coefficient	  weights.	  The	  bootstrap	  accuracy	  
was	  85.2%	  and	  the	  AUC	  was	  0.901.	  The	  complete	  list	  of	  quality	  parameters	  for	  this	  LR	  model	  are	  listed	  in	  
Table	  2,	  under	  the	  row	  label	  “LR	  Model	  (5	  Proteins).”	  This	  AUC	  is	  much	  higher	  than	  with	  the	  full	  protein	  
panel,	  indicating	  a	  better	  model	  fit.	  	  
Table	  3:	  List	  of	  protein	  predictor	  coefficients	  and	  significance	  values	  for	  LR	  mode	  (5	  Proteins).	  Significance	  markers:	  *	  =	  p	  <	  0.05,	  
.	  	  =	  p	  <	  0.1.	  
Protein	  Name	   p-­‐value	   Significance	   Avg.	  Coeff.	  
Weight	  
VEGF	   0.0231	   *	   5.21	  
VEGFR2	   0.00946	   *	   -­‐5.67	  
TGFb1	   0.00707	   *	   5.33	  
IL-­‐2	   0.0113	   *	   -­‐3.51	  
C3	   0.101	   .	   1.98	  
	  
2.3.4.3  –  Ensemble  Method  
The	  prediction	  accuracy	  of	  the	  three	  ensemble	  models	  was	  86.5%,	  75.3%,	  and	  74.1%	  for	  the	  LR,	  
kNN,	  and	  RF	  models,	  respectively.	  The	  correlation	  table	  of	  their	  predictions	  is	  shown	  in	  Table	  4,	  with	  no	  
correlation	  exceeding	  0.574.	  These	  correlations	  were	  low	  enough	  to	  perform	  an	  ensemble	  prediction.	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Table	  4:	  Correlation	  table	  of	  ensemble	  predictions.	  	  
Ensemble	  
Correlations	   LR	   kNN	   RF	  
LR	   1	   0.556	   0.456	  
kNN	   0.556	   1	   0.574	  
RF	   0.456	   0.574	   1	  
	  
The	  quality	  parameters	  for	  the	  ensemble	  model	  are	  shown	  in	  Table	  1,	  under	  the	  row	  labeled	  
“Ensemble	  Model.”	  	  
2.4  -­‐  Discussion  
Though	  the	  CV%	  of	  protein	  measurements	  were	  typically	  lower	  than	  20%	  in	  our	  experiments,	  it	  
would	  be	  desirable	  to	  reduce	  their	  values	  to	  10%	  or	  lower.	  According	  to	  Reed	  et	  al.,	  a	  CV%	  of	  20%	  in	  a	  
protein	  measurement	  will	  be	  off	  by	  a	  factor	  of	  1.5x	  ~15%	  of	  the	  time	  and	  off	  by	  a	  factor	  of	  2x	  ~2%	  of	  the	  
time	  [36].	  However,	  if	  our	  CV%	  was	  reduced	  to	  10%,	  the	  chance	  of	  being	  off	  by	  a	  factor	  of	  1.5x	  or	  2x	  
goes	  to	  ~0%.	  	  
In	  our	  study,	  HGF	  was	  found	  to	  be	  upregulated	  in	  the	  patients	  with	  tumor	  growth	  relative	  to	  
those	  with	  no	  growth.	  It	  has	  previously	  been	  observed	  in	  colorectal	  cancer	  that	  HGF	  increases	  with	  
tumor	  growth	  during	  anti-­‐VEGF	  therapy	  [39].	  HGF	  is	  responsible	  for	  many	  functions,	  including	  cell	  
mobility,	  angiogenesis,	  and	  cell	  growth	  [40].	  It	  is	  secreted	  from	  mesenchymal	  cells,	  which	  was	  
interesting	  in	  respect	  to	  its	  strong	  correlation	  with	  TGFb1.	  This	  is	  because	  TGFb1	  is	  secreted	  primarily	  by	  
leukocytes,	  rather	  than	  mesenchymal	  cells	  [41].	  Their	  correlation	  was	  likely	  indirectly	  correlated	  through	  
regulatory	  mechanisms.	  TGFb1	  has	  very	  similar	  functions	  in	  the	  body	  as	  HGF.	  Therefore,	  it	  is	  possible	  
that	  general	  regulatory	  mechanisms	  for	  cell	  growth,	  cell	  mobility,	  and	  angiogenesis	  caused	  their	  levels	  
to	  become	  correlated.	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Our	  results	  show	  promise	  in	  predicting	  whether	  a	  GBM	  patient	  was	  responding	  to	  Bevacizumab	  
treatment.	  Both	  the	  logistic	  regression	  and	  ensemble	  models	  predicting	  with	  greater	  than	  80%	  accuracy.	  
The	  quality	  of	  the	  predictions	  obtained	  were	  comparable	  to	  other	  protein	  biomarker	  diagnostics.	  In	  
various	  studies	  of	  early	  detection	  of	  breast	  cancer,	  sensitivity/specificity	  ranged	  from	  80	  to	  100%	  [42].	  
The	  ensemble	  model	  did	  have	  a	  significantly	  higher	  sensitivity	  than	  the	  individual	  models,	  meaning	  it	  
was	  better	  able	  to	  pick	  out	  true	  positives	  (tumor	  growth)	  as	  positive.	  In	  our	  case,	  this	  is	  more	  important,	  
since	  these	  patients	  are	  the	  ones	  we	  want	  to	  catch	  early	  in	  order	  to	  stop	  treatment.	  Therefore,	  in	  the	  
real	  world	  setting,	  the	  ensemble	  model	  would	  be	  chosen,	  rather	  than	  the	  LR	  model.	  
The	  LR	  model	  yielded	  good	  results,	  with	  an	  AUC	  >	  0.9,	  which	  is	  equivalent	  to	  an	  “A”	  grade	  in	  a	  
standard	  grading	  scale	  [37].	  The	  validity	  of	  this	  model	  was	  supported	  by	  the	  fact	  that	  two	  of	  the	  
predictors	  in	  the	  model,	  TGFb1	  and	  VEGFR2,	  were	  significantly	  distinguishable	  between	  the	  Growth	  and	  
No	  Growth	  groups.	  	  
Two	  immune	  proteins	  were	  found	  to	  be	  predictive	  in	  the	  logistic	  regression	  model:	  IL-­‐2	  and	  C3.	  
None	  of	  these	  proteins	  were	  expressed	  to	  significantly	  different	  levels	  on	  their	  own.	  However,	  they	  both	  
had	  low	  standard	  error	  values	  in	  the	  logistic	  regression	  model,	  indicating	  they	  had	  a	  relationship	  with	  
the	  patient	  outcome.	  C3	  had	  a	  positive	  coefficient,	  meaning	  an	  increase	  in	  its	  levels	  predicts	  a	  worse	  
outcome,	  whereas	  IL-­‐2	  had	  a	  negative	  coefficient,	  meaning	  an	  increase	  predicts	  a	  better	  outcome.	  
Because	  logistic	  regression	  model	  coefficients	  give	  the	  relationship	  between	  a	  single	  protein,	  with	  all	  
others	  held	  constant,	  we	  can	  make	  hypotheses	  as	  to	  how	  each	  predictor	  weight	  may	  be	  related	  to	  
patient	  response	  [34].	  	  
High	  levels	  of	  C3	  would	  indicate	  the	  innate	  immune	  system	  is	  active	  [43].	  This	  is	  at	  its	  highest	  
during	  the	  initiation	  of	  an	  adaptive	  immune	  response.	  Therefore,	  the	  positive	  correlation	  between	  C3	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levels	  and	  tumor	  growth	  may	  be	  because	  the	  patient’s	  immune	  system	  is	  still	  in	  its	  initial	  stages	  of	  
launching	  an	  immune	  response	  towards	  the	  tumor,	  or	  perhaps	  is	  stagnated	  at	  that	  stage.	  	  
High	  levels	  of	  IL-­‐2	  would	  indicate	  T	  cell	  expansion	  during	  the	  initiation	  of	  a	  Type	  I	  immune	  
response.	  Because	  our	  model	  showed	  that	  higher	  levels	  of	  IL-­‐2	  is	  a	  predictor	  of	  “No	  Growth,”	  this	  could	  
imply	  that	  adaptive	  immunity	  is	  a	  positive	  correlator	  with	  tumor	  reduction	  in	  Bevacizumab	  treatment	  of	  
GBM.	  IL-­‐2	  has	  previously	  been	  observed	  to	  cause	  tumor	  reduction	  in	  GBM,	  though	  most	  references	  on	  
this	  topic	  come	  from	  the	  1990s	  [44,	  45].	  	  	  
It	  was	  observed	  that	  VEGF	  was	  a	  positive	  predictor	  in	  the	  LR	  model,	  which	  means	  high	  levels	  
indicate	  a	  progressing	  tumor.	  Intuitively,	  this	  makes	  sense:	  if	  VEGF	  is	  higher,	  one	  expects	  the	  tumor	  to	  
have	  more	  blood	  vessels	  and	  be	  growing	  faster.	  This	  observation	  has	  been	  seen	  in	  multiple	  studies	  
predicting	  patient	  response	  via	  VEGF	  levels	  [46,	  47].	  
TGFb1	  and	  VEGFR2	  were	  the	  most	  discriminating	  proteins	  between	  growth	  and	  no-­‐growth	  and	  
were	  best	  predictors	  in	  the	  LR	  model.	  We	  observed	  that	  TGFb1	  was	  overexpressed	  in	  the	  GBM	  patients	  
with	  growing	  tumors,	  and	  consequently	  was	  a	  positive	  predictor	  in	  the	  LR	  model	  (increased	  level	  
indicated	  the	  patient	  was	  more	  likely	  to	  have	  a	  growing	  tumor).	  Normally,	  TGFb1	  has	  many	  roles,	  
including	  a	  cell	  proliferation	  regulator,	  immunosuppressor,	  extra	  cellular	  membrane	  remodeler,	  and	  
angiogenesis	  promoter	  [48,	  49,	  50].	  It	  has	  been	  shown	  to	  promote	  cancer	  growth	  by	  suppressing	  NK	  
cells,	  which	  enhances	  tumor	  cell	  metastasis	  [51,	  52].	  Furthermore,	  increased	  levels	  of	  TGFb1	  have	  been	  
documented	  in	  colorectal,	  prostate,	  bladder,	  liver,	  and	  brain	  cancers	  like	  GBM	  [53,	  50].	  Therefore,	  it	  is	  
logical	  that	  TGFb1	  is	  a	  positive	  predictor	  for	  tumor	  growth	  in	  GBM.	  	  
We	  observed	  that	  VEGFR2	  was	  underexpressed	  in	  patients	  with	  growing	  tumors	  and	  it	  was	  a	  
negative	  predictor	  in	  the	  LR	  model.	  This	  indicates	  that	  less	  VEGFR2	  in	  one’s	  blood	  stream	  predicts	  a	  
growing	  tumor.	  Because	  VEGFR2	  is	  a	  membrane	  receptor	  found	  on	  endothelial	  cells,	  one	  would	  typically	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not	  assume	  VEGFR2	  would	  be	  present	  in	  the	  bloodstream	  unless	  these	  cells	  were	  being	  lysed	  [54].	  
Therefore,	  if	  VEGFR2	  is	  found	  in	  the	  blood	  stream,	  this	  indicates	  that	  endothelial	  cells	  are	  being	  lysed.	  
One	  hypothesis	  is	  that	  the	  higher	  levels	  of	  VEGFR2	  in	  “No	  Growth”	  patients	  are	  coming	  from	  the	  lysed	  
tumor	  blood	  vessels.	  Their	  destruction	  would,	  in	  turn,	  starve	  the	  tumor,	  which	  we	  believe	  is	  why	  
VEGFR2	  is	  a	  negative	  predictive	  of	  tumor	  growth.	  	  
An	  alternative	  to	  this	  hypothesis	  about	  VEGFR2	  would	  be	  that	  we	  are	  measuring	  the	  soluble	  
form	  of	  VEGFR2,	  referred	  to	  as	  sVEGFR2.	  The	  role	  of	  sVEGFR2	  is	  hypothesized	  to	  be	  a	  blocking	  agent	  for	  
VEGF,	  thereby	  reducing	  angiogenesis	  [55].	  This	  makes	  sense	  in	  light	  of	  our	  results,	  since	  an	  increase	  in	  
sVEGFR2	  would	  imply	  less	  angiogenesis	  and	  slower	  tumor	  growth.	  	  
2.5  –  Conclusions  
	   Two	  statistical	  learning	  models	  were	  developed	  that	  predicted	  whether	  a	  GBM	  patient	  was	  
responding	  to	  Bevacizumab	  treatment	  with	  >80%	  accuracy.	  The	  LR	  model	  revealed	  that	  TGFb1	  and	  
VEGFR2	  were	  key	  predictors,	  with	  TGFb1	  being	  a	  positive	  predictor	  and	  VEGFR2	  being	  a	  negative	  
predictor.	  An	  ensemble	  model	  was	  developed	  using	  LR,	  kNN,	  and	  RF,	  which	  showed	  slightly	  better	  
accuracy	  than	  the	  LR	  model	  alone.	  These	  models	  have	  demonstrated	  a	  powerful	  means	  to	  predict	  
whether	  Bevacizumab	  is	  effective	  or	  not	  for	  a	  GBM	  patient.	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Figure	  1:	  Overview	  of	  DEAL	  method.	  a)	  DNA	  is	  patterned	  onto	  a	  surface	  using	  spotted	  microarray	  printer	  or	  PDMS	  template	  
(shown).	  b)	  The	  DNA	  is	  then	  attached	  to	  the	  slide	  surface.	  Different	  sequences	  of	  DNA	  are	  shown	  with	  different	  colors.	  c)	  DEAL	  
conjugates	  are	  introduced,	  which	  hybridize	  with	  the	  surface	  bound	  DNA.	  This	  converts	  the	  DNA	  array	  into	  an	  antibody	  array.	  d)	  
The	  sample’s	  proteins	  are	  captured	  by	  the	  surface	  bound	  antibodies.	  e-­‐f)	  Finally,	  biotinylated	  secondary	  antibodies	  and	  a	  






Figure	  2:	  Correlation	  of	  protein	  levels	  from	  background	  subtracted	  data.	  	  	  
	  
Appendix	  A	  Table	  1:	  Patient	  information	  of	  92	  samples	  measured.	  	  
	   Age	   Gender	   Drug	   Recurrence	  
	   Mean	   Range	   Male	   Female	   Avastin	   Avastin	  
184	  
New	   1st	   2nd	   3rd+	   N/A	  
Tumor	  
Growth	  










Appendix	  A	  Table	  2:	  Dataset	  of	  Mann-­‐Whitey	  U	  tests	  results	  of	  significance	  when	  comparing	  protein	  levels	  between	  Growth	  and	  
No-­‐Growth	  patients.	  Background	  subtracted	  dataset	  was	  used.	  	  
Protein	  Name	   p-­‐value	  
Significance	  
(Bonferroni	  
Cutoff:	  0.0014)	  	  
IL.2	   0.203	   	  
MCP1	   0.327	   	  
IL.6	   0.924	   	  
G.CSF	   0.258	   	  
MIF	   0.930	   	  
EGF	   0.738	   	  
VEGF	   0.258	   	  
PDGF	   0.493	   	  
TGFa	   0.152	   	  
IL.8	   0.239	   	  
MMP3	   0.220	   	  
HGF	   0.000979	   *	  
Cy3	   0.787	   	  
CXCL10	   0.356	   	  
CXCL12	   0.981	   	  
IGFBP2	   0.524	   	  
IGFBP5	   0.762	   	  
MIP1a	   0.00746	   .	  
TGFb1	   0.000002	   **	  
CH3L1	   0.126	   	  
VEGFR3	   0.627	   	  
TNFa	   0.627	   	  
C3	   0.297	   	  
MMP2	   0.054	   	  
IL.10	   0.738	   	  
IL.1b	   0.981	   	  
IL.12	   0.0269	   	  
MMP9	   0.054	   	  
TGFb2	   0.098	   	  
GM.CSF	   0.245	   	  
CRP	   0.949	   	  
VEGFR2	   0.000801	   *	  
IL.13	   0.0274	   	  
IL.23	   0.532	   	  
Serpin	   0.949	   	  
Fibr	   0.768	   	  
	  
Appendix	  A	  Table	  3:	  Statistical	  leaning	  model	  results	  when	  Raw	  dataset	  was	  used.	  	  
Model	  Name	  
(Raw	  Data) 
Bagging	  Accuracy	  (%) Sensitivity	  (%) Specificity	  (%) PPV	  (%) NPV	  (%) AUC	  
LR 85 83 86 77 90 0.82	  
RF 70 65 72 48 84 	  
kNN 74 73 74 52 88 	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Chapter  3:  Phenotyping  Cells  in  Microfluidic  Devices  using  a  
Photocleavable  Conjugate  
3.1  -­‐  Introduction  
Single	  cell	  proteomic	  technologies	  have	  been	  expanding	  since	  in	  the	  1970s,	  when	  fluorescence	  
activated	  cell	  sorting	  (FACS)	  was	  developed	  [1].	  Since	  then,	  FACS	  has	  seen	  great	  strides	  in	  analyzing	  cell	  
populations	  in	  a	  rapid	  and	  multiplexed	  fashion,	  with	  techniques	  like	  CyTOF	  allowing	  over	  30	  surface	  
makers	  to	  be	  tested	  simultaneously	  [2].	  In	  addition	  to	  FACS	  technologies,	  microfluidics-­‐based	  single	  cell	  
technology	  have	  become	  more	  prolific	  in	  the	  field.	  Recently,	  the	  Heath	  Lab	  measured	  multiple	  secreted	  
proteins	  from	  T	  cells	  in	  a	  microfluidic	  device	  [3,	  4].	  C.	  Love’s	  group	  investigated	  the	  temporal	  secretion	  
dynamics	  of	  T	  cells	  under	  different	  stimulation	  conditions	  [5].	  In	  this	  study,	  the	  authors	  not	  only	  
investigated	  the	  protein	  secretion	  but	  also	  the	  phenotype	  of	  each	  cell.	  This	  was	  accomplished	  using	  
fluorophore	  conjugated	  antibodies	  that	  bound	  specific	  surface	  markers.	  During	  the	  experiment,	  images	  
were	  taken	  of	  each	  single	  cell	  chamber	  using	  a	  fluorescent	  microscope	  and	  the	  cells	  phenotyped	  based	  
on	  which	  fluorophores	  were	  excited.	  This	  type	  of	  technology	  has	  been	  adapted	  in	  the	  Heath	  Lab,	  as	  
described	  in	  Chapter	  5.2.6.	  	  We	  phenotyped	  the	  cells	  in	  a	  similar	  fashion	  to	  C.	  Love’s	  group,	  which	  
allowed	  us	  to	  determine	  two	  different	  phenotypes:	  CD8+	  and	  CD4	  (CD8-­‐)	  T	  cells.	  
Phenotyping	  with	  fluorescent	  markers	  on	  a	  standard	  3	  color	  microscope	  allows	  for	  the	  
determination	  of	  8	  phenotypes	  at	  most.1	  	  This	  is	  miniscule	  relative	  to	  a	  standard	  FACS	  instrument,	  which	  
can	  measure	  >	  256	  phenotypes.	  	  Therefore,	  there	  is	  a	  need	  for	  single	  cell	  technologies	  to	  catch	  up	  to	  
FACS	  in	  terms	  of	  phenotype	  detection	  capabilities.	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  The	  equation	  for	  this	  is	  2n,	  where	  n	  is	  the	  number	  of	  fluorophores.	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One	  phenotype	  detection	  method	  developed	  by	  Weissleder	  et	  al.	  can	  detect	  nearly	  infinite	  
phenotypes	  using	  the	  detection	  of	  amplified	  DNA.	  It	  is	  performed	  as	  follows:	  1)	  antibodies	  that	  
recognize	  cell	  surface	  markers	  are	  linked	  to	  unique	  DNA	  strands,	  2)	  cells	  are	  incubated	  with	  these	  
antibody-­‐DNA	  conjugates	  and	  unbound	  antibodies	  are	  washed	  away,	  3)	  the	  DNAs	  are	  cleaved	  off	  the	  
antibodies	  and	  amplified	  via	  a	  polymerase	  chain	  reaction,	  and	  measured	  to	  identify	  which	  surface	  
markers	  were	  bound	  to	  cells	  [6].	  This	  method	  allows	  for	  the	  measurement	  of	  nearly	  unlimited	  
phenotypes,	  limited	  only	  by	  the	  number	  of	  different	  PCR	  products	  they	  can	  detect.	  Therefore,	  the	  
application	  of	  this	  technology	  to	  a	  single	  cell	  microfluidic	  platform	  would	  easily	  match	  the	  number	  of	  
phenotypes	  detected	  by	  FACS.	  	  
In	  the	  current	  chapter,	  we	  describe	  a	  method	  that	  adapts	  Weissleder’s	  phenotyping	  technique	  
with	  the	  Heath	  Lab’s	  DEAL	  method	  in	  order	  to	  detect	  complex	  phenotypes	  on	  microfluidic	  devices.	  The	  
general	  schematic	  for	  this	  is	  shown	  in	  Figure	  1.	  We	  use	  Weissleder’s	  method	  of	  binding	  antibody-­‐DNA	  
conjugates	  to	  cells	  (Figure	  1a)	  and	  then	  release	  the	  DNA	  in	  the	  microfluidic	  single	  cell	  chamber	  using	  
photocleavage	  (Figure	  1b).	  Instead	  of	  detecting	  with	  PCR,	  we	  attach	  a	  fluorophore	  to	  the	  DNA.	  This	  
ssDNA-­‐fluorophore	  is	  then	  captured	  on	  the	  surface	  bound	  ssDNA	  used	  in	  the	  DEAL	  method	  (Figure	  1c).	  
Each	  antibody	  will	  have	  a	  unique	  DNA	  and	  be	  fluorophore-­‐labeled.	  This	  will	  not	  only	  multiplex	  detection	  
of	  surface	  markers	  but	  also	  allow	  for	  its	  quantitation	  (Figure	  1d).	  Using	  this	  technique,	  we	  have	  
demonstrated	  the	  detection	  of	  surface	  bound	  streptavidin	  (SA)	  on	  protein	  coated	  beads	  and	  CD3	  on	  




Figure	  1:	  Overview	  of	  photocleavage	  conjugate	  (PC	  conjugate)	  detection	  of	  cell	  surface	  markers.	  a)	  The	  PC	  conjugate	  binds	  to	  a	  
surface	  marker	  on	  a	  cell.	  b)	  The	  cell	  is	  then	  trapped	  in	  a	  microfluidic,	  single	  cell	  chamber	  and	  UV	  is	  introduced	  to	  photocleave	  a	  
DNA-­‐fluorophore	  conjugate.	  c)	  The	  DNA-­‐fluorophore	  then	  binds	  to	  the	  slide’s	  surface,	  using	  the	  Heath	  Lab’s	  DEAL	  method.	  d)	  
Finally,	  the	  slide	  is	  scanned	  to	  obtain	  a	  fluorescence	  intensity	  for	  where	  the	  DNA-­‐fluorophore	  bound.	  	  
3.2  –  Materials  and  Methods    
3.2.1  -­‐  Synthesis  of  conjugate  
	   The	  photocleavable	  (PC)	  conjugate	  is	  synthesized	  in	  the	  same	  manner	  as	  standard	  DEAL	  
conjugates.	  This	  method	  is	  described	  in	  detail	  in	  Chapter	  2.2.1.	  The	  DNA	  used,	  however,	  is	  different	  
from	  the	  standard	  ssDNA	  used	  to	  make	  DEAL	  conjugates.	  The	  base	  ssDNA	  is	  attached	  to	  an	  internal	  Cy3,	  
an	  internal	  photocleavable	  group,	  and	  terminated	  with	  an	  amine	  group.	  The	  DNA	  is	  custom	  made	  by	  IDT	  
DNA.	  	  	  
5’-­‐Amine/Internal	  Photocleavable	  Spacer/Internal	  Cy3/Base-­‐DNA-­‐3’	  
	   In	  order	  to	  optimize	  the	  linkage	  of	  the	  DNA	  to	  antibody,	  multiple	  conditions	  were	  attempted.	  
First,	  two	  different	  amount	  of	  N,N-­‐Dimethylformaminde	  were	  added	  to	  the	  DNA	  solution	  during	  the	  
synthesis	  (10	  µL	  vs.	  20	  µL).	  This	  helps	  solubility	  when	  the	  DNA	  is	  hydrophobic.	  In	  addition,	  two	  
concentrations	  of	  DNA	  were	  tested,	  140	  µM	  and	  175	  uM.	  	  	  
	   In	  order	  to	  see	  if	  the	  PC	  conjugate	  could	  bind	  to	  surface	  proteins,	  an	  anti-­‐CD3	  PC	  conjugate	  was	  
synthesized	  and	  used	  to	  stain	  a	  J45.01	  Jurkat	  cell	  line	  (ATCC).	  The	  T	  cells	  were	  spun	  down	  for	  4	  minutes	  
at	  500xg	  to	  pellet	  them.	  Approximately	  95%	  of	  the	  solution	  was	  removed	  to	  obtain	  a	  high	  concentration	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of	  cell.	  Then	  5	  µL	  of	  PC	  conjugate	  at	  1	  µM	  was	  added	  and	  the	  cells	  were	  allowed	  to	  sit	  on	  ice	  for	  30	  
minutes.	  Afterwards,	  the	  cells	  were	  washed	  twice	  by	  diluting	  up	  with	  cold	  RPMI	  1640	  media	  (Life	  
Technologies)	  +10%	  Fetal	  Bovine	  Serum	  (FBS,	  Life	  Technologies),	  spinning	  down	  the	  cells,	  and	  then	  
removing	  the	  media.	  The	  cells	  were	  then	  placed	  on	  a	  microscope	  slide	  and	  visualized	  using	  an	  IX81	  
Fluorescence	  Microscope	  (Olympus).	  The	  GFP	  channel	  was	  used	  to	  visualize	  the	  Cy3	  present	  in	  the	  PC	  
conjugate.	  As	  a	  positive	  control,	  Jurkat	  cells	  were	  stained	  in	  the	  same	  fashion	  with	  anti-­‐CD3	  PE	  
(Biolegend).	  Images	  were	  acquired	  and	  saved	  for	  analysis.	  Quantification	  of	  fluorescence	  intensity	  
included	  cropping	  cells	  from	  the	  full	  image,	  isolating	  the	  clusters	  where	  the	  antibodies	  bound,	  and	  
averaging	  the	  fluorescence	  intensity	  in	  that	  region.	  	  	  
3.2.2  -­‐  Photocleavable  staining  and  release  experiments  
First,	  the	  optimum	  time	  for	  UV	  photocleavage	  was	  tested	  by	  measuring	  the	  amount	  of	  ssDNA-­‐
fluorophore	  release	  vs.	  UV	  exposure	  time.	  This	  was	  accomplished	  by	  synthesizing	  a	  PC	  conjugate	  with	  an	  
anti-­‐Streptavidin	  antibody.	  Streptavidin	  (SA)	  coated	  beads	  (10	  µm	  diameter,	  Spherotech)	  were	  used	  in	  
place	  of	  cells	  during	  control	  experiments.	  The	  beads	  were	  diluted	  to	  2x106	  beads/mL	  in	  1%	  BSA	  and	  
allowed	  to	  block	  for	  15	  minutes.	  The	  solution	  was	  then	  spun	  down	  at	  2000	  xg	  for	  2	  min	  and	  ~95%	  of	  the	  
solution	  was	  removed	  to	  concentrate	  the	  beads.	  5uL	  of	  PC	  Conjugate	  was	  then	  added	  to	  the	  solution	  
and	  allowed	  to	  incubate	  on	  ice	  for	  30	  min.	  The	  bead	  solution	  was	  then	  washed	  twice	  with	  1%	  BSA.	  The	  
beads	  were	  separated	  into	  multiple	  vials	  and	  exposed	  to	  either	  UV-­‐A	  (365	  nm),	  UV-­‐B	  (302	  nm),	  or	  UV-­‐C	  
(254	  nm)	  light	  in	  a	  VWR	  UV-­‐Crosslinker.	  Beads	  were	  exposed	  for	  varying	  amount	  of	  time,	  ranging	  from	  0	  
to	  15	  minutes	  at	  a	  dosage	  of	  150	  mW	  m-­‐2.	  In	  addition,	  negative	  control	  beads	  were	  used	  that	  had	  BSA	  
coating	  rather	  than	  streptavidin.	  	  
After	  exposure,	  each	  sample	  was	  spun	  down	  at	  2000	  xg	  for	  2	  minutes,	  and	  the	  supernatant	  was	  
collected	  and	  placed	  into	  a	  PDMS	  microwell.	  The	  PDMS	  microwell’s	  substrate	  was	  a	  DEAL	  patterned	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substrate	  that	  had	  the	  complementary	  ssDNA	  strand	  bound	  to	  the	  surface	  in	  order	  to	  capture	  the	  
released	  DNA-­‐fluorophore	  (see	  Chapter	  4	  for	  details	  on	  DEAL	  patterning).	  The	  samples	  were	  incubated	  
on	  the	  DEAL	  substrate	  for	  1	  hr	  at	  room	  temperature	  to	  allow	  capture	  of	  photocleaved	  ssDNA-­‐
fluorophore.	  During	  this	  time,	  the	  PDMS	  was	  covered	  with	  aluminum	  foil	  to	  prevent	  photobleaching.	  
The	  microwells	  were	  then	  washed	  with	  1%	  BSA	  three	  times	  and	  then	  the	  slide	  was	  washed	  with	  1x	  PBS,	  
and	  finally	  0.5x	  PBS.	  The	  slide	  was	  scanned	  on	  a	  Genepix	  4400A	  fluorescent	  slide	  scanner.	  The	  
fluorescence	  intensity	  of	  all	  spots	  in	  a	  microwell	  were	  averaged	  to	  obtain	  the	  relative	  amount	  of	  ssDNA-­‐
fluorophore	  that	  was	  released	  from	  the	  beads.	  This	  test	  was	  then	  repeated	  for	  Jurkat	  T	  cells	  using	  a	  PC	  
Conjugate	  specific	  to	  the	  CD3	  surface	  marker.	  	  
3.2.3  -­‐  Bead  Tests  in  microfluidic  device  
	   A	  proof	  of	  principle	  experiment	  was	  run	  using	  a	  similar	  method	  as	  3.2.2;	  however,	  instead	  of	  
measuring	  the	  amount	  of	  ssDNA-­‐fluorophore	  release	  in	  the	  supernatant,	  the	  beads	  were	  incubated	  in	  
single	  cell	  chambers	  and	  the	  ssDNA-­‐fluorophore	  was	  captured	  therein.	  The	  general	  procedure	  was	  
shown	  in	  Figure	  1.	  Beads	  were	  incubated	  with	  PC	  conjugate	  as	  described	  before,	  washed,	  and	  then	  
loaded	  into	  a	  microfluidic	  device	  at	  a	  density	  of	  1x106	  beads/mL.	  The	  beads	  were	  then	  trapped	  in	  single	  
cell	  chambers	  and	  exposed	  to	  UV-­‐A	  light	  for	  6	  minutes.	  The	  microfluidic	  device	  was	  then	  incubated	  for	  1	  
hour	  in	  order	  to	  allow	  diffusion	  of	  the	  ssDNA-­‐fluorophore	  throughout	  the	  single	  cell	  chambers.	  During	  
this	  time,	  video	  was	  captured	  to	  obtain	  bead	  counts	  in	  each	  chamber.	  Afterwards,	  beads	  were	  washed	  
out	  and	  the	  slide	  was	  washed	  and	  scanned	  as	  described	  above.	  	  
	   The	  data	  was	  analyzed	  by	  measuring	  the	  fluorescence	  signal	  levels	  in	  each	  chamber	  using	  the	  
Genepix	  Pro	  software.	  This	  data	  was	  then	  aligned	  with	  the	  cell	  counts	  obtained	  by	  analyzing	  the	  capture	  
video	  of	  each	  chamber.	  The	  actual	  cell	  count	  was	  acquired	  by	  counting	  the	  number	  of	  beads	  in	  each	  
chamber	  from	  the	  light	  microscope	  image.	  This	  was	  considered	  the	  “actual	  cell	  count.”	  To	  determine	  if	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the	  fluorescence	  signal	  could	  positively	  identify	  a	  chamber	  with	  beads	  in	  it,	  the	  mean	  plus	  two	  standard	  
deviations	  from	  the	  zero	  cell	  signal	  level	  was	  used	  as	  a	  cutoff.	  A	  Mann-­‐Whiteney	  U	  test	  was	  used	  to	  
determine	  whether	  the	  fluorescence	  signal	  could	  separate	  zero	  and	  one	  bead	  chamber.	  	  
3.2.4  –  T  cell  tests  
	   In	  order	  to	  test	  the	  PC	  conjugate	  method	  of	  phenotype	  detection	  on	  cells,	  CD3	  was	  detected	  on	  
J45.01	  Jurkat	  cell	  line.	  The	  toxicity	  of	  the	  anti-­‐CD3	  PC	  conjugate	  was	  tested	  with	  Jurkat	  T	  cells	  by	  mixing	  
50	  ug/mL	  with	  1x106	  cells/mL.	  The	  cell	  viability	  was	  measured	  after	  16	  hours	  of	  incubation.	  A	  control	  
sample	  was	  tested	  by	  adding	  PBS	  solution	  instead	  of	  PC	  conjugate.	  	  
In	  addition	  to	  testing	  toxicity	  of	  the	  PC	  conjugate,	  the	  toxicity	  of	  UV-­‐A	  light	  was	  tested	  on	  Jurkat	  
cells.	  This	  was	  accomplished	  by	  exposing	  Jurkats	  to	  UV-­‐A	  light	  (dosage:	  150	  W	  m-­‐2)	  for	  different	  amounts	  
of	  time	  and	  measuring	  the	  presence	  of	  apoptotic	  markers	  using	  Annexin-­‐V	  staining	  (Biolegend).	  	  
Testing	  the	  Jurkats	  on	  the	  microfluidic	  device	  was	  performed	  in	  a	  similar	  fashion	  to	  the	  bead	  
experiment	  from	  Chapter	  3.2.3.	  The	  Jurkats	  were	  concentrated	  down	  at	  500	  xg	  for	  4	  minutes	  and	  5	  µL	  of	  
an	  anti-­‐CD3	  PC	  conjugate	  was	  added	  (stock	  concentration	  was	  0.5mg/mL).	  This	  was	  incubated	  on	  ice	  for	  
30	  min	  and	  then	  washed	  twice	  by	  spinning	  down,	  discarding	  supernatant,	  and	  diluting	  back	  up	  with	  
RPMI	  1640	  media.	  The	  Jurkats	  were	  loaded	  into	  the	  microfluidic	  device	  at	  a	  concentration	  of	  1x106	  
cells/mL.	  The	  device	  was	  then	  exposed	  to	  UV-­‐A	  light	  for	  6	  minutes.	  The	  remaining	  procedure	  and	  data	  
analysis	  were	  conducted	  as	  described	  in	  Chapter	  3.2.3.	  	  
3.3  –  Results  
3.3.1  -­‐  Synthesis  of  conjugate  
	   The	  initial	  yield	  for	  the	  PC	  conjugate	  was	  lower	  than	  a	  standard	  DEAL	  conjugate	  by	  a	  factor	  of	  
~2.	  After	  increasing	  the	  conjugate	  DNA	  from	  140	  to	  175	  µM	  and	  decreasing	  the	  DMF	  amount	  from	  20	  µL	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to	  10	  µL,	  the	  FPLC	  peak	  was	  improved	  by	  a	  factor	  of	  four	  (Figure	  2).	  This	  improvement	  resulted	  in	  a	  
drastic	  difference	  in	  subsequent	  experiments.	  Before	  the	  improved	  method	  of	  synthesis,	  the	  signal	  to	  
noise	  ratio	  was	  approximately	  1.6:1.	  After	  the	  improved	  method	  of	  synthesis,	  the	  signal	  to	  noise	  ratio	  
was	  2.8:1.	  
	  
Figure	  2:	  Overlaid	  FPLC	  peaks	  of	  PC	  conjugate	  made	  with	  140uM	  DNA	  +	  20	  µL	  DMF	  (Purple	  Line)	  or	  175	  µM	  DNA	  +	  10	  µL	  DMF	  
(Pink	  Line).	  The	  x-­‐axis	  is	  the	  mL	  of	  solution	  eluted	  from	  the	  FPLC	  column	  and	  the	  y-­‐axis	  is	  the	  mAU	  absorbance	  at	  280	  nm.	  	  
	  
Figure	  3:	  Fluorescence	  image	  of	  Jurkat	  cells	  stained	  with	  a)	  anti-­‐CD3	  PE	  or	  b)	  anti-­‐CD3	  PC	  Conjugate.	  
Images	  of	  Jurkats	  stained	  with	  a	  standard	  fluorophore	  and	  PC	  conjugate	  are	  shown	  in	  Figure	  3.	  A	  
standard	  staining	  fluorophore	  (anti-­‐CD3	  with	  PE	  dye)	  used	  in	  FACS	  experiments	  is	  shown	  in	  Figure	  3a.	  
Figure	  3b	  is	  the	  PC	  conjugate.	  The	  maximum	  fluorescence	  of	  the	  PC	  conjugate	  was	  64%	  that	  of	  the	  




3.3.2  –  Photocleavable  staining  and  release  experiments  
	   Beads	  stained	  with	  PC	  conjugate	  are	  shown	  in	  Figure	  4	  after	  0,	  5,	  and	  15	  minutes	  of	  UV-­‐A	  light	  
exposure.	  The	  average	  intensity	  of	  the	  beads	  vs.	  UV-­‐A	  exposure	  time	  is	  shown	  in	  Figure	  5	  with	  the	  
microarray	  captured	  fluorescence	  signal	  overlayed.	  The	  graph	  clearly	  shows	  that	  the	  fluorescence	  of	  the	  
beads	  decreases	  as	  the	  ssDNA-­‐fluorophore	  is	  photocleaved	  off.	  Simultaneously,	  the	  ssDNA-­‐fluorophore	  
captured	  on	  the	  microarray	  increases.	  	  
	  
Figure	  4:	  Fluorescent	  images	  of	  SA	  coated	  bead	  stained	  with	  PC	  Conjugate	  after	  0,	  5,	  and	  15	  minutes	  of	  UV-­‐photocleavage.	  The	  




Figure	  5:	  Graph	  of	  average	  bead	  fluorescence	  intensity	  as	  a	  function	  of	  UV	  exposure	  time,	  as	  well	  as	  the	  measured	  Genepix	  
fluorescence	  intensity	  measured	  at	  the	  same	  time.	  The	  dashed	  black	  line	  is	  the	  background	  level	  for	  the	  bead	  fluorescence.	  	  
	  	  
The	  average	  fluorescence	  signal	  captured	  by	  the	  substrate	  after	  0,	  5,	  and	  15	  minutes	  is	  shown	  
for	  all	  wavelength	  of	  UV	  light	  in	  Figure	  6.	  UV-­‐A	  and	  UV-­‐B	  are	  significantly	  better	  at	  photocleaving	  the	  PC-­‐
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conjugate	  than	  UV-­‐C.	  Furthermore,	  UV-­‐B	  has	  a	  slight	  advantage	  over	  UV-­‐A,	  with	  UV-­‐B	  photocleaving	  
23%	  and	  8%	  more	  ssDNA-­‐fluorophore	  at	  5	  and	  15	  minutes	  of	  exposure	  time,	  respectively.	  	  
	  
Figure	  6:	  Comparison	  of	  UV	  exposure	  time	  and	  measured	  Genepix	  fluorescence	  signal	  versus	  the	  UV	  wavelength.	  Each	  point	  is	  
the	  average	  intensity	  of	  the	  DNA-­‐fluorophore	  captured	  on	  a	  DEAL	  substrate.	  	  	  
The	  average	  PC	  conjugates	  released	  over	  time	  were	  then	  measured	  with	  higher	  frequency	  to	  
determine	  the	  optimum	  photocleavage	  time.	  The	  results	  from	  this	  experiment	  are	  shown	  in	  Figure	  7.	  
The	  signal	  to	  noise	  was	  4.4:1	  at	  6	  minutes	  and	  5.6:1	  at	  15	  minutes.	  	  
	  
Figure	  7:	  Plot	  of	  Genepix	  Fluorescence	  intensity	  and	  UV	  exposure	  time	  with	  high	  frequency	  measurements.	  Each	  data	  point	  
shows	  the	  average	  and	  standard	  deviation	  of	  the	  DNA-­‐fluorophore	  intensity	  captured	  on	  a	  DEAL	  substrate.	  The	  DNA-­‐fluorophore	  
was	  released	  from	  beads	  exposed	  for	  the	  indicated	  time.	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Jurkats	  were	  stained	  and	  photocleaved	  in	  a	  similar	  fashion;	  however,	  only	  UV-­‐A	  was	  used	  due	  to	  
the	  phototoxic	  effects	  of	  UV-­‐B	  and	  UV-­‐C	  [7].	  The	  average	  fluorescence	  signal	  captured	  after	  
photocleaving	  for	  0	  and	  15	  minutes	  was	  6,500	  and	  17,000.	  This	  corresponded	  to	  a	  signal	  to	  noise	  ratio	  of	  
2.6:1.	  	  
3.3.3  -­‐  Bead  Tests  in  microfluidic  device  
	   Figure	  8	  shows	  an	  example	  of	  anti-­‐Streptavidin	  PC	  conjugate-­‐labeled	  beads	  in	  microfluidic	  
chambers.	  	  In	  the	  light	  microscope	  image	  (Figure	  8a),	  the	  beads	  show	  up	  as	  small	  black	  dots.	  In	  the	  
fluorescence	  image	  (Figure	  8b),	  they	  show	  up	  as	  red	  dots	  due	  to	  the	  fluorophore	  on	  the	  PC	  conjugate.	  	  
	  
Figure	  8:	  Images	  of	  beads	  in	  single	  cell	  microfluidic	  device.	  a)	  Bright	  field	  image	  of	  beads	  in	  four	  different	  single	  cell	  chambers.	  
The	  bead	  counts	  in	  each	  chamber,	  counting	  from	  the	  top	  chamber	  down,	  are	  1,	  0,	  3,	  and	  1.	  b)	  The	  same	  region	  as	  the	  image	  in	  
part	  a,	  taken	  with	  a	  Cy5	  filter	  on	  a	  fluorescence	  microscope.	  	  	  
A	  representative	  image	  of	  the	  captured	  fluorescence	  signal	  in	  single	  cell	  chambers	  is	  shown	  in	  
Figure	  9.	  Each	  chamber’s	  actual	  bead	  count	  is	  displayed	  at	  the	  top	  and	  the	  white	  boundary	  shows	  the	  
single	  cell	  chamber’s	  edge.	  Visually,	  the	  difference	  in	  fluorescence	  can	  be	  discerned	  between	  chambers	  




Figure	  9:	  Genepix	  Fluorescence	  Image	  of	  seven	  single	  cell	  chambers.	  The	  green	  fluorescence	  is	  the	  captured	  ssDNA-­‐fluorophore	  
released	  during	  the	  bead	  test	  in	  the	  microfluidics	  device.	  Each	  chamber	  has	  the	  number	  of	  beads	  displayed	  at	  the	  top.	  
	   The	  positive	  predictive	  rate	  of	  cell	  detection	  (that	  a	  chamber	  had	  at	  least	  one	  cell)	  was	  92%	  
using	  the	  photocleavable	  fluorescence	  signal.	  The	  false	  positive	  rate	  was	  low	  as	  0.5%.	   	  
The	  distribution	  of	  fluorescence	  signal	  captured	  vs.	  bead	  count	  is	  shown	  in	  Figure	  10a	  and	  a	  
scatter	  plot	  in	  Figure	  10b.	  Bead	  count	  distributions	  were	  significantly	  distinguishable	  using	  a	  Mann-­‐
Whitney	  U	  Test	  (0	  bead,	  1	  bead,	  and	  2	  beads).	  Most	  importantly,	  91.4%	  of	  single	  cell	  chambers	  had	  a	  
fluorescence	  signal	  higher	  than	  all	  zero	  cells	  chambers.	  97%	  of	  two	  bead	  chambers	  had	  a	  fluorescence	  
signal	  higher	  than	  all	  zero	  bead	  chambers.	  This	  indicates	  that	  zero	  and	  two	  bead	  chambers	  were	  very	  
distinguishable	  from	  zero	  bead	  chambers	  in	  terms	  of	  their	  fluorescence	  signal,	  which	  demonstrates	  a	  








Figure	  10:	  Single	  cell	  chamber	  signal	  vs.	  number	  of	  beads	  per	  chamber.	  a)	  Data	  is	  represented	  as	  a	  histogram.	  b)	  Data	  is	  
represented	  as	  a	  scatter	  plot,	  where	  each	  point	  is	  a	  different	  microfluidic	  chamber.	  	  
3.3.4  -­‐  T  cell  tests  in  microfluidic  device  
	   A	  graph	  of	  Jurkat	  viability	  vs.	  treatment	  is	  shown	  in	  Figure	  11.	  The	  y-­‐axis	  is	  the	  percent	  of	  
apoptotic	  T	  cells	  found	  after	  exposing	  to	  UV-­‐A	  light	  or	  to	  the	  stimulant	  phorbol	  12-­‐myristate	  13-­‐
56	  
	  
acetate/Ionomycin	  (PMA/I).	  The	  percent	  of	  apoptotic	  cells	  found	  after	  15	  minutes	  was	  significantly	  
higher	  than	  5	  minutes.	  Furthermore,	  the	  percent	  of	  apoptotic	  T	  cells	  found	  at	  5	  minutes	  was	  less	  than	  
the	  PMA/I	  stimulation.	  Therefore,	  using	  this	  information,	  and	  the	  fact	  that	  the	  amount	  of	  DNA-­‐
fluorophore	  released	  between	  6-­‐15	  minutes	  did	  not	  change	  significantly,	  a	  UV-­‐A	  exposure	  time	  of	  6	  
minutes	  was	  subsequently	  used	  for	  Jurkat	  experiments.	  
	  
Figure	  11:	  Cell	  apoptosis	  percentage	  vs.	  treatment	  type.	  Jurkat	  T	  cells	  were	  measured	  for	  the	  presence	  of	  Annexin	  V	  after	  16	  
hours	  of	  each	  treatment.	  
	   	  
A	  representative	  image	  of	  a	  single	  cell	  microfluidic	  test	  performed	  using	  Jurkats	  is	  shown	  in	  





Figure	  12:	  Images	  of	  single	  cell	  microfluidic	  chambers	  with	  Jurkat	  T	  cells.	  a)	  Bright	  field	  image	  of	  chambers.	  b)	  Fluorescence	  
image	  of	  chambers.	  	  
	   Using	  the	  fluorescence	  signal	  from	  the	  release	  PC	  conjugate,	  the	  positive	  predictive	  rate	  was	  
49%	  with	  a	  false	  positive	  rate	  of	  1.4%.	  Figure	  13	  shows	  a	  scatter	  plot	  of	  fluorescence	  signal	  vs.	  cell	  count	  
per	  chamber.	  	  
	  
Figure	  13:	  Scatter	  plot	  of	  single	  chamber	  signals	  vs.	  number	  of	  Jurkat	  in	  chamber.	  The	  significance	  indicator	  is	  shown	  above	  the	  
geoms.	  Significance	  markers:	  *	  =	  p	  <	  0.05.	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3.4  –  Discussion  
	   Comparing	  the	  fluorescence	  signal	  of	  T	  cells	  with	  anti-­‐CD3	  PE	  and	  the	  PC	  conjugate,	  we	  
observed	  a	  significantly	  higher	  signal	  in	  the	  case	  of	  anti-­‐CD3	  PE.	  This	  is	  likely	  because	  of	  the	  higher	  
extinction	  coefficient	  of	  PE	  relative	  to	  the	  Cy3	  fluorophore	  used	  in	  the	  PC	  conjugate	  (max	  extinction	  
coefficients	  for	  PE	  and	  Cy3	  are	  2x106	  and	  1.4x105	  M-­‐1cm-­‐1,	  respectively)	  [8,	  9].	  In	  spite	  of	  its	  lower	  
extincition	  coefficient,	  Cy3	  was	  used	  because	  of	  its	  ready	  integration	  as	  an	  “internal”	  group	  in	  the	  
photocleavable	  DNA-­‐fluorophore	  synthesis.	  If	  a	  stronger	  fluorophore	  was	  able	  to	  be	  integrated	  as	  an	  
internal	  group,	  this	  would	  likely	  improve	  the	  detection	  sensitivity	  of	  the	  photocleavable	  marker.	  	  
	   The	  detection	  sensitivity	  of	  the	  Jurkats	  was	  significantly	  lower	  than	  that	  of	  the	  streptavidin	  
coated	  beads:	  the	  rate	  of	  distinguishing	  one	  cell	  chambers	  from	  zero	  cell	  was	  49%	  for	  Jurkats	  and	  92%	  
for	  the	  beads.	  This	  demonstrates	  a	  significant	  gap	  between	  these	  two	  systems.	  The	  Jurkat	  experiment’s	  
lower	  positive	  predictive	  value	  demonstrates	  there	  are	  significant	  differences	  between	  the	  beads	  and	  
cells.	  One	  key	  difference	  is	  that	  the	  surface	  coverage	  of	  streptavidin	  on	  beads	  is	  much	  higher	  than	  CD3	  
on	  Jurkats.	  Human	  T	  cells	  regularly	  have	  ~6x104	  CD3	  per	  cell,	  whereas	  beads	  have	  1.8x107	  SA	  proteins	  
per	  bead.2	  [10]	  	  Another	  difference	  was	  that	  cell	  membrane	  proteins	  like	  CD3	  can	  be	  internalized	  and	  
degraded,	  which	  would	  reduce	  the	  number	  of	  PC	  conjugates	  detected	  [11].	  In	  order	  to	  improve	  the	  
lower	  sensitivity	  of	  detecting	  CD3	  on	  Jurkats,	  one	  could	  1)	  use	  stronger	  fluorophores	  (as	  discussed	  in	  the	  
first	  paragraph),	  2)	  increase	  the	  loading	  of	  fluorophores	  on	  the	  PC	  conjugate,	  3)	  amplify	  the	  detected	  
signal,	  or	  4)	  reduce	  the	  internalization	  of	  CD3	  with	  Filipin.	  The	  first	  three	  ideas	  would	  be	  the	  most	  facile	  
changes,	  as	  they	  would	  not	  interfere	  with	  the	  biology,	  as	  the	  fourth	  idea	  would.	  	  
	   	  One	  problem	  with	  the	  PC	  conjugate	  was	  the	  stability	  of	  the	  construct	  itself.	  Batches	  would	  
come	  out	  working	  well,	  whereas	  other	  batches	  would	  have	  nearly	  no	  activity.	  Having	  reagents	  that	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  SA	  bead	  density	  was	  calculated	  using	  the	  following	  approximations:	  1)	  SA	  is	  a	  sphere	  with	  radius	  2.25nm	  [13],	  2)	  
SA	  arranged	  in	  a	  monolayer,	  hexagonal	  layout	  of	  SA,	  and	  3)	  the	  bead	  is	  a	  sphere	  is	  10	  µm	  in	  diameter.	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perform	  with	  varying	  degrees	  of	  success	  would	  not	  be	  acceptable	  in	  the	  long	  term,	  and	  therefore,	  time	  
would	  need	  to	  be	  spent	  debugging	  this	  issue.	  One	  likely	  cause	  of	  this	  is	  light	  exposure	  photocleaving	  the	  
DNA-­‐fluorophore	  off	  prematurely.	  These	  reagents	  were	  made	  in	  a	  communal	  lab,	  so	  there	  was	  a	  chance	  
they	  would	  inadvertently	  be	  exposed	  to	  light.	  In	  this	  project,	  the	  reagent	  was	  protected	  from	  
fluorescent	  lights	  by	  coating	  anything	  it	  was	  placed	  into	  with	  aluminum	  foil	  (e.g.,	  FPLC	  column,	  
microfluidic	  device)	  and	  storing	  it	  in	  black-­‐colored	  vials.	  However,	  it	  will	  inevitably	  be	  exposed	  to	  UV	  
during	  the	  FPLC	  run,	  where	  it	  used	  280	  nm	  wavelength	  light	  to	  determine	  the	  absorbance	  of	  each	  
fraction.	  Finding	  an	  alternative	  method	  to	  purify	  the	  PC	  conjugate	  would	  likely	  improve	  its	  stability.	  	  
	   The	  viability	  of	  the	  Jurkats	  limited	  the	  amount	  of	  UV-­‐A	  dose	  we	  could	  apply	  towards	  
photocleaving	  the	  PC	  conjugate.	  As	  shown	  in	  Figure	  11,	  the	  viability	  decreased	  rapidly	  between	  5	  min	  
and	  15	  minutes	  of	  UV-­‐A	  exposure.	  Malanado	  et	  al.	  showed	  that	  5000	  J	  m-­‐2	  is	  the	  maximum	  dosage	  that	  
thymocyes	  could	  receive	  before	  DNA	  fragmentation	  occurred	  [7].	  In	  our	  experiment,	  6	  minutes	  of	  UV-­‐A	  
was	  equal	  to	  5400	  J	  m-­‐2.	  Therefore,	  6	  minutes	  of	  UV-­‐A	  in	  our	  experiment	  is	  just	  at	  the	  safe	  limit	  for	  
Jurkats.	  The	  downside	  to	  such	  a	  short	  UV-­‐A	  exposure	  time	  is	  the	  PC	  conjugates	  may	  not	  be	  fully	  cleaved	  
after	  6	  minutes.	  This	  was	  demonstrated	  in	  Figure	  5	  when	  measuring	  the	  reduction	  in	  fluorescence	  as	  a	  
function	  of	  UV	  exposure	  time:	  the	  bead	  intensity	  did	  not	  reach	  the	  background	  level,	  even	  after	  15	  
minutes	  of	  UV-­‐A.	  Therefore,	  it	  would	  be	  advantageous	  to	  either	  1)	  improve	  the	  photocleaving	  efficiency	  
on	  the	  PC	  conjugate	  or	  2)	  find	  an	  alternative	  cleavage	  method.	  One	  such	  alternative	  cleavage	  method	  
would	  be	  to	  use	  DNA	  as	  a	  linker	  and	  cleave	  it	  using	  a	  restriction	  enzyme.	  	  
	   It	  is	  worth	  noting	  that	  this	  method	  is	  not	  designed	  to	  be	  a	  cell	  counting	  mechanism	  since	  1,	  2,	  
and	  3	  cell	  chambers	  were	  not	  perfectly	  separable,	  even	  in	  the	  bead	  test.	  The	  PC	  conjugate	  would	  best	  
be	  applied	  in	  situations	  where	  the	  cell	  count	  is	  determined	  automatically	  (see	  Chapter	  1.2.1)	  or	  a	  cell	  
trap	  is	  used	  in	  the	  microfluidics.	  A	  cell	  trap	  would	  guarantee	  that	  each	  chamber	  would	  only	  have	  one	  cell	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(or	  zero	  cells),	  allowing	  the	  user	  to	  trust	  that	  the	  phenotype	  data	  obtained	  from	  the	  PC	  conjugate	  
readout	  is	  from	  a	  single	  cell.	  	  
	   With	  the	  resolution	  of	  the	  issues	  raised	  in	  this	  Discussion	  section,	  this	  method	  holds	  great	  
promise.	  In	  a	  single	  cell	  experiment	  where	  three	  fluorescent	  dyes	  are	  tested	  on	  four	  separate	  
microfluidic	  devices,	  the	  method	  saves	  a	  great	  deal	  of	  time	  relative	  to	  manual	  analysis.	  Furthermore,	  the	  
potential	  ability	  to	  quantitate	  the	  data	  is	  a	  further	  advantage.	  	  	   	  
3.5  –  Conclusions  
	   A	  photocleavable	  conjugate	  was	  developed	  in	  order	  to	  detect	  surface	  markers	  and	  phenotype	  
cells	  in	  a	  single	  cell	  microfluidic	  device.	  Two	  proof	  of	  principle	  experiments	  were	  conducted	  with	  beads	  
and	  Jurkat	  T	  cells.	  Surface	  streptavidin	  on	  beads	  was	  readily	  detected	  with	  a	  92%	  positive	  predictive	  
rate.	  Jurkat	  T	  cells	  were	  detected	  with	  a	  49%	  positive	  predictive	  rate	  and	  zero	  cell	  chambers	  were	  
distinguishable	  from	  one	  cell	  chambers	  via	  a	  Mann-­‐Whiteny	  U	  test.	  These	  experiments	  show	  promise	  in	  
determining	  cell	  phenotype	  on-­‐chip	  via	  PC	  conjugates.	  	  
References  (Chapter  3)  
	  
[1]	  	   L.	  Herzenberg	  et	  al.,	  "The	  history	  of	  the	  fluorescence	  activated	  cell	  sorter	  and	  flow	  cytometry:	  
a	  view	  from	  Stanford.,"	  Clin	  Chem,	  vol.	  48,	  pp.	  1819-­‐1827,	  2002.	  	  
[2]	  	   G.	  Nolan	  et	  al.,	  "Single-­‐cell	  mass	  cytometry	  of	  differential	  immune	  and	  drug	  responses	  across	  a	  
human	  hematopoietic	  continuum,"	  Science,	  vol.	  332,	  pp.	  687-­‐696,	  2011.	  	  
[3]	  	   J.	  Heath	  et	  al.,	  "A	  clinical	  microchip	  for	  evaluation	  of	  single	  immune	  cells	  reveals	  high	  functional	  
61	  
	  
heterogeneity	  in	  phenotypically	  similar	  T	  cells,"	  Nature	  Medicine,	  vol.	  17,	  p.	  738–743,	  2011.	  	  
[4]	  	   J.	  Heath	  et	  al.,	  "Multifunctional	  T-­‐cell	  Analyses	  to	  Study	  Response	  and	  Progression	  in	  Adoptive	  Cell	  
Transfer	  Immunotherapy,"	  Cancer	  Discovery,	  vol.	  3,	  pp.	  418-­‐429,	  2013.	  	  
[5]	  	   C.	  Love	  et	  al.,	  "Polyfunctional	  responses	  by	  human	  T	  cells	  result	  from	  sequential	  release	  of	  
cytokines,"	  Proc.	  Natl.	  Acad.	  Sci.,	  vol.	  109,	  pp.	  1605-­‐1612,	  2012.	  	  
[6]	  	   S.	  Weissleder	  et	  al.,	  "Photocleavable	  DNA	  Barcode–Antibody	  Conjugates	  Allow	  Sensitive	  and	  
Multiplexed	  Protein	  Analysis	  in	  Single	  Cells,"	  J.	  Am.	  Chem.	  Soc.,	  vol.	  134,	  no.	  45,	  p.	  18499–18502,	  
2012.	  	  
[7]	  	   C.	  e.	  a.	  Maldonado,	  "Ultraviolet	  exposure	  of	  thymoctes:	  selective	  inhibition	  of	  apoptosis,"	  Int.	  J.	  
Radiat.	  Biol.,	  vol.	  90,	  no.	  6,	  pp.	  445-­‐450,	  2004.	  	  
[8]	  	   "EXTINCTION	  COEFFICIENTS	  AND	  FLUORESCENCE	  DATA,"	  Glen	  Research,	  [Online].	  Available:	  
http://www.glenresearch.com/Technical/Extinctions.html.	  [Accessed	  5	  May	  2015].	  
[9]	  	   L.	  Stryer	  et	  al.,	  "Fluorescent	  phycobiliprotein	  conjugates	  for	  analyses	  of	  cells	  and	  molecules,"	  J	  Cell	  
Biol.,	  vol.	  93,	  no.	  3,	  p.	  981–986,	  1982.	  	  
[10]	  	  C.	  Lambert	  et	  al.,	  "Variability	  of	  CD3	  membrane	  expression	  and	  T	  cell	  activation	  capacity,"	  
Cytometry	  Part	  B	  ,	  vol.	  78B,	  2010.	  	  
[11]	  	  W.	  Mitch	  et	  al.,	  "Protein	  Degradation	  by	  the	  Ubiquitin–Proteasome	  Pathway	  in	  Normal	  and	  Disease	  
States,"	  JASN,	  vol.	  17,	  no.	  7,	  pp.	  1807-­‐1819,	  2006.	  	  
[12]	  	  R.	  Fan	  et	  al.,	  "High-­‐throughput	  Secretomic	  Analysis	  of	  Single	  Cells	  to	  Assess	  Functional	  Cellular	  
Heterogeneity,"	  Analytical	  Chemistry,	  vol.	  85,	  no.	  4,	  p.	  2548–2556,	  2013.	  	  
62	  
	  
[13]	  	  M.	  Rao	  et	  al.,	  "Immobilization	  of	  streptavidin	  on	  4H–SiC	  for	  biosensor	  development,"	  Applied	  
















Chapter  4:  Predicting  Adoptive  Cell  Transfer  Therapy  Success  with  T  cell  
Polyfunctionality  using  Single  Cell  Microfluidic  Assays  
4.1  –  Introduction  
	   Immunotherapy	  has	  shown	  great	  promise	  in	  treating	  cancer.	  There	  exist	  multiple	  methods	  of	  
using	  the	  immune	  system	  to	  tumor	  cells,	  with	  the	  most	  prevalent	  being	  cancer	  vaccines,	  checkpoint	  
inhibitors,	  and	  adoptive	  cell	  transfers	  [1,	  2,	  3].	  Their	  unifying	  mechanism	  is	  harnessing	  the	  immune	  
system	  to	  dispose	  of	  tumor	  cells,	  rather	  than	  using	  a	  direct	  acting	  exogenous	  agent.	  	  
	   Adoptive	  cell	  transfer	  (ACT)	  has	  been	  developed	  over	  the	  past	  100	  years,	  reaching	  a	  sprint	  in	  the	  
late	  20th	  century.	  In	  1922,	  it	  was	  suggested	  that	  tumor	  infiltrating	  lymphocytes	  (TILs)	  were	  associated	  
with	  longer	  patient	  survival	  [4].	  After	  the	  discovery	  that	  TILs	  grown	  from	  melanoma	  tumors	  could	  lyse	  
autologous	  tumor	  cells,	  a	  clinical	  trial	  was	  run	  using	  TILs	  to	  treat	  metastatic	  melanoma	  [5,	  6,	  7].	  Since	  
then,	  this	  therapy	  has	  shown	  objective	  responses	  in	  40-­‐70%	  of	  Stage	  IV	  melanoma	  patients,	  and	  
complete	  response	  rates	  in	  10-­‐40%	  [8,	  9].	  However,	  the	  pre-­‐selection	  process	  requires	  the	  patient	  to	  
have	  resectable	  tumor	  with	  TILs	  present,	  which	  excludes	  10-­‐15%	  of	  candidates	  from	  taking	  part	  in	  this	  
promising	  therapy	  [10].	  
	   An	  alternative	  form	  of	  ACT	  uses	  genetically	  engineered,	  autologous	  T	  cells,	  which	  does	  away	  
with	  the	  need	  for	  TILs.	  The	  method	  is	  outlined	  in	  Figure	  1.	  First,	  a	  patient	  undergoes	  a	  leukapheresis	  to	  
harvest	  autologous	  T	  cells.	  A	  viral	  vector	  is	  then	  inserted	  into	  the	  T	  cells.	  This	  vector	  encodes	  for	  a	  T	  cell	  
receptor	  (TCR)	  that	  recognizes	  a	  specific	  tumor	  MHC	  peptide	  [11].	  Next,	  the	  T	  cells	  are	  expanded	  until	  
they	  reach	  billions	  to	  trillions	  in	  number.	  Finally,	  the	  patient	  undergoes	  lymphodepletion	  treatment	  and	  




Figure	  1:	  Overview	  of	  genetic	  engineered	  ACT.	  Adapted	  from	  [8].	  
	   Though	  genetically	  engineered	  ACT	  is	  promising	  in	  allowing	  more	  patients	  to	  undergo	  
immunotherapy,	  the	  response	  rates	  are	  lower	  than	  that	  of	  the	  tradition	  TIL	  ACT,	  ranging	  from	  10-­‐30%	  
for	  an	  objective	  response	  and	  complete	  response	  rates	  of	  <	  20%	  [12].	  Therefore,	  it	  would	  be	  desirable	  to	  
understand	  why	  a	  small	  percent	  of	  patients	  do	  well,	  and	  find	  an	  avenue	  to	  increase	  the	  success	  rate.	  
	   Previously,	  Ma	  et	  al.	  from	  the	  Heath	  Lab	  investigated	  the	  single	  cell	  protein	  secretion	  of	  T	  cells	  
from	  patients	  in	  a	  genetic	  engineered	  ACT	  trial	  [13].	  Measurements	  were	  taken	  every	  ~10	  days	  post-­‐T	  
cell	  infusion	  and	  showed	  a	  strong	  correlation	  between	  T	  cells	  polyfunctionality,	  or	  multiple	  protein	  
secretions	  from	  the	  same	  single	  cell,	  and	  tumor	  lysis.	  Polyfunctional	  T	  cells	  are	  known	  to	  be	  
advantageous	  in	  immune	  response,	  for	  instance,	  in	  the	  case	  of	  HIV-­‐1	  vs.	  HIV-­‐2.	  HIV-­‐2	  is	  considered	  a	  less	  
pathogenic	  disease,	  and	  has	  higher	  numbers	  of	  polyfunctional	  T	  cells,	  as	  compared	  to	  HIV-­‐1	  [14]	  [15].	  
Therefore,	  we	  hypothesized	  that	  T	  cell	  polyfunctionality	  was	  an	  important	  factor	  in	  the	  success	  of	  
genetically	  engineered	  ACT.	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   Using	  this	  hypothesis,	  we	  set	  out	  to	  determine	  if	  T	  cell	  polyfunctionality	  can	  be	  used	  to	  predict	  
whether	  a	  patient	  will	  succeed	  or	  fail	  a	  genetic	  engineered	  ACT	  therapy.	  The	  prediction	  was	  based	  on	  
the	  extent	  of	  polyfunctionlaity	  present	  in	  the	  initial	  T	  cells	  infusion	  product	  (referred	  to	  as	  “Pre-­‐Infusion”	  
T	  cells).	  Like	  Ma	  et	  al.	  from	  the	  Heath	  Lab,	  single	  cell	  microfluidics	  were	  employed	  to	  measure	  the	  
functional	  protein	  secretion	  of	  T	  cells	  from	  15	  patients	  in	  two	  different	  genetic	  engineered	  ACT	  trials.	  
Multiple	  data	  analysis	  methods	  were	  used	  to	  relate	  this	  single	  cell	  data	  with	  treatment	  success.	  
4.2  –  Materials  and  Methods    
4.2.1  –  DNA  Barcodes  
	   DNA	  barcodes	  were	  patterned	  using	  a	  PDMS	  template.	  The	  PDMS	  was	  made	  using	  Sylgard	  184	  
(Dow	  Corning)	  in	  a	  10	  to	  1	  ratio	  of	  Part	  A	  to	  Part	  B.	  The	  PDMS	  was	  mixed	  for	  2	  minutes	  by	  hand	  using	  a	  
glass-­‐stir	  rod	  and	  then	  10	  minutes	  in	  a	  Unicyclone	  (Fancort	  Industries,	  Inc.).	  The	  barcode	  masters	  were	  
treated	  with	  chlorotrimethylsilane	  (CTMS)	  for	  10	  minutes	  before	  the	  mixed	  PDMS	  was	  poured	  over	  top.	  
The	  PDMS	  was	  degassed	  for	  10	  minutes	  under	  vacuum	  and	  then	  baked	  for	  2	  hours	  at	  80	  degC.	  Holes	  
were	  punched	  into	  the	  PDMS	  using	  a	  0.5mm	  diameter	  punch.	  The	  PDMS	  was	  cleaned	  and	  adhered	  to	  a	  
poly-­‐lysine	  coated	  slide	  (Thermo	  Fisher).	  This	  was	  baked	  for	  another	  2	  hours	  at	  80	  °C	  to	  yield	  a	  
completed	  barcode.	  	  	  
	   	  The	  barcode	  was	  then	  used	  to	  flow	  pattern	  ssDNA	  onto	  the	  surface	  of	  the	  poly-­‐lysine	  slide.	  The	  
night	  before	  flowing	  the	  ssDNA,	  4uL	  of	  0.1%	  poly-­‐lysine	  (Sigma)	  was	  flowed	  into	  each	  chamber	  at	  4psi.	  
This	  was	  left	  to	  flow	  until	  the	  channels	  were	  dry,	  which	  was	  typically	  12-­‐16	  hours.	  Next,	  300	  µM	  ssDNA	  
(IDT	  DNA)	  in	  40%	  DMSO	  and	  PBS	  is	  mixed	  1:1	  with	  2mM	  BS3	  in	  PBS.	  This	  is	  repeated	  for	  every	  different	  
sequence	  of	  ssDNA.	  These	  are	  listed	  in	  Chapter	  2	  Appendix	  A.	  This	  is	  left	  to	  react	  at	  room	  temperature	  
for	  1	  hour.	  Afterwards,	  5uL	  of	  each	  ssDNA	  is	  flowed	  into	  the	  device	  for	  2	  hours.	  The	  devices	  are	  kept	  in	  a	  
100%	  humid	  chamber	  for	  another	  2	  hours	  before	  the	  PDMS	  is	  peeled	  from	  the	  slide	  and	  then	  washed	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with	  0.02%	  SDS	  once	  and	  water	  three	  times.	  The	  slides	  are	  stored	  in	  a	  dessicator	  (humidity	  <	  20%)	  until	  
use.	  	  
4.2.1  –  PDMS  Devices  
PDMS	  was	  originally	  made	  using	  RTV	  615	  PDMS	  (Momentive)	  but	  was	  switched	  to	  Sylgard	  184.	  
The	  Sylgard	  Part	  A	  and	  Part	  B	  were	  mixed	  in	  a	  ratio	  of	  10	  to	  1	  for	  the	  control	  (thick)	  layer	  and	  20	  to	  1	  for	  
the	  flow	  (thin)	  layer,	  mixing	  for	  2	  minutes	  by	  hand	  using	  a	  glass-­‐stir	  rod,	  then	  mixing	  on	  a	  Unicyclone	  for	  
10	  minutes.	  During	  this	  time,	  the	  silicon	  wafers	  with	  the	  single	  cell	  microfluidic	  design	  patterns	  were	  
placed	  in	  a	  chamber	  with	  5-­‐10	  drops	  of	  CTMS	  for	  at	  least	  2	  minutes.	  The	  control	  layer	  PDMS	  was	  poured	  
onto	  the	  silicon	  wafer	  masters	  to	  a	  thickness	  of	  ~6mm	  and	  then	  placed	  in	  a	  degassing	  chamber	  for	  45-­‐60	  
minutes.	  The	  thin	  layer	  PDMS	  was	  placed	  in	  the	  degassing	  chamber	  while	  still	  in	  the	  stirring	  cup.	  After	  
degassing	  the	  thin	  layer	  PDMS,	  it	  was	  poured	  over	  the	  silicon	  flow	  master,	  and	  spun	  at	  500	  rpm	  for	  5	  
seconds	  (100	  rpm/sec	  ramp),	  followed	  by	  2000	  rpm	  for	  60	  seconds	  (300	  rpm/sec	  ramp).	  After	  spinning,	  
the	  wafer	  was	  left	  on	  a	  flat	  surface	  for	  5	  minutes	  to	  allow	  the	  PDMS	  to	  settle.	  	  
Both	  the	  thick	  and	  thin	  layer	  PDMS	  were	  placed	  in	  an	  80	  °C	  oven	  for	  15-­‐20	  minutes,	  and	  then	  
allowed	  to	  cool	  for	  15	  minutes.	  Holes	  were	  then	  punched	  in	  the	  control	  ports	  in	  the	  thick	  layer.	  The	  two	  
layers	  were	  aligned	  and	  adhered,	  and	  the	  presence	  of	  dust	  between	  the	  layers	  was	  then	  searched	  for	  
using	  a	  light	  microscope.	  	  
The	  PDMS	  was	  then	  baked	  at	  80	  °C	  for	  another	  1.5	  hours	  to	  bond	  the	  two	  layers	  together.	  The	  
PDMS	  was	  cooled	  for	  15	  minutes	  and	  then	  the	  flow	  channel	  ports	  were	  punched	  using	  a	  1mm	  punch.	  
The	  PDMS	  was	  then	  bonded	  to	  a	  pre-­‐patterned	  barcode	  slide	  and	  baked	  for	  2	  hours.	  The	  device	  could	  
be	  used	  for	  a	  single	  cell	  experiment	  within	  one	  week	  of	  its	  creation.	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4.2.2  -­‐  Sorting  T  cells  
T	  cells	  were	  thawed	  overnight	  after	  washing/diluting	  in	  RPMI	  1640	  media	  +	  10%	  FBS.	  The	  T	  cells	  
were	  spun	  down	  at	  500	  xg	  for	  4	  minutes	  to	  pellet	  the	  cells.	  The	  following	  staining	  dyes	  were	  added	  per	  
the	  manufactutor’s	  instructions:	  7-­‐AAD	  (Biolegend),	  CD3	  (Biolegend,	  OKT3),	  CD4	  (Biolegend,	  OKT-­‐4),	  
CD8	  (Biolegend,	  HIT8a),	  and	  MART-­‐1	  tetramer	  (MBL	  Int.).	  The	  pellets	  were	  then	  broken	  up	  and	  placed	  
on	  ice	  for	  30	  minutes.	  The	  cells	  were	  then	  washed	  with	  cold	  media	  and	  diluted	  up	  to	  ~107	  cells/mL.	  	  
T	  cells	  were	  sorted	  using	  a	  BD	  Aria	  II	  or	  Aria	  III	  machine.	  Cells	  were	  gated	  on	  FSC-­‐A,	  FSC-­‐H,	  SSC-­‐A	  
(singlet,	  lymphocyte	  identification),	  7-­‐AAD,	  CD3,	  CD4,	  CD8,	  and	  MART-­‐1	  tetramer.	  The	  machine	  was	  
calibrated	  with	  CompBeads	  (BD	  Bioscience)	  prior	  to	  sorting.	  The	  T	  cells	  were	  sorted	  into	  two	  groups,	  7-­‐
AAD-­‐CD3+CD4+CD8-­‐MART-­‐1+	  and	  7-­‐AAD-­‐CD3+CD4-­‐CD8+MART-­‐1+,	  which	  are	  henceforth	  referred	  to	  as	  CD4	  
and	  CD8,	  respectively.	  	  
4.2.3  -­‐  Microfluidic  Test  
The	  microfluidic	  test	  was	  started	  concurrently	  with	  the	  sorting,	  so	  that	  when	  the	  cells	  were	  done	  
sorting,	  the	  microfluidic	  device	  was	  prepared.	  	  
First,	  a	  3%	  BSA	  in	  PBS	  solution	  was	  flowed	  in	  the	  microfluidic	  device	  and	  dead-­‐end	  filling	  was	  
performed	  to	  remove	  bubbles	  in	  the	  flow	  channels.	  The	  BSA	  was	  then	  flowed	  for	  1	  hour	  to	  block	  the	  
surface.	  Conjugates	  were	  then	  diluted	  to	  50	  µM	  in	  3%	  BSA	  and	  200	  µL	  was	  flowed	  in	  the	  device	  for	  1	  
hour.	  At	  this	  point,	  the	  sorted	  T	  cells	  were	  washed	  three	  times	  with	  RPMI	  1640	  +	  10%	  FBS,	  diluted	  up	  to	  
a	  concentration	  of	  106	  cells/mL	  and	  then	  stimulated.	  The	  stimulation	  included	  MART-­‐1	  tetramer	  alone	  (8	  
µL	  per	  3x106	  cells),	  and	  MART-­‐1	  plus	  CD28	  (CD28	  was	  diluted	  1:250	  from	  a	  stock	  0.5	  mg/mL	  
concentration).	  The	  T	  cells	  were	  allowed	  to	  sit	  with	  the	  stimulant	  for	  10	  minutes	  before	  loading	  into	  the	  
microfluidic	  device.	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The	  T	  cells	  were	  then	  flowed	  into	  the	  device	  and	  the	  pneumatic	  chambers	  were	  actuated	  to	  
sequester	  them	  into	  the	  microfluidic	  chambers.	  Videos	  were	  then	  taken	  of	  the	  cells	  and	  then	  the	  device	  
was	  placed	  in	  a	  37	  °C	  incubator	  with	  5%	  CO2	  for	  14	  hours.	  After	  this	  incubated,	  the	  microfluidic	  device	  
was	  removed	  from	  the	  incubator	  and	  the	  cells	  were	  washed	  out.	  The	  secondary	  antiboides	  were	  diluted	  
to	  50	  µM	  in	  3%	  BSA,	  along	  with	  Streptavidin-­‐Cy5	  (0.5mg/mL,	  eBioscience)	  and	  a	  reference	  ssDNA-­‐Cy3	  
(10uM),	  both	  diluted	  at	  a	  ratio	  of	  1:100	  in	  BSA.	  200	  µL	  of	  this	  solution	  was	  flowed	  over	  1	  hour,	  followed	  
by	  45	  minutes	  of	  3%	  BSA	  to	  wash	  the	  device	  out.	  The	  PDMS	  was	  then	  stripped	  off	  of	  the	  slide	  and	  the	  
slide	  was	  dunked	  in	  0.5x	  PBS	  three	  times.	  After	  drying	  the	  slide	  on	  a	  slide-­‐spinner	  (VWR),	  it	  was	  scanned	  
on	  a	  Genepix	  4400A.	  The	  gain	  and	  power	  were	  set	  at	  450/15%	  for	  Cy3	  and	  600/80%	  for	  Cy5.	  	  
4.2.4  -­‐  Patient  Study  
	   The	  T	  cells	  studied	  were	  collected	  from	  metastatic	  melanoma	  patients	  enrolled	  in	  a	  clinical	  study	  
performed	  at	  UCLA	  [UCLA,	  Los	  Angeles,	  CA;	  IRB	  (08-­‐02-­‐020	  and	  10-­‐001212)	  under	  an	  IND	  filed	  with	  the	  
U.S.	  Food	  and	  Drug	  Administration	  (IND	  13859)]	  [11].	  Patients	  were	  chosen	  based	  on	  the	  presence	  of	  
MART-­‐1	  marker	  on	  tumor	  immunohistochemistry	  assays	  and	  HLA-­‐A*0201+.	  The	  Response	  Evaluation	  
Criteria	  in	  Solid	  Tumors	  (RECIST)	  metric	  was	  used	  to	  determine	  tumor	  burden	  throughout	  the	  study.	  This	  
trial	  is	  henceforth	  referred	  to	  as	  the	  F5	  trial.	  A	  second	  trial	  performed	  by	  S.	  Rosenberg	  targeted	  NY-­‐ESO-­‐
1	  in	  synovial	  sarcoma	  and	  melanoma	  patients	  [16].	  This	  trial	  will	  henceforth	  be	  referred	  to	  as	  the	  NIH	  
trial.	  	  
	   The	  T	  cells	  measured	  in	  this	  study	  were	  frozen	  aliquots	  of	  T	  cells	  that	  most	  closely	  resembled	  
the	  “pre-­‐infusion	  product”	  that	  were	  to	  be	  injected	  into	  the	  patients:	  these	  T	  cells	  had	  been	  transduced	  
with	  the	  MART-­‐1	  or	  NY-­‐ESO-­‐1	  TCR	  viral	  vector	  and	  expanded	  previously.	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4.2.5  -­‐  Data  Analysis  
	   The	  cell	  count	  was	  acquired	  by	  counting	  the	  number	  of	  cells	  in	  each	  chamber	  using	  the	  videos	  
taken	  prior	  to	  incubating	  the	  cells	  overnight.	  The	  protein	  signals	  were	  acquired	  by	  using	  the	  “Block	  
Aligning”	  method	  in	  the	  Genepix	  Pro	  7	  software	  (Molecular	  Devices).	  A	  20	  µm	  spot	  size	  was	  aligned	  onto	  
the	  barcode,	  and	  the	  mean	  signal	  was	  used	  as	  the	  protein’s	  fluorescent	  signal.	  These	  datasets	  were	  then	  
aligned	  using	  custom	  written	  Matlab	  code.	  This	  program	  also	  scanned	  for	  possible	  cross-­‐talk	  and	  
calculated	  local	  background	  levels,	  as	  detailed	  in	  Chapter	  1.2.2.2.	  	  
	   The	  percent	  of	  T	  cells	  secreting	  a	  certain	  protein	  was	  calculated	  in	  both	  a	  relative	  and	  absolute	  
fashion:	  
𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒  𝑆𝑒𝑐𝑟𝑒𝑡𝑖𝑜𝑛  𝑅𝑎𝑡𝑒! =    1  𝑖𝑓  𝑃𝑟𝑜𝑡𝑒𝑖𝑛!" > 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑  𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑0  𝑖𝑓  𝑃𝑟𝑜𝑡𝑒𝑖𝑛!" < 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑  𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑!!!! 𝑛 ×100%	  
Where	  Proteinij	  is	  the	  protein	  level	  of	  the	  jth	  protein	  for	  the	  ith	  cell	  and	  n	  is	  the	  total	  number	  of	  single	  
cells	  for	  that	  patient.	  
	   𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒  𝑆𝑒𝑐𝑟𝑒𝑡𝑖𝑜𝑛  𝑅𝑎𝑡𝑒! =    !"#$%&'(  !"#$"%&  !  !"##$  !"#$"%&'(!!"#$%&'(  !"#$!"#  !  !"##$  !"#$"%&'(!!!!! ×100%	  
	   As	  an	  initial	  test,	  protein	  signal	  levels	  were	  correlated	  with	  patient	  outcome.	  This	  was	  done	  by	  
performing	  a	  Pearson’s	  and	  Spearsman’s	  correlation	  and	  recording	  the	  p	  value.	  A	  Bonferroni	  Correction	  
was	  used	  to	  account	  for	  the	  large	  number	  of	  correlation	  hypotheses	  tested.	  	  
	   To	  predict	  patient	  outcome,	  a	  partial	  least	  squares	  regression	  model	  was	  generated.	  This	  
method	  is	  useful	  in	  fitting	  multivariate	  data	  to	  response	  outcomes,	  as	  it	  uses	  algorithmically	  determined	  
principal	  components	  to	  fit	  the	  data	  (rather	  than	  standard	  principal	  components	  like	  in	  Principal	  
Component	  Regression).	  Feature	  selection	  was	  performed	  using	  a	  custom	  written	  Genetic	  Algorithm,	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which	  used	  Q2	  score	  as	  the	  quality	  metric	  for	  gene	  survival.	  Q2	  is	  a	  measure	  of	  the	  PLSR	  model’s	  
“goodness	  of	  fit”	  from	  cross-­‐validations,	  similar	  to	  R2	  in	  linear	  regression.	  It	  is	  defined	  as:	  
𝑄! = 1−   𝑃𝑅𝐸𝑆𝑆𝑇𝑆𝑆 	  
where	  PRESS	  is	  the	  Predictive	  Residual	  Sum	  of	  Squares	  and	  TSS	  is	  the	  total	  sum	  of	  squares.	  	  
	   Finally,	  the	  polyfunctional	  strength	  index	  (pSI)	  was	  fit	  to	  the	  response	  data	  to	  determine	  if	  it	  was	  
predictive.	  This	  was	  done	  by	  using	  a	  linear	  discriminant	  analysis	  estimation.	  The	  equation	  for	  calculating	  
the	  pSI	  is	  shown	  below	  [13]:	  	  
	  
where	  p	  is	  the	  number	  of	  proteins	  in	  the	  “function	  panel.”	  The	  function	  panels	  are	  proteins	  that	  share	  
the	  same	  role	  in	  the	  body,	  determined	  in	  reference	  [13].	  For	  a	  T	  cell	  to	  be	  considered	  as	  polyfunctional,	  
it	  was	  required	  to	  be	  secreting	  at	  least	  3	  of	  the	  total	  10	  proteins	  measured.	  The	  average	  protein	  levels	  of	  
T	  cells	  that	  expressed	  proteins	  for	  a	  specific	  function	  were	  then	  calculated	  and	  summed	  over	  all	  proteins	  
in	  that	  function.	  This	  is	  multiplied	  by	  the	  percent	  of	  T	  cells	  that	  had	  that	  function	  to	  obtain	  the	  pSI.	  	  
4.3  –  Results  
4.3.1  -­‐  Patient  and  T  cell  Statistics  
The	  patient	  statistics	  are	  detailed	  in	  Appendix	  A,	  Table	  2.	  	  
Cell	  viability	  of	  the	  patient	  T	  cells	  was	  15±9%	  and	  7±7%	  for	  the	  F5	  and	  NIH	  trial,	  respectively.	  In	  
order	  to	  rule	  out	  the	  cell	  viability	  accounting	  for	  differences	  in	  the	  T	  cell	  measurements,	  it	  was	  
correlated	  with	  individual	  protein	  levels	  and	  average	  pSI	  magnitude.	  This	  yielded	  R2	  values	  <	  0.01,	  
signifying	  no	  correlation	  between	  the	  viability	  and	  T	  cell	  functionality.	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The	  T	  cell	  statistics	  showed	  large	  differences	  between	  patient	  T	  cell	  functionality.	  A	  scatter	  plot	  
of	  the	  protein	  copy	  numbers	  per	  T	  cell	  is	  shown	  in	  Figure	  2.	  One	  can	  see	  strong	  variation	  in	  protein	  
secretion	  level	  between	  patients.	  This	  was	  especially	  true	  in	  the	  case	  of	  CCL4,	  where	  patient	  F5-­‐2’s	  T	  
cells	  secreted	  nearly	  10x	  higher	  on	  average	  than	  all	  the	  other	  patients.	  CCL4’s	  average	  signal	  CV%	  
between	  patients	  was	  109%,	  whereas	  the	  average	  of	  the	  remaining	  proteins	  was	  34.5%.	  Far	  fewer	  
copies	  of	  TNFa	  were	  secreted	  on	  average;	  however,	  this	  was	  not	  the	  case	  when	  PMA/I	  stimulation	  was	  
used	  to	  stimulate	  the	  T	  cells	  (not	  shown).	  An	  additional	  noteworthy	  aspect	  displayed	  in	  Figure	  2	  is	  the	  
right	  skew	  of	  CCL4,	  TNFa,	  and	  IFNg	  levels,	  due	  to	  large	  outliers.	  For	  instance,	  the	  average	  CV%	  of	  CCL4’s	  
protein	  levels	  from	  the	  same	  patient	  was	  305%.	  	  
The	  absolute	  and	  relative	  percent	  of	  T	  cells	  secreting	  a	  specific	  protein	  is	  shown	  for	  the	  F5	  trial	  
in	  Figure	  3a	  and	  3b,	  respectively.	  Across	  all	  proteins,	  the	  CV%	  of	  T	  cell	  secretion	  rate	  was	  52.5%±16	  and	  
38.8%±14	  for	  the	  absolute	  and	  relative	  cases,	  respectively.	  This	  shows	  that	  the	  distribution	  of	  the	  
relative	  T	  cell	  secretion	  rate	  is	  fairly	  similar	  across	  patients,	  as	  can	  be	  seen	  visually	  in	  Figure	  3b.	  Much	  of	  
the	  difference	  in	  this	  comes	  from	  patient	  F5-­‐7.	  When	  this	  patient	  was	  removed,	  the	  CV%	  for	  dropped	  to	  





Figure	  2:	  Scatter	  plot	  of	  single	  T	  cell	  protein	  secretion	  levels	  from	  five	  F5	  trial	  patients.	  Each	  point	  represents	  a	  measured	  single	  




Figure	  3:	  Secretion	  rates	  of	  T	  cells	  from	  F5	  trial	  patients.	  a)	  The	  absolute	  percent	  of	  all	  individual	  T	  cells	  that	  were	  considered	  
positive	  secretors	  for	  each	  protein.	  b)	  The	  relative	  rate	  of	  T	  cell	  secretion	  rate.	  This	  was	  obtained	  using	  the	  equation	  in	  Chapter	  
4.2.5.	  
	   From	  correlating	  measured	  parameters	  with	  the	  progression	  free	  survival	  (PFS)	  of	  each	  patient,	  
no	  significant	  correlations	  were	  found.	  This	  was	  the	  case	  both	  with	  Pearson’s	  and	  Spearsman’s	  
correlation.	  The	  full	  list	  of	  p	  values	  is	  summarized	  in	  Appendix	  A	  Table	  3.	  Only	  the	  standard	  deviation	  of	  
IL-­‐2	  showed	  good	  correlation	  (Figure	  4).	  However,	  because	  of	  the	  large	  number	  of	  hypotheses	  tested,	  its	  




Figure	  4:	  Correlation	  between	  standard	  deviation	  of	  IL-­‐2	  and	  progression	  free	  survival	  in	  the	  F5	  Trial.	  The	  p-­‐value	  was	  0.0069,	  
which	  was	  close	  to	  the	  significance	  threshold	  determined	  by	  the	  Bonferroni	  correction	  (p	  <	  0.0014).	  
	   The	  percent	  of	  cells	  with	  a	  certain	  number	  of	  functions	  is	  shown	  in	  Figure	  5.	  This	  shows	  that	  
patient	  F5-­‐2	  has	  significantly	  higher	  polyfunctional	  cells,	  regardless	  of	  the	  number	  of	  functions.	  All	  other	  
patients	  exhibited	  a	  similar	  trend.	  
	  
Figure	  5:	  Percent	  of	  T	  cells	  with	  a	  certain	  number	  of	  functions	  for	  patients	  in	  the	  F5	  trial.	  Each	  data	  point	  gives	  the	  percent	  of	  
total	  single	  T	  cells	  that	  had	  that	  number	  of	  functions	  or	  more.	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4.3.2  -­‐  PLSR  Prediction  
	   There	  were	  many	  well	  predicting	  PLSR	  models,	  with	  Q2	  values	  of	  >0.9.	  However,	  because	  of	  the	  
limited	  number	  of	  patients,	  cross-­‐validation	  was	  not	  possible.	  Therefore,	  no	  definite	  conclusions	  could	  
be	  made	  regarding	  the	  best	  model	  to	  predict	  PFS	  using	  single	  cell	  T	  cells	  data.	  	  
4.3.3  -­‐  pSI  Prediction  
	   Pie	  charts	  showing	  the	  pSI	  are	  shown	  for	  the	  best,	  average,	  and	  worst	  responders	  in	  Figure	  6.	  
The	  diameter	  of	  the	  pie	  chart	  is	  proportional	  to	  the	  average	  pSI	  value,	  with	  the	  pie	  slices	  representing	  
each	  function’s	  contribution.	  Across	  all	  patient,	  the	  MIP1b	  (CCL4)	  function	  dominated	  the	  contribution,	  
with	  the	  Killing	  function	  coming	  second.	  The	  correlations	  between	  each	  function	  and	  the	  PFS	  time	  for	  
patients	  was	  measured	  in	  Appendix	  A	  Table	  3.	  There	  were	  no	  strong	  correlations	  with	  the	  current	  
datasets.	  However,	  the	  patients	  with	  the	  highest	  average	  pSI	  were	  the	  two	  top	  responders	  in	  the	  F5	  
trial.	  This	  can	  be	  seen	  in	  Figures	  7a.	  The	  relationship	  between	  average	  pSI	  and	  PFS	  in	  the	  NIH	  trial	  is	  
shown	  in	  Figure	  7b.	  In	  both	  cases,	  the	  blue	  line	  represents	  the	  estimated	  linear	  discriminant	  analysis	  
boundary	  for	  what	  was	  considered	  a	  “non-­‐responder”	  and	  “responder,”	  according	  to	  the	  leading	  
doctors	  of	  the	  study.	  This	  was	  the	  red	  line	  demarcates	  the	  idea	  separation	  based	  on	  pSI	  to	  predict	  “non-­‐





Figure	  6:	  pSI	  pie	  charts	  for	  the	  best,	  average,	  and	  worst	  responders	  in	  the	  F5	  trial.	  Pie	  charts	  are	  scaled	  in	  proportion	  to	  the	  
average	  pSI	  value.	  Each	  slice	  represents	  a	  pSI	  function.	  	  




Figure	  7:	  Scatter	  plot	  of	  average	  pSI	  vs.	  progression	  free	  survival	  (PFS)	  for	  the	  a)	  F5	  trial	  and	  b)	  NIH	  trial.	  The	  blue	  line	  shows	  the	  
general	  boundary	  for	  responders	  and	  non-­‐responders.	  Below	  the	  line	  is	  a	  non-­‐responder,	  and	  above	  is	  a	  responder.	  The	  red	  line	  
represents	  the	  boundary	  line	  for	  the	  best	  separation	  of	  responders/non-­‐responders	  based	  on	  average	  pSI.	  	  
4.4  –  Discussion  
	   Though	  we	  did	  not	  observe	  a	  correlation	  between	  pSI	  and	  patient	  PFS,	  this	  does	  not	  negate	  our	  
ability	  to	  predict	  response.	  Firstly,	  we	  require	  more	  data	  before	  making	  a	  solid	  conclusion	  about	  
polyfunctionality’s	  relationship	  to	  patient	  success	  in	  genetic	  engineered	  ACT.	  Secondly,	  our	  method	  
successfully	  captured	  the	  top	  two	  responding	  patients	  in	  the	  F5	  trial	  by	  using	  average	  pSI	  as	  a	  prediction	  
metric.	  This	  shows	  promise	  that	  our	  method	  could	  be	  used	  as	  a	  predictive	  model	  for	  only	  the	  patients	  
with	  the	  highest	  polyfunctional	  T	  cells,	  without	  making	  predictions	  for	  patients	  that	  had	  average	  pSI	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values	  below	  a	  certain	  threshold.	  Therefore,	  it	  would	  be	  interesting	  to	  further	  investigate	  this	  
phenomenon	  with	  more	  statistics.	  	  
One	  possible	  reason	  our	  study	  did	  not	  show	  a	  strong	  correlation	  between	  polyfunctionality	  and	  
patient	  response	  was	  that	  it	  could	  not	  take	  epitope	  spreading	  into	  account.	  Epitope	  spreading	  is	  when	  
protein	  fragments	  are	  released	  from	  a	  lysed	  tumor	  and	  then	  captured	  by	  DCs.	  These	  DCs	  go	  on	  to	  prime	  
naïve	  T	  cells	  in	  the	  draining	  lymph	  nodes.	  This	  generates	  a	  second	  generation	  of	  T	  cells	  with	  a	  diverse	  set	  
of	  epitope	  targets,	  hence	  the	  name	  epitope	  spreading.	  This	  phenomenon	  has	  been	  shown	  to	  correlate	  
with	  successful	  immunotherapy	  trials,	  in	  the	  case	  of	  Type	  I	  immune	  responses	  [17].	  Therefore,	  because	  
we	  were	  not	  able	  to	  measure	  the	  potential	  magnitude	  of	  epitope	  spreading,	  our	  predications	  may	  be	  
missing	  a	  key	  component	  to	  determining	  immunotherapy	  success.	  	  
	   	  Another	  possible	  reasons	  we	  did	  see	  a	  strong	  correlation	  between	  polyfunctionality	  and	  patient	  
response	  was	  that	  the	  T	  cell	  viability	  was	  low.	  We	  opted	  to	  test	  the	  T	  cells	  directly	  after	  thawing	  rather	  
than	  culturing	  them,	  because	  this	  was	  closer	  to	  the	  actual	  T	  cell	  infusion	  product	  that	  the	  patients	  
received.	  Culturing	  would	  mature/differentiate	  the	  T	  cells	  and	  may	  not	  reflect	  the	  actual	  population	  
phenotype	  they	  would	  have	  received	  upon	  infusion	  [18].	  This	  unfortunately	  meant	  that	  we	  had	  to	  sort	  
out	  a	  significant	  amount	  of	  dead	  cells,	  and	  use	  the	  remainder	  for	  our	  tests.	  	  	  
	   The	  PLSR	  model	  showed	  promise	  in	  obtaining	  a	  relationship	  between	  single	  cell	  T	  cell	  data	  and	  
patient	  response;	  however,	  there	  was	  not	  enough	  data	  to	  train	  and	  test	  a	  full	  model.	  Therefore,	  we	  
believe	  that	  with	  additional	  patients,	  it	  is	  still	  possible	  to	  relate	  single	  cell	  T	  cell	  information	  to	  patient	  
response.	  	  
4.5  –  Conclusions  
	   Single	  T	  cell	  protein	  measurements	  were	  conducted	  on	  the	  Pre-­‐Infusion	  product	  of	  15	  
metastatic	  melanoma	  patients	  undergoing	  genetically	  engineered	  ACT.	  In	  one	  of	  the	  two	  trials,	  the	  top	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two	  patients	  were	  predicted	  as	  good	  responders	  based	  on	  their	  polyfunctional	  strength	  index.	  Further	  
data	  is	  necessary	  to	  conclude	  if	  polyfunctionality	  is	  predictive	  for	  ACT	  success.	  	  
Appendix  A  (Chapter  4)  
Table	  1:	  Proteins	  used	  and	  ssDNA	  sequences.	  
Protein	  Name	   Vendor	   Capture	  Antibody	   Detection	  Antibody	   DNA	  ID	   ssDNA	  Sequence	  
IL-­‐2	   R&D	  Systems	   MAB602	   BAF202	   B	   5'-­‐AAA	  AAA	  AAA	  AAA	  AGC	  CTC	  ATT	  GAA	  TCA	  TGC	  CTA	  -­‐3'	  
IL-­‐17	   R&D	  Systems	   MAB317	   BAF317	   C	   5'-­‐	  AAA	  AAA	  AAA	  AAA	  AGC	  ACT	  CGT	  CTA	  CTA	  TCG	  CTA	  -­‐3'	  
IFNg	   R&D	  Systems	   MAB2852	   BAF285	   D	   5'-­‐AAA	  AAA	  AAA	  AAA	  AAT	  GGT	  CGA	  GAT	  GTC	  AGA	  GTA	  -­‐3'	  
TNFa	   Biolegend	   502802	   502904	   E	   5'-­‐AAA	  AAA	  AAA	  AAA	  AAT	  GTG	  AAG	  TGG	  CAG	  TAT	  CTA	  -­‐3'	  
CCL4	  (MIP1b)	   R&D	  Systems	   MAB271	   BAF271	   F	   5'-­‐AAA	  AAA	  AAA	  AAA	  AAT	  CAG	  GTA	  AGG	  TTC	  ACG	  GTA	  -­‐3'	  
Perforin	   	   	   	   H	   5'-­‐AAA	  AAA	  AAA	  AAT	  TGA	  CCA	  AAC	  TGC	  GGT	  GCG-­‐3'	  
Granzyme	  B	   R&D	  Systems	   EL2906	   EL2906	   I	   5'-­‐AAA	  AAA	  AAA	  ATG	  CCC	  TAT	  TGT	  TGC	  GTC	  GGA-­‐3'	  
IL-­‐4	   Biolegend	   500701	   500804	   K	   5'-­‐AAA	  AAA	  AAA	  ATA	  ATC	  TAA	  TTC	  TGG	  TCG	  CGG-­‐3'	  
IL-­‐10	   R&D	  Systems	   MAB2172	   BAF217	   L	   5'-­‐AAA	  AAA	  AAA	  AGT	  GAT	  TAA	  GTC	  TGC	  TTC	  GGC-­‐3'	  
IL-­‐6	   R&D	  Systems	   MAB206	   BAF206	   M	   5'-­‐Cy3-­‐AAA	  AAA	  AAA	  AGT	  CGA	  GGA	  TTC	  TGA	  ACC	  TGT-­‐3'	  
	  
	  
Table	  2:	  Patient	  information	  from	  F5	  Trial.	  	  



















Bone	   6	   1	   74.1	   15.9	  x	  10^5	  
F5-­‐3	   M	   White	   61	   -­‐	   Lung,	  Liver	   13	   1	   74.6	   3.4	  x	  10^5	  
F5-­‐7	   M	   White	   48	   IL-­‐2	   SC,	  Bone	   9	   1	   63.7	   4.2	  x	  10^5	  
F5-­‐8	   M	   White	   44	   -­‐	   LN,	  Liver	   11	   1	   66.7	   7.8	  x	  10^5	  
F5-­‐9	   F	   White	   46	   -­‐	   Skin,	  LN	   11	   1	   69.7	   11	  x	  10^5	  
F5-­‐
10	   F	   White	   47	   -­‐	  
Liver,	  
Adrenal,	  SC,	  
LN,	  Orbit	   14	   5	   55.9	   4.7	  x	  10^5	  
F5-­‐










SC	   4	   4.4	   49.7	   8.7	  x	  10^5	  
	  
Table	  3:	  P	  values	  of	  correlation	  data	  from	  measured	  parameters	  and	  progression	  free	  survival.	  Both	  Spearsman’s	  and	  Pearson’s	  




















































Spearsman	   0.546	   0.8512	   0.3579	   0.9444	   0.8004	   0.5841	   0.9444	   0.8004	   0.4647	  
























































Spearsman	   0.9444	   0.1556	   1	   0.8988	   0.546	   0.8004	   0.3706	   0.2948	   0.8512	  



































Spearsman	   0.8512	   0.2948	   0.129	   0.3401	   0.406	   0.148	   0.1937	   0.7349	   0.9885	  
























Spearsman	   0.9885	   0.406	   0.3873	   0.4647	   0.1024	   0.8988	   0.148	   0.0361	   0.9444	  

























Spearsman	   0.3873	   0.3706	   0.2405	   0.0183	   0.8004	   0.7956	   0.6417	   0.6417	   0.8952	  



























Spearsman	   0.7147	   0.2663	   0.3254	   0.9135	   0.6262	   0.4988	   0.6667	   0.9885	   0.1548	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Chapter  5:  T  cell-­‐T  cell  Contact  and  its  Effect  on  Protein  Secretion  in  
Microfluidic  Cell  Assays  
5.1  –  Introduction  
Leukocyte	  communication	  is	  a	  critical	  aspect	  of	  the	  immune	  response	  that	  drives	  adaptive	  
immunity	  [1].	  In	  one	  arm	  of	  the	  adaptive	  immune	  response,	  naive	  T	  (TN)	  cells	  communicate	  with	  
dendritic	  cells	  in	  the	  lymph	  nodes,	  where	  they	  are	  primed	  to	  become	  T	  memory	  (TM)	  or	  effector	  (TE)	  cells	  
[1].	  The	  determination	  of	  a	  TN’s	  fate	  to	  become	  either	  a	  memory	  or	  effector	  T	  cell	  is	  still	  not	  fully	  
understood;	  however,	  much	  effort	  has	  been	  put	  towards	  elucidating	  this	  mechanism	  [2,	  3].	  This	  is	  
critical	  to	  understand,	  because	  it	  can	  determine	  whether	  a	  patient	  will	  become	  immunized	  towards	  a	  
certain	  foreign	  species	  or	  not.	  This	  is	  critical	  in	  vaccines	  and	  the	  developing	  field	  of	  immunotherapy.	  	  
One	  such	  immunotherapy,	  Adoptive	  T	  cell	  immunotherapy	  (ACT),	  has	  shown	  great	  promise	  in	  
treating	  late	  stage	  cancer	  patients	  [4].	  As	  mentioned	  in	  Chapter	  4,	  ACT	  rates	  of	  success	  vary	  drastically	  
from	  patient	  to	  patient.	  One	  metric	  for	  predicting	  its	  long	  term	  success	  is	  the	  persistence	  of	  T	  cells	  
beyond	  one	  months	  [5].	  This	  indicates	  a	  memory	  pool	  of	  T	  cells	  is	  necessary	  for	  ACT	  success.	  Therefore,	  
applications	  like	  immunotherapy	  would	  be	  much	  more	  viable,	  if	  T	  cell	  priming	  could	  be	  manipulated	  to	  
increasing	  the	  number	  of	  memory	  cells	  produced.	  	  
A	  recent	  theory	  in	  T	  cell	  memory	  formation	  is	  that	  T	  cell-­‐T	  cell	  interactions	  promote	  long-­‐term	  
memory.	  These	  interactions	  are	  similar	  to	  that	  of	  T	  cells	  communicating	  with	  dendritic	  cells	  (DCs).	  M.	  
Krummel	  et	  al.	  demonstrated	  that	  after	  priming	  from	  DCs,	  T	  cells	  will	  cluster	  together	  and	  form	  
synapses	  [6].	  These	  synapses	  focus	  protein	  secretion	  towards	  the	  other	  T	  cell,	  enhancing	  the	  capture	  
efficiency	  of	  paracrine	  signaling	  [7].	  Disrupting	  this	  T	  cell-­‐T	  cell,	  or	  homotypic,	  interaction	  slowed	  down	  
immune	  activation	  rate.	  Furthermore,	  inhibiting	  T-­‐T	  contact	  reduces	  the	  number	  of	  TM	  cells	  produced	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after	  an	  infection	  [8,	  9].	  This	  has	  been	  demonstrated	  by	  inhibiting	  T	  cell	  adhesion	  molecules	  (e.g.,	  LFA-­‐1	  
and	  ICAM-­‐1)	  prior	  to	  infection	  and	  measuring	  the	  numbers	  of	  persisting	  TM	  cells	  post-­‐infection.	  
Additionally,	  J.	  Zhou	  has	  demonstrated	  that	  the	  strength	  of	  T	  cell	  response	  is	  increased	  when	  T	  cells	  are	  
incubated	  together	  [Unpublished]	  Using	  mice	  with	  OT-­‐1+	  tumors,	  she	  performed	  an	  ACT	  with	  T	  cells	  that	  
were	  either	  directly	  injected	  into	  mice	  or	  incubated	  together	  before	  injecting.	  The	  mice	  that	  received	  T	  
cells	  incubated	  together	  showed	  significantly	  stronger	  tumor	  responses.	  Therefore,	  there	  is	  much	  
promise	  in	  improving	  immunotherapies	  by	  better	  understanding	  the	  mechanism	  behind	  T-­‐T	  
communication.	  	  
The	  topic	  of	  this	  chapter	  is	  understanding	  the	  functional	  effect	  of	  T-­‐T	  communication.	  We	  wish	  
to	  better	  understand	  how	  T	  cell	  communication	  influences	  the	  strength	  of	  the	  T	  cell	  response,	  
specifically,	  its	  functional	  protein	  secretion.	  As	  in	  the	  previous	  chapter,	  this	  investigation	  was	  
accomplished	  using	  single	  cell	  proteomic	  technology.	  Additional	  software	  was	  developed	  in	  order	  to	  
automate	  the	  analysis	  of	  parameters	  related	  to	  two	  cell	  data	  measured	  in	  this	  project	  (e.g.,	  distance	  
between	  cells)	  	  
5.2  –  Methods  
5.2.1  -­‐  Microfluidic  Device  
	   The	  microfluidic	  device	  used	  for	  this	  study	  was	  the	  same	  design	  as	  that	  used	  in	  Chapter	  4.	  The	  
process	  of	  making	  this	  device	  is	  detailed	  in	  Chapter	  4.2.1.	  One	  difference	  in	  the	  process	  was	  that	  the	  
PDMS	  device	  was	  cured	  in	  an	  aluminum	  block	  to	  attain	  a	  flat-­‐top	  surface,	  as	  detailed	  in	  Chapter	  1.2.1.1.	  
This	  allowed	  for	  the	  automated	  imaging	  of	  the	  cells	  through	  the	  PDMS	  by	  an	  Olympus	  IX81	  microscope.	  	  
5.2.2  -­‐  Automated  programs  
The	  general	  function	  of	  the	  cell	  counting	  programs	  used	  to	  count	  the	  cells	  and	  analyze	  the	  
secreted	  protein	  levels	  is	  detailed	  in	  Chapter	  1.2.1	  and	  Chapter	  1.2.2,	  respectively.	  In	  addition,	  two	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functions	  were	  added	  to	  the	  automated	  cell	  counting	  program:	  T	  cell-­‐T	  cell	  distance	  calculation	  and	  
fluorescence	  detection.	  	  
For	  the	  distance	  calculation,	  the	  pixel-­‐value	  distance	  between	  two	  cells	  was	  measured	  by	  the	  
program	  and	  converted	  to	  microns,	  using	  reference	  dimensions	  on	  the	  microfluidic	  device.	  After	  all	  two	  
cell	  chamber	  distances	  had	  been	  calculated,	  the	  user	  manually	  inspects	  each	  two	  cell	  chamber.	  They	  
then	  input	  whether	  the	  T	  cells	  are	  contacting	  or	  non-­‐contacting,	  or	  reject	  it	  as	  a	  faulty	  chamber.	  	  
The	  fluorescence	  detection	  was	  accomplished	  by	  overlaying	  the	  bright-­‐field	  microscope	  image	  
of	  the	  microfluidic	  device	  with	  the	  fluorescence	  image	  of	  the	  device	  and	  using	  the	  cellular	  regions	  of	  
interest	  from	  the	  bright-­‐field	  image	  to	  crop	  the	  fluorescence	  image.	  The	  average	  fluorescence	  intensity	  
was	  used	  to	  determine	  if	  a	  cell	  had	  “positive”	  fluorescence	  or	  not.	  In	  the	  fluorescence	  detection,	  the	  
GFP	  channel	  was	  used	  to	  visualize	  the	  CD8	  (FITC)	  on	  T	  cells.	  If	  the	  program	  detected	  significant	  
fluorescence	  from	  a	  T	  cell	  for	  that	  channel,	  it	  would	  be	  regarded	  as	  a	  CD8	  T	  cell.	  Otherwise,	  it	  was	  
regarded	  as	  a	  CD4	  T	  cell,	  since	  the	  population	  of	  T	  cells	  was	  pre-­‐sorted	  for	  CD4	  or	  CD8	  single	  positives.	  	  
5.2.3  -­‐  FACS  Cell  Sorting  
	   The	  T	  cells	  used	  were	  from	  the	  F5	  or	  NIH	  immunotherapy	  trial,	  as	  described	  in	  Chapter	  4.2.	  
T	  cells	  were	  sorted	  using	  a	  BD	  Aria	  II	  or	  Aria	  III	  machine.	  Cells	  were	  gated	  on	  FSC-­‐A,	  FSC-­‐H,	  SSC-­‐A	  
(singlet,	  lymphocyte	  identification),	  7-­‐AAD	  (viability),	  CD4	  (Biolegend,	  OKT-­‐4),	  CD8	  (Biolegend,	  HIT8a),	  
and	  MART-­‐1	  tetramer	  (MBL	  Int.).	  The	  machine	  was	  calibrated	  with	  CompBeads	  (BD	  Biosci.)	  prior	  to	  
sorting.	  The	  T	  cells	  were	  sorted	  into	  two	  groups,	  CD4+CD8-­‐MART-­‐1+	  and	  CD4-­‐CD8+MART-­‐1+,	  which	  are	  
henceforth	  referred	  to	  as	  CD4	  and	  CD8,	  respectively.	  
	   T	  cells	  were	  sorted	  with	  specific	  colors,	  in	  order	  to	  allow	  for	  fluorescence	  imaging	  on	  an	  
Olympus	  IX81	  microscope.	  CD4	  (fluorohpore:	  APC/Cy7)	  and	  7-­‐AAD	  (PerCP)	  were	  used	  because	  these	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fluorophores	  were	  undetected	  in	  the	  IX81	  microscope.	  Because	  CD8	  was	  to	  be	  detected,	  FITC	  was	  
selected	  as	  a	  fluorophore	  as	  it	  was	  detectable	  on	  the	  IX81	  microscope.	  	  
5.2.4  -­‐  Two  Cell  Secretome  Experiment  
	   T	  cell	  experiments	  were	  run	  in	  a	  similar	  fashion	  to	  the	  experiments	  described	  in	  5.2.3	  with	  a	  
minor	  change	  to	  the	  protocol:	  the	  devices	  were	  imaged	  on	  an	  Olympus	  IX81	  microscope	  to	  obtain	  a	  full-­‐
view,	  stitched	  image	  of	  the	  cells	  in	  the	  microfluidic	  device.	  The	  resulting	  data	  was	  analyzed	  using	  the	  
automated	  programs	  described	  in	  Chapter	  1.	  Cells	  were	  counted	  in	  every	  microfluidic	  chamber	  and	  the	  
two	  cells	  chambers	  were	  further	  analyzed	  for	  T	  cell-­‐T	  cell	  distance,	  as	  well	  as	  if	  the	  T	  cells	  were	  
contacting.	  	  
	   The	  percent	  of	  T	  cells	  secreting	  a	  specific	  protein	  was	  gated	  by	  “contacting”	  and	  “non-­‐
contacting,”	  and	  then	  plotted	  by	  protein.	  This	  was	  accomplished	  by	  first	  determining	  the	  threshold	  for	  
what	  is	  considered	  to	  be	  a	  “positive-­‐secreting”	  T	  cells.	  The	  cutoff	  used	  was	  the	  95	  percentile	  of	  the	  
protein	  level	  in	  zero	  cell	  chambers	  (Meanzero	  cell	  +	  2	  *	  StandardDeviationzero	  cell).	  The	  percent	  of	  T	  cells	  
considered	  positive	  secretors	  was	  then	  calculated	  for	  both	  contacting	  two	  cell	  chambers	  and	  non-­‐
contacting	  two	  cell	  chambers.	  	  
In	  addition,	  the	  theoretical	  percent	  of	  two	  T	  cells	  that	  should	  have	  been	  secreting	  was	  calculated	  
using	  the	  single	  cell	  data.	  This	  equation	  was	  used	  for	  calculating	  the	  probability	  for	  at	  least	  one	  of	  two	  
independent	  events	  (X	  and	  Y)	  to	  occur	  [10].	  
Pr(X|Y)	  =	  Pr(X)	  +	  Pr(Y)	  –	  Pr(X	  &	  Y)	  
where	  X	  is	  the	  event	  that	  one	  of	  the	  two	  single	  cells	  in	  a	  chamber	  secretes	  a	  certain	  protein	  and	  Y	  is	  the	  
probability	  that	  the	  other	  cell	  secretes	  the	  protein.	  In	  our	  case,	  because	  X	  and	  Y	  have	  the	  same	  
probability	  value,	  we	  can	  simplify	  using:	  P(X)	  =	  P(Y)	  and	  P(X	  &	  Y)	  =	  P(X)2	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   Pr(X|Y)	  =	  2Pr(X)	  –	  Pr(X)2	  	   	   	   	   	   	   	   	  	  	  	  	  	  Equation	  (1)	  
5.2.5  -­‐  Nature  of  T-­‐T  contact  
To	  determine	  if	  TCR	  clustering	  occurred	  in	  the	  T-­‐T	  contact	  synapse,	  MART-­‐1+	  Jurkat	  T	  cells	  were	  
obtained	  from	  the	  Baltimore	  Lab,	  courtesy	  of	  Michael	  Bethune.	  These	  T	  cells	  were	  stained	  with	  PE-­‐
MART-­‐1	  Tetramer	  (MBL	  Int.)	  and	  imaged	  on	  an	  Olympus	  IX81	  microscope	  both	  under	  bright-­‐field	  and	  
TxRed	  fluorescence.	  The	  images	  were	  analyzed	  to	  get	  the	  percent	  of	  contacting	  T	  cells	  that	  have	  
tetramer	  bridging	  their	  synapse.	  	  
To	  investigate	  the	  effect	  of	  blocking	  synapse	  formation,	  different	  molecules	  were	  added	  to	  
observe	  how	  they	  altered	  the	  degree	  of	  contact.	  To	  106	  cells/mL	  in	  100	  µL,	  each	  of	  following	  molecules	  
were	  added	  separately:	  anti-­‐CD3	  (eBioscience,	  5uL	  of	  0.5mg/mL),	  MART-­‐1	  Tetramer	  (MBL	  Int,	  5	  µL),	  and	  
1x	  PBS	  (5	  µL).	  The	  cells	  were	  allowed	  to	  incubate	  overnight	  for	  16	  hours.	  They	  were	  then	  imaged	  and	  the	  
percent	  of	  cells	  in	  contact	  was	  counted	  by	  hand.	  	  	  
5.2.6  -­‐  Two  Cell  Phenotype  Experiment  
	   This	  experiment	  was	  run	  in	  a	  similar	  fashion	  to	  Chapter	  4.2.4,	  with	  the	  addition	  of	  fluorescent	  
images	  being	  acquired	  during	  testing	  to	  detect	  CD8	  and	  CD4	  phenotypes.	  Prior	  to	  loading	  the	  T	  cells	  into	  
the	  microfluidic	  device,	  the	  T	  cells	  were	  stained	  with	  CD8-­‐FITC	  for	  30	  min	  to	  improve	  coverage	  of	  the	  
fluorophore.	  	  
	   Data	  analysis	  involved	  acquiring	  cell	  count,	  two	  cell	  distances,	  and	  determining	  if	  each	  cell	  was	  
CD8	  positive.	  CD8	  detection	  was	  ascertained	  using	  a	  method	  similar	  to	  that	  of	  the	  normal	  cell	  detection:	  
the	  fluorescence	  image	  was	  split	  into	  RGB	  layers	  and	  the	  user	  selects	  which	  layer	  should	  be	  used.	  For	  
example,	  the	  GFP	  fluorophore	  would	  be	  the	  green	  layer.	  Next,	  the	  chambers	  are	  cropped	  out	  according	  
to	  the	  chamber	  boundaries	  defined	  in	  the	  normal	  cell	  counting	  program	  (Chapter	  1.2.1.3).	  Each	  chamber	  
is	  then	  binarized	  using	  a	  user	  set	  threshold	  value	  and	  then	  features	  are	  found	  using	  the	  cell	  detection	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method	  used	  in	  Chapter	  1.2.1.	  In	  the	  final	  output,	  each	  chamber	  has	  an	  additional	  value	  added:	  the	  
number	  of	  fluorescent	  cells.	  	  
	   The	  theoretical	  values	  for	  the	  contacting	  CD4-­‐CD4,	  CD4-­‐CD8,	  and	  CD8-­‐CD8	  were	  calculated	  from	  
the	  percent	  of	  CD4	  and	  CD8s	  sorted	  in	  the	  FACS.	  Additionally,	  the	  theoretical	  percent	  of	  two	  cell	  
chambers	  secreting	  a	  certain	  protein	  was	  calculated	  similar	  to	  Equation	  (1).	  However,	  this	  was	  
calculated	  separately	  for	  chambers	  with	  CD4-­‐CD4,	  CD4-­‐CD8,	  and	  CD8-­‐CD8	  phenotype	  cells.	  These	  
theoretical	  percentages	  of	  T	  cells	  secreting	  were	  then	  used	  to	  see	  if	  the	  two	  cells	  in	  contact,	  with	  that	  
same	  phenotype,	  were	  secreting	  more	  than	  the	  theoretical	  value.	  A	  chamber	  was	  considered	  to	  be	  
secreting	  significantly	  higher	  when	  its	  levels	  were	  two	  standard	  deviations	  higher	  than	  the	  mean	  of	  the	  
theoretical	  value	  calculated	  from	  the	  single	  cell	  chambers.	  	  
5.3  –  Results  
5.3.1  -­‐  Two  Cell  Secretome  Experiment  
	   The	  distribution	  of	  cell-­‐cell	  distances	  is	  plotted	  for	  four	  different	  patients	  in	  Figure	  1.	  Note,	  the	  
distance	  value	  (x-­‐axis)	  are	  binned	  in	  intervals	  that	  range	  400	  µm,	  with	  an	  additional	  bin	  at	  0	  with	  a	  single	  
value	  of	  0	  µm	  (contact).	  All	  patients	  showed	  a	  non-­‐statistical	  amount	  of	  cells	  at	  zero	  distance	  
(contacting).	  The	  percent	  contacting	  T	  cells	  varied	  between	  patients,	  ranging	  from	  5%	  to	  27%,	  with	  a	  
mean	  of	  17.3%	  ±	  7.3.	  This	  was	  not	  affected	  by	  stimulation	  type,	  as	  the	  mean	  contact	  percentage	  for	  a	  




Figure	  1:	  Distance	  distributions	  of	  two	  cell	  chambers	  from	  four	  patients	  in	  the	  F5	  and	  NIH	  trial.	  The	  cell-­‐cell	  distance	  was	  
measured	  between	  from	  the	  bright	  field	  image	  of	  the	  microfluidic	  device.	  These	  datapoints	  are	  only	  from	  two	  cell	  chambers.	  	  
The	  average	  protein	  level	  of	  CCL4,	  a	  protein	  related	  to	  T	  cell	  chemotaxis,	  was	  plotted	  against	  T	  
cell-­‐T	  cell	  distance	  for	  four	  patients	  in	  Figure	  2.	  These	  demonstrated	  an	  enhancement	  of	  protein	  signal	  
when	  cells	  are	  contacting.	  It	  was	  also	  investigated	  whether	  close	  proximity	  (<	  100um)	  but	  not	  contact	  
enhanced	  protein	  levels.	  Only	  4.7%	  of	  these	  “close	  proximity”	  cases	  secreted	  either	  CCL4,	  TNFa,	  GB,	  or	  
IFNg	  to	  a	  significant	  level,	  compared	  to	  52.4%	  of	  cells	  in	  contact.	  Because	  there	  was	  no	  trend	  in	  protein	  
signal	  vs.	  distance,	  subsequent	  analyses	  binned	  the	  data	  based	  on	  if	  two	  cells	  were	  at	  0	  distance	  




Figure	  2:	  CCL4	  (MIP1b)	  signal	  vs.	  T	  cell-­‐T	  cell	  distance	  for	  four	  patients	  from	  the	  NIH	  trial.	  Each	  data	  point	  represents	  a	  
measurement	  from	  a	  two	  cell	  chamber.	  	  
	   The	  average	  protein	  levels	  of	  contacting	  and	  non-­‐contacting	  two	  cell	  chambers	  were	  plotted	  in	  
Figure	  3.	  The	  data	  was	  pooled	  from	  T	  cells	  from	  four	  patients	  in	  the	  NIH	  trial.	  T	  cells	  with	  protein	  levels	  
less	  than	  the	  background	  level	  are	  not	  shown	  in	  the	  plot	  but	  were	  included	  in	  significance	  calculations.	  
The	  five	  proteins	  displayed	  in	  the	  figure	  were	  the	  most	  statistically	  discriminating	  proteins,	  and	  the	  
remaining	  proteins	  tested	  (IL-­‐6,	  IL-­‐4,	  IL-­‐17,	  IL-­‐2)	  were	  not	  significantly	  changed	  upon	  contact.	  A	  Mann-­‐
Whitney	  U	  Test	  showed	  that	  TNFa,	  CCL4	  (MIP1b),	  and	  GB	  were	  statistically	  distinguishable	  between	  the	  




Figure	  3:	  Scatter	  plot	  of	  protein	  levels	  from	  two	  cell	  chambers.	  This	  data	  was	  gated	  on	  if	  the	  T	  cells	  were	  in	  contact	  or	  not.	  Each	  
point	  represents	  a	  two	  cell	  chamber	  measurement	  of	  a	  specific	  protein.	  Points	  that	  were	  below	  what	  was	  considered	  a	  positive	  
secretion	  for	  that	  protein	  were	  excluded	  from	  this	  plot.	  Significance	  indicators	  are	  shown	  above	  proteins	  that	  were	  statistically	  
distinguishable.	  Significance	  marker:	  *	  =	  p<0.05.	  
	   The	  percent	  of	  T	  cells	  considered	  positive	  secretors	  was	  plotted	  for	  each	  protein,	  and	  gated	  on	  
contact,	  and	  non-­‐contact	  (Figure	  4a).	  Additionally,	  the	  theoretical	  percent	  of	  two	  T	  cells	  secreting	  a	  
protein	  based	  on	  single	  cell	  data	  was	  plotted,	  as	  calculated	  from	  Equation	  1.	  All	  patient	  samples	  showed	  
that	  contacting	  T	  cells	  enhanced	  their	  ability	  to	  secrete	  certain	  proteins.	  This	  occurred	  for	  a	  subset	  of	  
proteins,	  including	  Granzyme	  B	  (GB),	  Perforin,	  CCL4	  (MIP1b),	  TNFa,	  and	  IFNg.	  The	  protein	  expression	  
frequency	  was	  averaged	  over	  all	  patients,	  as	  shown	  in	  Figure	  4b.	  This	  shows	  a	  general	  trend	  of	  
upregulation	  for	  the	  subset	  of	  proteins	  mentioned	  above.	  	  Finally,	  the	  theoretical	  value	  protein	  






Figure	  4:	  Percent	  of	  two	  cell	  chambers	  with	  positive	  protein	  secretion,	  gated	  based	  on	  if	  the	  T	  cells	  were	  in	  contact	  or	  not.	  a)	  The	  
percent	  of	  T	  cells	  secreting	  a	  specific	  protein	  is	  shown	  for	  four	  different	  patients,	  and	  is	  gated	  on	  contact,	  non-­‐contact,	  or	  
estimated	  values	  from	  single	  cell	  data.	  b)	  The	  averaged	  frequency	  of	  protein	  expressed,	  gated	  on	  contact,	  and	  non-­‐contact.	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5.3.2  -­‐  Nature  of  T-­‐T  contact  
	   The	  percent	  of	  contacting	  T	  cells	  that	  had	  TCR	  localized	  at	  the	  intercell	  synapse	  was	  measured.	  
Only	  a	  small	  percentage	  of	  contacting	  T	  cells	  (<	  10%)	  show	  co-­‐localization	  of	  their	  MART-­‐1	  receptor,	  as	  
shown	  in	  Figure	  5.	  The	  majority	  of	  cells	  had	  TCR	  clusters	  spread	  non-­‐specifically	  over	  the	  plasma	  
membrane.	  	  
A	  summary	  of	  the	  percent	  contacting	  cell	  vs.	  stimulation	  are	  shown	  in	  Table	  1.	  There	  was	  a	  
significant	  reduction	  in	  T	  cell	  contact	  when	  anti-­‐CD3	  was	  added	  to	  the	  T	  cells	  (p=0.0139).	  However,	  
relative	  to	  the	  control	  T	  cells,	  there	  was	  no	  enhancement	  of	  T	  cell-­‐T	  cell	  contact	  when	  the	  tetramer	  was	  
present.	  	  
	   	  	  
Table	  1:	  Results	  from	  contact	  experiment.	  T	  cells	  were	  incubated	  with	  different	  molecules	  and	  the	  percent	  of	  contacting	  T	  cells	  
was	  measured.	  
Stimulation	   %	  Contacting	  
T	  cells	  
Total	  pairs	  
of	  T	  cells	  
Total	  Two	  Cell	  
Chambers	  
Control	   5.8	   22	   379	  
Anti-­‐CD3	   2.0	   6	   299	  
MART-­‐1	  Tetramer	   4.41	   3	   68	  
	  
	  
Figure	  5:	  Image	  of	  Jurkat	  T	  cells	  stained	  with	  fluorescent	  tetramer	  that	  bridge	  the	  intercellular	  synapse.	  a)	  Bright	  field	  image	  of	  
two	  contacting	  Jurkats.	  b)	  Fluorescence	  image	  of	  the	  same	  contacting	  Jurkats.	  Note	  the	  TCR	  is	  localized	  at	  the	  junction	  between	  
the	  two	  cells.	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5.3.3  -­‐  Two  Cell  Phenotype  Experiment  
	   T	  cells	  behaved	  in	  a	  similar	  fashion	  to	  previous	  experiments,	  with	  the	  contacting	  two	  cell	  having	  
enhanced	  protein	  signals	  for	  IFNg,	  CCL4,	  and	  GB	  (Figure	  6).	  
	  
Figure	  6:	  Protein	  expression	  levels	  for	  phenotype	  experiment,	  gated	  on	  contact	  or	  non-­‐contact.	  Each	  point	  represents	  a	  two	  cell	  
chamber	  measurement	  of	  a	  specific	  protein	  level.	  Significance	  indictors	  are	  displayed	  above	  the	  geoms.	  Significance	  markers:	  *	  =	  




Figure	  7:	  Fluorescence	  and	  bright	  field	  image	  of	  contacting	  T	  cells	  with	  CD8-­‐CD8,	  CD4-­‐CD4,	  and	  CD8-­‐CD4	  contacting.	  On	  the	  left	  
is	  the	  fluorescence	  image	  with	  the	  type	  of	  contact	  pair.	  One	  the	  right	  side	  is	  the	  same	  region,	  taken	  as	  a	  bright	  field	  image.	  	  
	   	  
	  
Figure	  8:	  Plot	  of	  protein	  levels	  for	  in	  single	  cell	  chambers	  from	  the	  phenotype	  experiment,	  gated	  on	  T	  cell	  phenotype.	  Each	  point	  
represents	  a	  single	  T	  cell	  measurement	  for	  a	  specific	  protein.	  The	  red	  line	  shows	  the	  average	  secretion	  level	  of	  each	  protein.	  
Significance	  plots	  are	  shown	  above	  the	  geoms.	  Significance	  marker:	  *=	  p<0.05.	  
T	  cells	  were	  successfully	  loaded	  on	  the	  chip	  and	  phenotyped,	  as	  visualized	  in	  Figure	  7.	  The	  figure	  
shows	  the	  three	  different	  combinations	  of	  T	  cell	  sub-­‐phenotypes:	  CD8-­‐CD8,	  CD4-­‐CD4,	  and	  CD8-­‐CD4.	  The	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contact	  percentages	  are	  listed	  in	  Table	  2,	  with	  their	  theoretical	  values	  shown	  in	  parentheses.	  The	  CD4-­‐
CD8	  contact	  percentage	  was	  much	  lower	  than	  the	  theoretical	  value,	  with	  the	  CD8-­‐CD8	  contact	  being	  
higher	  than	  anticipated.	  	  
	  
Table	  2:	  Measured	  and	  theoretical	  percentages	  of	  two	  T	  cells	  in	  contact,	  gated	  on	  phenotype.	  The	  measured	  phenotype	  is	  shown	  
in	  each	  box,	  with	  the	  theoretical	  value	  in	  parentheses	  next	  to	  it.	  The	  theoretical	  value	  was	  calculated	  from	  the	  percent	  of	  each	  
phenotype	  sorted	  by	  FACS.	  
	   CD4	   CD8	  
CD4	   16	  %	  (10%)	   16%	  (42%)	  
CD8	   	   68%	  (48%)	  
	  
A	  plot	  showing	  the	  difference	  in	  protein	  secretion	  level	  between	  individual	  CD4	  and	  CD8	  cells	  is	  
shown	  in	  Figure	  8.	  The	  only	  protein	  that	  discriminated	  between	  CD4	  and	  CD8s	  was	  Granzyme	  B.	  
For	  each	  of	  the	  combination	  of	  T	  cell	  subtypes,	  the	  significantly	  enhanced	  protein	  levels	  are	  
shown	  in	  Table	  3.	  This	  demonstrated	  that	  CD4s	  in	  contact	  with	  CD4s	  will	  secrete	  IFNg	  at	  a	  rate	  that	  was	  
significantly	  higher	  than	  that	  of	  two	  individual	  CD4s	  secreting	  in	  a	  chamber.	  CD4-­‐CD8	  had	  two	  proteins	  
that	  were	  secreted	  at	  a	  significantly	  higher	  rate:	  IFNg	  and	  CCL4.	  Finally,	  CD8-­‐CD8	  chambers	  secreted	  GB	  
and	  CCL4	  at	  a	  higher	  rate.	  	  
	  
Table	  3:	  Enhanced	  proteins	  in	  two	  cell,	  contacting	  chamber,	  gated	  by	  phenotype	  of	  T	  cells.	  	  
	   CD4	   CD8	  
CD4	   IFNg	   IFNg,	  CCL4	  




5.4  –  Discussion  
	   Two	  cells	  communication	  has	  received	  attention	  by	  many	  groups,	  including	  Krummel	  and	  Xiang	  
[7,	  11].	  They	  have	  demonstrated	  that	  T	  cells	  can	  form	  synapses	  with	  each	  other	  and	  exchange	  cytokines	  
in	  a	  targeted	  fashion	  [7].	  Furthermore,	  Xiang	  demonstrated	  that	  preventing	  T	  cell	  communication	  in	  the	  
priming	  stage	  of	  an	  immune	  response	  would	  significantly	  reduce	  the	  number	  of	  antigen	  specific	  memory	  
T	  cells	  found	  post-­‐infection	  [11].	  Here,	  we	  show	  that	  T	  cells	  in	  contact	  tend	  to	  be	  higher	  producers	  of	  
select	  proteins.	  The	  fact	  that	  we	  are	  detecting	  higher	  levels	  of	  proteins	  implies	  that	  either	  the	  cells	  are	  
producing	  more	  absolute	  value	  of	  proteins,	  or	  that	  contacting	  reduces	  the	  number	  of	  proteins	  uptaken	  
into	  the	  cells	  (thereby	  increasing	  the	  amount	  our	  devices	  can	  detect).	  Because	  Krummel	  et	  al.	  have	  
shown	  that	  synapse	  formation	  also	  centers	  receptors	  to	  the	  proteins	  in	  the	  synapse,	  this	  implies	  that	  T	  
cells	  in	  contact	  tend	  to	  secrete	  towards	  each	  other	  [7].	  Therefore,	  in	  our	  case,	  it	  is	  unlikely	  that	  we	  are	  
seeing	  high	  protein	  levels	  because	  of	  reduced	  uptake/degradation,	  and	  so	  the	  former	  hypothesis	  of	  
protein	  upregulation	  is	  more	  likely.	  This	  could	  be	  confirmed	  by	  performing	  single	  cell	  RNA-­‐seq	  to	  
determine	  if	  copy	  numbers	  increase.	  	  
In	  elucidating	  the	  nature	  of	  the	  T	  cell-­‐T	  cell	  contact,	  we	  demonstrated	  that	  the	  addition	  of	  anti-­‐
CD3	  significantly	  reduced	  the	  number	  of	  contacting	  T	  cells.	  We	  do	  not	  believe,	  that	  CD3	  is	  a	  driving	  force	  
of	  contact	  however.	  Our	  hypothesis	  was	  that	  anti-­‐CD3	  creates	  a	  steric	  hindrance	  that	  impedes	  synapse	  
formation.	  What	  we	  believe	  to	  be	  the	  driving	  force	  of	  the	  contact	  is	  LFA-­‐1	  and	  ICAM-­‐1,	  which	  have	  been	  
shown	  to	  be	  critical	  in	  homotypic	  T	  cell-­‐T	  cell	  contact	  [8,	  12].	  We	  have	  tested	  this	  at	  a	  bulk	  level,	  and	  
showed	  that	  T	  cells	  do	  not	  contact	  when	  anti-­‐LFA-­‐1	  is	  added	  at	  10	  ug/mL	  [13].	  It	  would	  be	  interesting	  to	  
detect	  which	  proteins	  localize	  at	  the	  T	  cell-­‐T	  cell	  synapse,	  as	  this	  would	  give	  us	  an	  idea	  as	  to	  which	  
receptors	  are	  responsible	  for	  the	  protein	  upregulation	  observed.	  	  
99	  
	  
	   Contacting	  two	  cells	  did	  not	  upregulate	  all	  proteins	  equally.	  Many	  proteins	  were	  not	  
upregulated	  at	  all.	  The	  proteins	  that	  were	  enhanced	  were	  related	  to	  either	  cell	  killing	  (GB,	  Perforin),	  T	  
cell	  mobility	  (CCL4),	  or	  general	  immune	  activation	  (IFNg,	  TNFa).	  In	  contrast,	  IL-­‐10	  –	  an	  anti-­‐inflammatory	  
protein	  –	  was	  not	  enhanced.	  This	  may	  be	  the	  mechanism	  behind	  why	  co-­‐culturing	  T	  cells	  together	  prior	  
to	  ACT	  improves	  tumor	  killing	  ability	  [Unpublished]	  There	  are	  two	  possible	  explanations	  for	  the	  selective	  
upregulation:	  1)	  the	  exchange	  of	  information	  through	  cytokines	  and/or	  receptors	  only	  triggered	  certain	  
protein	  synthesis	  pathways	  in	  the	  cells	  or	  2)	  the	  single	  cell	  test	  was	  not	  sensitive	  enough	  to	  detect	  
changes	  in	  protein	  expression	  for	  certain	  proteins.	  	  
For	  the	  first	  possibility,	  there	  is	  ample	  evidence	  that	  cytokine	  exchange	  can	  selectively	  enhance	  
protein	  secretion.	  For	  example,	  pretreatment	  of	  T	  cells	  with	  IL-­‐10	  can	  enhance	  TNFa,	  and	  IFNg	  levels	  in	  
later	  secretion,	  without	  enhancing	  IL-­‐2	  or	  IL-­‐4	  levels	  [14].	  In	  addition,	  it	  is	  well	  known	  that	  different	  
stimulants	  cause	  selective	  protein	  expression	  upregulation.	  For	  instance,	  PMA/I	  turns	  on	  TNFa	  
expression	  in	  leukocyotes	  [15].	  Therefore,	  it	  is	  reasonable	  to	  assume	  that	  proteins	  exchanged	  by	  the	  T	  
cell,	  or	  receptors	  activated,	  enhanced	  the	  expression	  of	  select	  proteins.	  To	  test	  this,	  one	  could	  perform	  
selective	  knock-­‐outs	  of	  pathways	  downstream	  of	  relevant	  cytokine/receptors	  exchanged	  by	  the	  T	  cells.	  
Performing	  blocking	  experiments,	  rather	  than	  knock-­‐outs,	  would	  not	  be	  useful	  in	  this	  case,	  for	  two	  
reasons:	  one,	  antibodies	  for	  blocking	  cytokines	  would	  not	  likely	  enter	  into	  the	  T	  cell	  synapse,	  and	  two,	  
antibodies	  against	  receptors	  would	  likely	  cause	  steric	  hindrance	  in	  the	  synapse	  formation,	  as	  shown	  in	  
the	  Nature	  of	  T-­‐T	  contact	  (Chapter	  5.3.3).	  	  	  
For	  the	  second	  possibility,	  it	  was	  possible	  our	  single	  cell	  test	  did	  not	  pick	  up	  smaller	  changes	  in	  
select	  proteins,	  especially	  those	  outside	  of	  the	  linear	  region	  of	  detection	  [16].	  These	  regions	  show	  small	  
changes	  in	  fluorescence	  signal,	  even	  with	  significant	  protein	  concentration	  changes.	  To	  test	  this,	  one	  
would	  have	  to	  develop	  higher	  sensitivity	  technologies,	  such	  as	  nanowire-­‐based	  detection	  of	  proteins	  or	  
resonator	  cavity	  detection,	  and	  integrate	  these	  into	  single	  cells	  experiments	  [17,	  18].	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In	  the	  CD4/CD8	  phenotype	  experiment,	  it	  was	  observed	  that	  there	  were	  less	  CD4-­‐CD8s	  in	  
contact	  than	  the	  theoretical	  value	  anticipated	  (-­‐62%).	  Consequently,	  there	  were	  more	  CD8-­‐CD8	  contacts	  
than	  anticipated	  (+48%).	  One	  possible	  explanation	  for	  this	  would	  be	  the	  detection	  of	  false	  positive	  CD8	  
phenotypes.	  However,	  every	  chamber	  with	  two	  cells	  was	  checked	  by	  hand,	  so	  there	  was	  no	  chance	  for	  a	  
false	  positive	  detection.	  Another	  possibility	  would	  be	  that	  the	  CD8	  T	  cells	  were	  more	  “sticky”	  than	  the	  
CD4s.	  However,	  this	  was	  also	  not	  the	  case,	  since	  the	  CD4-­‐CD4	  contact	  was	  actually	  higher	  than	  
anticipated.	  One	  last	  possibility,	  which	  we	  believe	  was	  most	  likely,	  was	  that	  our	  statistics	  were	  too	  low.	  
This	  could	  be	  remedied	  by	  increasing	  the	  chamber	  count	  of	  the	  device	  or	  engineering	  cell	  traps	  in	  the	  
device	  that	  retain	  contacting	  cells	  rather	  than	  having	  it	  be	  purely	  stochastic	  [19].	  
There	  are	  numerous	  further	  experiments	  to	  perform	  using	  this	  experimental	  platform.	  First	  and	  
foremost,	  it	  would	  be	  interesting	  to	  test	  younger	  T	  cells.	  The	  T	  cell	  samples	  tested	  came	  from	  metastatic	  
melanoma	  patients	  whose	  T	  cells	  were	  expanded	  significantly.	  This	  expansion	  can	  “age”	  or	  differentiate	  
the	  T	  cells	  [20].	  Krummel	  et	  al.	  showed	  that	  this	  communication	  exists	  in	  younger	  T	  cells	  and	  it	  would	  be	  
interesting	  to	  see	  if	  enhanced	  protein	  expression	  exists	  in	  the	  younger	  T	  cells.	  This	  would	  require	  
detecting	  additional	  phenotypes	  in	  the	  microfluidic	  device.	  Adding	  phenotypes	  for	  T	  cell	  age	  would	  be	  a	  
natural	  extension	  for	  this	  experiment.	  The	  addition	  of	  CCR7	  and	  CD45RA	  would	  be	  sufficient	  for	  a	  simple	  
panel	  for	  T	  cell	  differentiation	  state	  (or	  age)	  [2,	  21].	  If	  further	  surface	  markers	  were	  detected,	  one	  could	  
use	  the	  photocleavable	  construct,	  described	  in	  Chapter	  3.	  	  
One	  could	  also	  extend	  this	  technology	  towards	  studying	  heterotypic	  contact	  between	  other	  
immune	  cells;	  for	  instance,	  T	  cells	  and	  dendritic	  cells	  during	  the	  priming	  stage.	  This	  is	  a	  critical	  step	  in	  
the	  adaptive	  immune	  response,	  as	  poor	  contact	  between	  T	  cells	  and	  dendritic	  cells	  can	  reduce	  the	  
formation	  of	  T	  cell	  memory	  [22,	  1].	  Using	  our	  microfluidic	  technology	  would	  give	  researchers	  a	  platform	  
to	  study	  isolated	  interactions	  between	  different	  immune	  cells.	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5.5  –  Conclusions  
	   Two	  cell	  protein	  assays	  conduced	  with	  T	  cells	  demonstrated	  that	  cell-­‐cell	  contact	  can	  selectively	  
enhance	  protein	  expression.	  T	  cells	  in	  close	  proximity	  (<	  100	  µm)	  did	  not	  exhibit	  the	  same	  enhancement,	  
and	  therefore,	  direct	  contact	  is	  key.	  The	  proteins	  that	  were	  upregulated	  upon	  contact	  were	  related	  to	  
cell	  killing,	  mobility,	  and	  immune	  activation,	  demonstrating	  a	  potential	  mechanism	  behind	  why	  T	  cell-­‐T	  
cell	  contact	  can	  improve	  the	  effectiveness	  of	  ACT.	  Therefore,	  this	  method	  has	  demonstrated	  that	  T	  cells	  
communicate	  with	  each	  other	  and	  enhance	  their	  cytokine	  release	  upon	  contact.	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